Publications

(See also the personal webpage of our group members)

Group highlights

(For a full list of publications, see below, and see also the personal webpage of our group members)

PANTHER Trial Publications

At the 5-year analysis, tailored dose-dense adjuvant chemotherapy did not significantly improve breast cancer recurrence–free survival compared with standard 3-weekly treatment, despite modest improvement in event-free survival and increased toxicity. However, after 10.3 years of follow-up in the PANTHER trial, dose-dense chemotherapy significantly improved recurrence-free, event-free, and distant disease–free survival—marking the first demonstration of benefit over an optimal control regimen that included docetaxel administered every 3 weeks—although overall survival remained not statistically significant.

T. Foukakis, A. Matikas, et al., SweBCG, GBG, ABCSG Consortia

JAMA (2016)

Journal of Clinical Oncology (2024)

Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing

In this study of 20 patients with triple-negative breast cancer undergoing neoadjuvant chemotherapy, single-cell and bulk sequencing revealed that treatment resistance arose from adaptive selection of pre-existing resistant clones rather than new genomic mutations. While resistant genotypes were already present before therapy, chemotherapy induced transcriptional reprogramming that shaped resistant cellular states.

C. Kim, R. Gao, E. Sei, R. Brandt, J. Hartman, T. Hatschek, N. Crosetto, T. Foukakis, N. E. Navin

Cell (2018)

Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer

In the randomized phase 2 PREDIX HER2 trial of 202 patients with ERBB2-positive breast cancer, neoadjuvant trastuzumab emtansine (T-DM1) achieved a pathologic complete response rate similar to standard docetaxel, trastuzumab, and pertuzumab (43.9% vs 45.5%; not statistically significant). These findings suggest that, in selected patients, neoadjuvant therapy may be safely de-escalated to T-DM1 monotherapy, with comparable efficacy to standard combination treatment.

T. Hatschek, T. Foukakis, J. Bjöhle, T. Lekberg, H. Fredholm, E. Elinder, A. Bosch, G. Pekar, H. Lindman, A. Schiza, Z. Einbeigi, J. Adra, A. Andersson, L. Carlsson, A. C. Dreifaldt, E. Isaksson‑Friman, S. Agartz, E. Azavedo, P. Grybäck, M. Hellström, H. Johansson, C. Maes, I. Zerdes, J. Hartman, Y. Brandberg, J. Bergh

JAMA Oncology (2021)

Longitudinal molecular profiling elucidates immunometabolism dynamics in breast cancer.

This study longitudinally profiles immunometabolic changes in breast tumors before, during, and after neoadjuvant chemotherapy using multi-omics approaches, revealing dynamic interactions between tumor metabolism and immune states. Distinct metabolic programs in tumor and immune cells were associated with treatment response, supporting tumor metabolism as a target for immunomodulation.

K. Wang, I. Zerdes, H. J. Johansson, D. Sarhan, Y. Sun, D. C. Kanellis, E. G. Sifakis, A. Mezheyeuski, X. Liu, N. Loman, I. Hedenfalk, J. Bergh, J. Bartek, T. Hatschek, J. Lehtiö, A. Matikas, T. Foukakis

Nature Communications (2024)

 

Recent Publications (2025)

  1. “Prognosis After Pathologic Complete Response to Neoadjuvant Therapy in Early-Stage Breast Cancer: A Population-Based Study.”.
    C. Boman et al.
    J Natl Compr Canc Netw, vol. 23, no. 4, Mar. 2025

    BIB
    @article{boman_prognosis_2025,
      title = {Prognosis {After} {Pathologic} {Complete} {Response} to {Neoadjuvant} {Therapy} in {Early}-{Stage} {Breast} {Cancer}: {A} {Population}-{Based} {Study}.},
      volume = {23},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/40073831},
      doi = {10.6004/jnccn.2024.7093},
      language = {eng},
      number = {4},
      journal = {J Natl Compr Canc Netw},
      author = {Boman, C and Tranchell, C and Liu, X and Eriksson Bergman, L and Toli, MA and Bergh, J and Foukakis, T and Matikas, A},
      month = mar,
      year = {2025},
      note = {Publisher: United States},
      keywords = {Pathologic Complete Response},
      published = {1},
      tag = {}
    }
  2. “Adherence to adjuvant endocrine therapy including GnRH-analogues and survival: a population-based cohort study.”.
    L. Eriksson Bergman, A. Matikas, X. Liu, and T. Foukakis.
    EClinicalMedicine, vol. 88, p. 103493, Oct. 2025

    BIB
    @article{eriksson_bergman_adherence_2025,
      title = {Adherence to adjuvant endocrine therapy including {GnRH}-analogues and survival: a population-based cohort study.},
      volume = {88},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/41181852},
      doi = {10.1016/j.eclinm.2025.103493},
      language = {eng},
      journal = {EClinicalMedicine},
      author = {Eriksson Bergman, L and Matikas, A and Liu, X and Foukakis, T},
      month = oct,
      year = {2025},
      note = {Publisher: England},
      keywords = {Survival},
      pages = {103493},
      published = {1},
      tag = {}
    }
  3. “Associations of sarcopenia, sarcopenia components and sarcopenic obesity with cancer incidence: A prospective cohort study of 414,094 participants in UK Biobank.”.
    P. Filis et al.
    Int J Cancer, vol. 157, no. 7, pp. 1316–1332, Oct. 2025

    BIB
    @article{filis_associations_2025,
      title = {Associations of sarcopenia, sarcopenia components and sarcopenic obesity with cancer incidence: {A} prospective cohort study of 414,094 participants in {UK} {Biobank}.},
      volume = {157},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/40396701},
      doi = {10.1002/ijc.35480},
      language = {eng},
      number = {7},
      journal = {Int J Cancer},
      author = {Filis, P and Papagiannopoulos, CK and Markozannes, G and Chalitsios, CV and Zerdes, I and Valachis, A and Papandreou, C and Christakoudi, S and Tsilidis, KK},
      month = oct,
      year = {2025},
      note = {Publisher: United States},
      keywords = {UK Biobank},
      pages = {1316-1332},
      published = {1},
      tag = {}
    }
  4. “Breakthrough in RAS targeting with pan-RAS(ON) inhibitors RMC-7977 and RMC-6236.”.
    P. Filis, D. Salgkamis, A. Matikas, and I. Zerdes.
    Drug Discov Today, vol. 30, no. 1, p. 104250, Jan. 2025

    BIB
    @article{filis_breakthrough_2025,
      title = {Breakthrough in {RAS} targeting with pan-{RAS}({ON}) inhibitors {RMC}-7977 and {RMC}-6236.},
      volume = {30},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/39586491},
      doi = {10.1016/j.drudis.2024.104250},
      language = {eng},
      number = {1},
      journal = {Drug Discov Today},
      author = {Filis, P and Salgkamis, D and Matikas, A and Zerdes, I},
      month = jan,
      year = {2025},
      note = {Publisher: England},
      keywords = {Carcinoma, Non-Small-Cell Lung},
      pages = {104250},
      published = {1},
      tag = {}
    }
  5. “Grading the evidence for physical activity and any outcome in cancer survivors: An Umbrella review of 740 meta-analytic associations.”.
    P. Filis et al.
    Crit Rev Oncol Hematol, vol. 207, p. 104602, Mar. 2025

    BIB
    @article{filis_grading_2025,
      title = {Grading the evidence for physical activity and any outcome in cancer survivors: {An} {Umbrella} review of 740 meta-analytic associations.},
      volume = {207},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/39730034},
      doi = {10.1016/j.critrevonc.2024.104602},
      language = {eng},
      journal = {Crit Rev Oncol Hematol},
      author = {Filis, P and Markozannes, G and Chan, DS and Mauri, D and Foukakis, T and Matikas, A and Droufakou, S and Pentheroudakis, G and Tsilidis, K},
      month = mar,
      year = {2025},
      note = {Publisher: Netherlands},
      keywords = {Female},
      pages = {104602},
      published = {1},
      tag = {}
    }
  6. “Benefit from dose-dense adjuvant chemotherapy for breast cancer: subgroup analyses from the randomised phase 3 PANTHER trial.”.
    A. Matikas et al.
    Lancet Regional Health Europe, vol. 49, p. 101162, Feb. 2025

    BIB
    @article{matikas_benefit_2025,
      title = {Benefit from dose-dense adjuvant chemotherapy for breast cancer: subgroup analyses from the randomised phase 3 {PANTHER} trial.},
      volume = {49},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/39703564},
      doi = {10.1016/j.lanepe.2024.101162},
      language = {eng},
      journal = {Lancet Regional Health Europe},
      author = {Matikas, A and Papakonstantinou, A and Loibl, S and Steger, GG and Untch, M and Johansson, H and Tsiknakis, N and Hellstrom, M and Greil, R and Mobus, V and Gnant, M and Bergh, J and Foukakis, T},
      month = feb,
      year = {2025},
      note = {Publisher: England},
      keywords = {STEPP},
      pages = {101162},
      published = {1},
      tag = {},
      trial = {panther}
    }
  7. “Randomised trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: a study protocol of ARIADNE.”.
    A. Matikas et al.
    BMJ Open, vol. 15, no. 8, p. e102626, Aug. 2025

    BIB
    @article{matikas_randomised_2025,
      title = {Randomised trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for {HER2}-positive breast cancer: a study protocol of {ARIADNE}.},
      volume = {15},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/40866060},
      doi = {10.1136/bmjopen-2025-102626},
      language = {eng},
      number = {8},
      journal = {BMJ Open},
      author = {Matikas, A and Naume, B and Wildiers, H and Sonke, G and Dieci, MV and Karakatsanis, A and Andersson, A and Barnekow, E and Kessler, LE and Einbeigi, Z and Killander, F and Linderholm, B and Schiza, A and Valachis, A and Nearchou, A and Engebraaten, O and Porojnicu, A and Soland, MH and Mannsaker, B and Raj, SX and Blix, ES and Nordstrand, CS and Lambertini, M and Vernieri, C and Punie, K and Sotiriou, C and Bergh, J and Villacampa, G and Zouzos, A and Hellstrom, M and Hartman, J and Foukakis, T},
      month = aug,
      year = {2025},
      note = {Publisher: England},
      keywords = {Camptothecin},
      pages = {e102626},
      published = {1},
      tag = {},
      trial = {ariadne}
    }
  8. “Long-term trastuzumab safety in tailored dose-dense anthracycline containing adjuvant chemotherapy in the PANTHER phase III trial.”.
    A. Papakonstantinou, M. Hellstrom, A. Andersson, P. Malmstrom, J. C. S. Bergh, and T. Foukakis.
    Journal of Clinical Oncology, vol. 43, no. 16_suppl, pp. 12024–12024, Jun. 2025

    BIB
    @article{papakonstantinou_long-term_2025,
      title = {Long-term trastuzumab safety in tailored dose-dense anthracycline containing adjuvant chemotherapy in the {PANTHER} phase {III} trial.},
      volume = {43},
      issn = {0732-183X},
      journal = {Journal of Clinical Oncology},
      author = {Papakonstantinou, A and Hellstrom, M and Andersson, A and Malmstrom, P and Bergh, JCS and Foukakis, T},
      month = jun,
      year = {2025},
      note = {Publisher: American Society of Clinical Oncology (ASCO)},
      keywords = {Cancer},
      pages = {12024-12024},
      published = {1},
      tag = {}
    }
  9. “Neoadjuvant treatment of HER2-positive breast cancer: has the era of antibody-drug conjugates arrived?”.
    A. Papakonstantinou and T. Foukakis.
    Ann Oncol, vol. 36, no. 6, pp. 603–605, Jun. 2025

    BIB
    @article{papakonstantinou_neoadjuvant_2025,
      title = {Neoadjuvant treatment of {HER2}-positive breast cancer: has the era of antibody-drug conjugates arrived?},
      volume = {36},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/40194621},
      doi = {10.1016/j.annonc.2025.03.022},
      language = {eng},
      number = {6},
      journal = {Ann Oncol},
      author = {Papakonstantinou, A and Foukakis, T},
      month = jun,
      year = {2025},
      note = {Publisher: England},
      pages = {603-605},
      published = {1},
      tag = {}
    }
  10. “Prognostic significance of tumour Ki-67 dynamics during neoadjuvant treatment in patients with breast cancer: a population-based cohort study.”.
    M. A. Toli et al.
    Lancet Regional Health Europe, vol. 58, p. 101432, Nov. 2025

    BIB
    @article{toli_prognostic_2025,
      title = {Prognostic significance of tumour {Ki}-67 dynamics during neoadjuvant treatment in patients with breast cancer: a population-based cohort study.},
      volume = {58},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/40980814},
      doi = {10.1016/j.lanepe.2025.101432},
      language = {eng},
      journal = {Lancet Regional Health Europe},
      author = {Toli, MA and Liu, X and Massa, D and Lando, S and Boman, C and Tsiknakis, N and Tranchell, C and Papakonstantinou, A and Fotia, G and Vernieri, C and Guarneri, V and Bergh, J and Dieci, MV and Bergman, LE and Matikas, A and Foukakis, T},
      month = nov,
      year = {2025},
      note = {Publisher: England},
      keywords = {Survival},
      pages = {101432},
      published = {1},
      tag = {},
      trial = {panther}
    }
  11. “Gene Expression patterns in early ER+/HER2-breast cancer treated with neoadjuvant chemotherapy versus CDK4/6 inhibitor therapy: results from the Swedish PREDIX Luminal B trial”.
    E. Tzoras et al.
    CLINICAL Cancer Research, vol. 31, no. 12, pp. P20130–P20130, Jun. 2025

    BIB
    @article{tzoras_gene_2025,
      title = {Gene {Expression} patterns in early {ER}+/{HER2}-breast cancer treated with neoadjuvant chemotherapy versus {CDK4}/6 inhibitor therapy: results from the {Swedish} {PREDIX} {Luminal} {B} trial},
      volume = {31},
      issn = {1078-0432},
      url = {https://www.webofscience.com/api/gateway?GWVersion=2\&SrcApp=kielementsprod\&SrcAuth=WosAPI\&KeyUT=WOS:001551270100014\&DestLinkType=FullRecord\&DestApp=WOS_CPL},
      doi = {10.1158/1557-3265.SABCS24-P2-01-30},
      number = {12},
      journal = {CLINICAL Cancer Research},
      author = {Tzoras, E and Sarafidis, M and Sifakis, EG and Salgkamis, D and Acs, B and Sun, W and Zerdes, I and Wang, K and Bergh, J and Hatschek, T and Matikas, A and Foukakis, T},
      month = jun,
      year = {2025},
      pages = {P20130-P20130},
      published = {1},
      tag = {}
    }
  12. “Comprehensive genome profiling for treatment decisions in patients with metastatic tumors: real-world evidence meta-analysis and registry data implementation.”.
    I. Zerdes et al.
    J Natl Cancer Inst, vol. 117, no. 6, pp. 1117–1124, Jun. 2025

    BIB
    @article{zerdes_comprehensive_2025,
      title = {Comprehensive genome profiling for treatment decisions in patients with metastatic tumors: real-world evidence meta-analysis and registry data implementation.},
      volume = {117},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/39842854},
      doi = {10.1093/jnci/djaf015},
      language = {eng},
      number = {6},
      journal = {J Natl Cancer Inst},
      author = {Zerdes, I and Filis, P and Fountoukidis, G and El-Naggar, AI and Kalofonou, F and D'Alessio, A and Pouptsis, A and Foukakis, T and Pentheroudakis, G and Ahlgren, J and Smith, D and Valachis, A},
      month = jun,
      year = {2025},
      note = {Publisher: United States},
      keywords = {Clinical Decision-Making},
      pages = {1117-1124},
      published = {1},
      tag = {}
    }
  13. “Machine learning-based spatial characterization of tumor-immune microenvironment in the EORTC 10994/BIG 1-00 early breast cancer trial.”.
    I. Zerdes et al.
    NPJ Breast Cancer, vol. 11, no. 1, p. 23, Mar. 2025

    BIB
    @article{zerdes_machine_2025,
      title = {Machine learning-based spatial characterization of tumor-immune microenvironment in the {EORTC} 10994/{BIG} 1-00 early breast cancer trial.},
      volume = {11},
      issn = {2374-4677},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/40055382},
      doi = {10.1038/s41523-025-00730-1},
      language = {eng},
      number = {1},
      journal = {NPJ Breast Cancer},
      author = {Zerdes, I and Matikas, A and Mezheyeuski, A and Manikis, G and Acs, B and Johansson, H and Boyaci, C and Boman, C and Poncet, C and Ignatiadis, M and Bai, Y and Rimm, DL and Cameron, D and Bonnefoi, H and Bergh, J and MacGrogan, G and Foukakis, T},
      month = mar,
      year = {2025},
      note = {Publisher: United States},
      pages = {23},
      published = {1},
      tag = {}
    }

 

Full List of publications

2025

  1. “Pathologist-Read vs AI-Driven Assessment of Tumor-Infiltrating Lymphocytes in Melanoma.”.
    T. N. Aung et al.
    JAMA Network Open, vol. 8, no. 7, p. e2518906, Jul. 2025

    BIB
    @article{aung_pathologist-read_2025,
      title = {Pathologist-{Read} vs {AI}-{Driven} {Assessment} of {Tumor}-{Infiltrating} {Lymphocytes} in {Melanoma}.},
      volume = {8},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/40608341},
      doi = {10.1001/jamanetworkopen.2025.18906},
      language = {eng},
      number = {7},
      journal = {JAMA Network Open},
      author = {Aung, TN and Liu, M and Su, D and Shafi, S and Boyaci, C and Steen, S and Tsiknakis, N and Vidal, JM and Maher, N and Micevic, G and Tan, SX and Vesely, MD and Nourmohammadi, S and Bai, Y and Djureinovic, D and Wong, PF and Bates, K and Chan, NNN and Gavirelatou, N and He, M and Burela, S and Barna, R and Bosic, M and Brautigam, K and Illabochaca, I and Chenhao, Z and Gama, J and Kreis, B and Mohacsi, R and Pillar, N and Pinto, J and Poulios, C and Toli, MA and Tzoras, E and Bracero, Y and Bosisio, F and Cserni, G and Dema, A and Fortarezza, F and Gonzalez, MS and Gullo, I and Queipo Gutierrez, FJ and Hacihasanoglu, E and Jovic, V and Lazar, B and Olinca, M and Neppl, C and Oliveira, RC and Pezzuto, F and Gomes Pinto, D and Plotar, V and Pop, O and Rau, T and Skok, K and Sun, W and Serbes, ED and Solass, W and Stanowska, O and Szasz, M and Szymonski, K and Thimm, F and Vignati, D and Vigdorovits, A and Prieto, V and Sinnberg, T and Wilmott, J and Cowper, S and Warrell, J and Saenger, Y and Hartman, J and Plummer, J and Osman, I and Rimm, DL and Acs, B},
      month = jul,
      year = {2025},
      note = {Publisher: United States},
      keywords = {Machine Learning},
      pages = {e2518906},
      published = {1},
      tag = {}
    }
  2. “Expert recommendations on treatment sequencing and challenging clinical scenarios in human epidermal growth factor receptor 2-positive (HER2-positive) metastatic breast cancer.”.
    R. Bartsch et al.
    Cancer Treatment Reviews, vol. 132, p. 102853, Jan. 2025

    BIB
    @article{bartsch_expert_2025,
      title = {Expert recommendations on treatment sequencing and challenging clinical scenarios in human epidermal growth factor receptor 2-positive ({HER2}-positive) metastatic breast cancer.},
      volume = {132},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/39580869},
      doi = {10.1016/j.ctrv.2024.102853},
      language = {eng},
      journal = {Cancer Treatment Reviews},
      author = {Bartsch, R and Cameron, D and Ciruelos, E and Criscitiello, C and Curigliano, G and Duhoux, FP and Foukakis, T and Gligorov, J and Harbeck, N and LeVasseur, N and Okines, A and Penault-Llorca, F and Muller, V},
      month = jan,
      year = {2025},
      note = {Publisher: Netherlands},
      keywords = {Practice Guidelines as Topic},
      pages = {102853},
      published = {1},
      tag = {}
    }
  3. “Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy.”.
    E. B. C. T. C. G. Collaborative.
    Lancet, vol. 406, no. 10503, pp. 603–614, Aug. 2025

    BIB
    @article{bcoverviewndphoxacuk_extending_2025,
      title = {Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy.},
      volume = {406},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/40783288},
      doi = {10.1016/S0140-6736(25)01013-X},
      language = {eng},
      number = {10503},
      journal = {Lancet},
      author = {Collaborative, EBCTCG},
      month = aug,
      year = {2025},
      note = {Publisher: England},
      keywords = {Aged},
      pages = {603-614},
      published = {1},
      tag = {}
    }
  4. “Prognosis After Pathologic Complete Response to Neoadjuvant Therapy in Early-Stage Breast Cancer: A Population-Based Study.”.
    C. Boman et al.
    J Natl Compr Canc Netw, vol. 23, no. 4, Mar. 2025

    BIB
    @article{boman_prognosis_2025,
      title = {Prognosis {After} {Pathologic} {Complete} {Response} to {Neoadjuvant} {Therapy} in {Early}-{Stage} {Breast} {Cancer}: {A} {Population}-{Based} {Study}.},
      volume = {23},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/40073831},
      doi = {10.6004/jnccn.2024.7093},
      language = {eng},
      number = {4},
      journal = {J Natl Compr Canc Netw},
      author = {Boman, C and Tranchell, C and Liu, X and Eriksson Bergman, L and Toli, MA and Bergh, J and Foukakis, T and Matikas, A},
      month = mar,
      year = {2025},
      note = {Publisher: United States},
      keywords = {Pathologic Complete Response},
      published = {1},
      tag = {}
    }
  5. “Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study.”.
    R. Dent et al.
    Breast Cancer Research, vol. 27, no. 1, p. 35, Mar. 2025

    BIB
    @article{dent_molecular_2025,
      title = {Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b {KEYNOTE}-173 study.},
      volume = {27},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/40069763},
      doi = {10.1186/s13058-024-01946-y},
      language = {eng},
      number = {1},
      journal = {Breast Cancer Research},
      author = {Dent, R and Cortes, J and Park, YH and Munoz-Couselo, E and Kim, S-B and Sohn, J and Im, S-A and Holgado, E and Foukakis, T and Kummel, S and Yearley, J and Wang, A and Nebozhyn, M and Huang, L and Cristescu, R and Jelinic, P and Karantza, V and Schmid, P},
      month = mar,
      year = {2025},
      note = {Publisher: England},
      keywords = {Treatment Outcome},
      pages = {35},
      published = {1},
      tag = {}
    }
  6. “Adherence to adjuvant endocrine therapy including GnRH-analogues and survival: a population-based cohort study.”.
    L. Eriksson Bergman, A. Matikas, X. Liu, and T. Foukakis.
    EClinicalMedicine, vol. 88, p. 103493, Oct. 2025

    BIB
    @article{eriksson_bergman_adherence_2025,
      title = {Adherence to adjuvant endocrine therapy including {GnRH}-analogues and survival: a population-based cohort study.},
      volume = {88},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/41181852},
      doi = {10.1016/j.eclinm.2025.103493},
      language = {eng},
      journal = {EClinicalMedicine},
      author = {Eriksson Bergman, L and Matikas, A and Liu, X and Foukakis, T},
      month = oct,
      year = {2025},
      note = {Publisher: England},
      keywords = {Survival},
      pages = {103493},
      published = {1},
      tag = {}
    }
  7. “Associations of sarcopenia, sarcopenia components and sarcopenic obesity with cancer incidence: A prospective cohort study of 414,094 participants in UK Biobank.”.
    P. Filis et al.
    Int J Cancer, vol. 157, no. 7, pp. 1316–1332, Oct. 2025

    BIB
    @article{filis_associations_2025,
      title = {Associations of sarcopenia, sarcopenia components and sarcopenic obesity with cancer incidence: {A} prospective cohort study of 414,094 participants in {UK} {Biobank}.},
      volume = {157},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/40396701},
      doi = {10.1002/ijc.35480},
      language = {eng},
      number = {7},
      journal = {Int J Cancer},
      author = {Filis, P and Papagiannopoulos, CK and Markozannes, G and Chalitsios, CV and Zerdes, I and Valachis, A and Papandreou, C and Christakoudi, S and Tsilidis, KK},
      month = oct,
      year = {2025},
      note = {Publisher: United States},
      keywords = {UK Biobank},
      pages = {1316-1332},
      published = {1},
      tag = {}
    }
  8. “Breakthrough in RAS targeting with pan-RAS(ON) inhibitors RMC-7977 and RMC-6236.”.
    P. Filis, D. Salgkamis, A. Matikas, and I. Zerdes.
    Drug Discov Today, vol. 30, no. 1, p. 104250, Jan. 2025

    BIB
    @article{filis_breakthrough_2025,
      title = {Breakthrough in {RAS} targeting with pan-{RAS}({ON}) inhibitors {RMC}-7977 and {RMC}-6236.},
      volume = {30},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/39586491},
      doi = {10.1016/j.drudis.2024.104250},
      language = {eng},
      number = {1},
      journal = {Drug Discov Today},
      author = {Filis, P and Salgkamis, D and Matikas, A and Zerdes, I},
      month = jan,
      year = {2025},
      note = {Publisher: England},
      keywords = {Carcinoma, Non-Small-Cell Lung},
      pages = {104250},
      published = {1},
      tag = {}
    }
  9. “Grading the evidence for physical activity and any outcome in cancer survivors: An Umbrella review of 740 meta-analytic associations.”.
    P. Filis et al.
    Crit Rev Oncol Hematol, vol. 207, p. 104602, Mar. 2025

    BIB
    @article{filis_grading_2025,
      title = {Grading the evidence for physical activity and any outcome in cancer survivors: {An} {Umbrella} review of 740 meta-analytic associations.},
      volume = {207},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/39730034},
      doi = {10.1016/j.critrevonc.2024.104602},
      language = {eng},
      journal = {Crit Rev Oncol Hematol},
      author = {Filis, P and Markozannes, G and Chan, DS and Mauri, D and Foukakis, T and Matikas, A and Droufakou, S and Pentheroudakis, G and Tsilidis, K},
      month = mar,
      year = {2025},
      note = {Publisher: Netherlands},
      keywords = {Female},
      pages = {104602},
      published = {1},
      tag = {}
    }
  10. “EORTC-2129-BCG: Elacestrant for treating ER+/HER2-breast cancer patients with ctDNA relapse (TREAT ctDNA).”.
    M. Ignatiadis et al.
    JOURNAL OF CLINICAL ONCOLOGY, vol. 43, no. 16_SUPPL, pp. TPS620–TPS620, Jun. 2025

    BIB
    @article{ignatiadis_eortc-2129-bcg_2025,
      title = {{EORTC}-2129-{BCG}: {Elacestrant} for treating {ER}+/{HER2}-breast cancer patients with {ctDNA} relapse ({TREAT} {ctDNA}).},
      volume = {43},
      issn = {0732-183X},
      url = {https://www.webofscience.com/api/gateway?GWVersion=2\&SrcApp=kielementsprod\&SrcAuth=WosAPI\&KeyUT=WOS:001608875300001\&DestLinkType=FullRecord\&DestApp=WOS_CPL},
      number = {16\_SUPPL},
      journal = {JOURNAL OF CLINICAL ONCOLOGY},
      author = {Ignatiadis, M and Saloustros, ES and Joaquim, A and Grillet, F and Marcou, Y and Pernas, S and Neven, P and Berron, SDB and Ponce-Lorenzo, JJ and Menke-van der Houven Van Oordt, CW and Kelly, CM and Fehr, MK and Razis, E and Foukakis, T and Lambertini, M and Bidard, FC and Poncet, C and Janni, W},
      month = jun,
      year = {2025},
      pages = {TPS620-TPS620},
      published = {1},
      tag = {}
    }
  11. “Optimization of guidelines for Risk Of Recurrence/Prosigna testing using a machine learning model: a Swedish multicenter study.”.
    U. Kjallquist et al.
    Breast, vol. 82, p. 104489, Aug. 2025

    BIB
    @article{kjallquist_optimization_2025,
      title = {Optimization of guidelines for {Risk} {Of} {Recurrence}/{Prosigna} testing using a machine learning model: a {Swedish} multicenter study.},
      volume = {82},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/40347583},
      doi = {10.1016/j.breast.2025.104489},
      language = {eng},
      journal = {Breast},
      author = {Kjallquist, U and Tsiknakis, N and Acs, B and Margolin, S and Kessler, LE and Levy, S and Ekholm, M and Lundgren, C and Olsson, E and Lindman, H and Valachis, A and Hartman, J and Foukakis, T and Matikas, A},
      month = aug,
      year = {2025},
      note = {Publisher: Netherlands},
      keywords = {Practice Guidelines as Topic},
      pages = {104489},
      published = {1},
      tag = {}
    }
  12. “Prognostic and predictive implications of sterile alpha motif and HD domain-containing protein 1 (SAMHD1) expression in breast cancer.”.
    M. Kouvaraki et al.
    Int J Cancer, vol. 156, no. 8, pp. 1621–1633, Apr. 2025

    BIB
    @article{kouvaraki_prognostic_2025,
      title = {Prognostic and predictive implications of sterile alpha motif and {HD} domain-containing protein 1 ({SAMHD1}) expression in breast cancer.},
      volume = {156},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/39729390},
      doi = {10.1002/ijc.35319},
      language = {eng},
      number = {8},
      journal = {Int J Cancer},
      author = {Kouvaraki, M and Zerdes, I and Sifakis, EG and Sarafidis, M and Matikas, A and Tzoras, E and Kjallquist, U and Stathopoulou, K and Lovrot, J and Alkodsi, A and Hartman, J and Sotiriou, C and Richard, F and Hatschek, T and Herold, N and Bergh, J and Rassidakis, GZ and Foukakis, T},
      month = apr,
      year = {2025},
      note = {Publisher: United States},
      keywords = {Disease-Free Survival},
      pages = {1621-1633},
      published = {1},
      tag = {},
      trial = {tex}
    }
  13. “Computational pathology annotation enhances the resolution and interpretation of breast cancer spatial transcriptomics data.”.
    T. Li et al.
    NPJ Precis Oncol, vol. 9, no. 1, p. 310, Sep. 2025

    BIB
    @article{li_computational_2025,
      title = {Computational pathology annotation enhances the resolution and interpretation of breast cancer spatial transcriptomics data.},
      volume = {9},
      issn = {2397-768X},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/40925915},
      doi = {10.1038/s41698-025-01104-3},
      language = {eng},
      number = {1},
      journal = {NPJ Precis Oncol},
      author = {Li, T and Yang, Q and Acs, B and Sifakis, EG and Toosi, H and Engblom, C and Thrane, K and Lin, Q and Mold, JE and Sun, W and Boyaci, C and Steen, S and Frisen, J and Lagergren, J and Lundeberg, J and Chen, X and Hartman, J},
      month = sep,
      year = {2025},
      note = {Publisher: England},
      pages = {310},
      published = {1},
      tag = {}
    }
  14. “Long-term outcome for neoadjuvant versus adjuvant chemotherapy in early breast cancer and the prognostic impact of nodal therapy response: A population-based study.”.
    X. Liu, L. Eriksson Bergman, C. Boman, T. Foukakis, and A. Matikas.
    Eur J Surg Oncol, vol. 51, no. 3, p. 109587, Mar. 2025

    BIB
    @article{liu_long-term_2025,
      title = {Long-term outcome for neoadjuvant versus adjuvant chemotherapy in early breast cancer and the prognostic impact of nodal therapy response: {A} population-based study.},
      volume = {51},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/39794172},
      doi = {10.1016/j.ejso.2025.109587},
      language = {eng},
      number = {3},
      journal = {Eur J Surg Oncol},
      author = {Liu, X and Eriksson Bergman, L and Boman, C and Foukakis, T and Matikas, A},
      month = mar,
      year = {2025},
      note = {Publisher: England},
      keywords = {Mastectomy},
      pages = {109587},
      published = {1},
      tag = {}
    }
  15. “Prevalence and prognosis of patients with breast cancer eligible for adjuvant abemaciclib or ribociclib: a nationwide population-based study.”.
    X. Liu et al.
    Lancet Regional Health Europe, vol. 59, p. 101471, Dec. 2025

    BIB
    @article{liu_prevalence_2025,
      title = {Prevalence and prognosis of patients with breast cancer eligible for adjuvant abemaciclib or ribociclib: a nationwide population-based study.},
      volume = {59},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/41080912},
      doi = {10.1016/j.lanepe.2025.101471},
      language = {eng},
      journal = {Lancet Regional Health Europe},
      author = {Liu, X and Binicy, B and Acs, B and Eriksson Bergman, L and Loibl, S and Gnant, M and Untch, M and Valachis, A and Bergh, J and Hartman, J and Foukakis, T and Matikas, A},
      month = dec,
      year = {2025},
      note = {Publisher: England},
      keywords = {monarchE},
      pages = {101471},
      published = {1},
      tag = {}
    }
  16. “Benefit from dose-dense adjuvant chemotherapy for breast cancer: subgroup analyses from the randomised phase 3 PANTHER trial.”.
    A. Matikas et al.
    Lancet Regional Health Europe, vol. 49, p. 101162, Feb. 2025

    BIB
    @article{matikas_benefit_2025,
      title = {Benefit from dose-dense adjuvant chemotherapy for breast cancer: subgroup analyses from the randomised phase 3 {PANTHER} trial.},
      volume = {49},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/39703564},
      doi = {10.1016/j.lanepe.2024.101162},
      language = {eng},
      journal = {Lancet Regional Health Europe},
      author = {Matikas, A and Papakonstantinou, A and Loibl, S and Steger, GG and Untch, M and Johansson, H and Tsiknakis, N and Hellstrom, M and Greil, R and Mobus, V and Gnant, M and Bergh, J and Foukakis, T},
      month = feb,
      year = {2025},
      note = {Publisher: England},
      keywords = {STEPP},
      pages = {101162},
      published = {1},
      tag = {},
      trial = {panther}
    }
  17. “Randomised trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: a study protocol of ARIADNE.”.
    A. Matikas et al.
    BMJ Open, vol. 15, no. 8, p. e102626, Aug. 2025

    BIB
    @article{matikas_randomised_2025,
      title = {Randomised trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for {HER2}-positive breast cancer: a study protocol of {ARIADNE}.},
      volume = {15},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/40866060},
      doi = {10.1136/bmjopen-2025-102626},
      language = {eng},
      number = {8},
      journal = {BMJ Open},
      author = {Matikas, A and Naume, B and Wildiers, H and Sonke, G and Dieci, MV and Karakatsanis, A and Andersson, A and Barnekow, E and Kessler, LE and Einbeigi, Z and Killander, F and Linderholm, B and Schiza, A and Valachis, A and Nearchou, A and Engebraaten, O and Porojnicu, A and Soland, MH and Mannsaker, B and Raj, SX and Blix, ES and Nordstrand, CS and Lambertini, M and Vernieri, C and Punie, K and Sotiriou, C and Bergh, J and Villacampa, G and Zouzos, A and Hellstrom, M and Hartman, J and Foukakis, T},
      month = aug,
      year = {2025},
      note = {Publisher: England},
      keywords = {Camptothecin},
      pages = {e102626},
      published = {1},
      tag = {},
      trial = {ariadne}
    }
  18. “Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13).”.
    E. L. Mayer et al.
    Ann Oncol, Oct. 2025

    BIB
    @article{mayer_palbociclib_2025,
      title = {Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase {III} {PALLAS} trial ({ABCSG}-42/{AFT}-05/{PrE0109}/{BIG}-14-13).},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/41110701},
      doi = {10.1016/j.annonc.2025.10.003},
      language = {eng},
      journal = {Ann Oncol},
      author = {Mayer, EL and Hlauschek, D and Gnant, M and O'Brien, PJ and Bellet-Ezquerra, M and Goetz, MP and Ruiz-Borrego, M and Chan, A and Clifton, K and Egle, D and Lake, D and Cabrera, P and Mamounas, T and Pristauz-Telsnigg, G and Dayao, Z and Gil Gil, M and Cameron, D and Traina, T and Morris, PG and Sabanathan, D and Rinnerthaler, G and Meisel, J and Prat, A and Wolff, AC and Tseng, L-M and Isaacs, C and Singer, CF and Rubovszky, G and Foukakis, T and Jassem, J and Winer, EP and Vetter, M and Federmann, J and Metzger, O and Schurmans, C and Gauthier, E and Lu, DR and Fesl, C and Dueck, A and DeMichele, A},
      month = oct,
      year = {2025},
      note = {Publisher: England},
      keywords = {palbociclib},
      published = {1},
      tag = {}
    }
  19. “Long-term trastuzumab safety in tailored dose-dense anthracycline containing adjuvant chemotherapy in the PANTHER phase III trial.”.
    A. Papakonstantinou, M. Hellstrom, A. Andersson, P. Malmstrom, J. C. S. Bergh, and T. Foukakis.
    Journal of Clinical Oncology, vol. 43, no. 16_suppl, pp. 12024–12024, Jun. 2025

    BIB
    @article{papakonstantinou_long-term_2025,
      title = {Long-term trastuzumab safety in tailored dose-dense anthracycline containing adjuvant chemotherapy in the {PANTHER} phase {III} trial.},
      volume = {43},
      issn = {0732-183X},
      journal = {Journal of Clinical Oncology},
      author = {Papakonstantinou, A and Hellstrom, M and Andersson, A and Malmstrom, P and Bergh, JCS and Foukakis, T},
      month = jun,
      year = {2025},
      note = {Publisher: American Society of Clinical Oncology (ASCO)},
      keywords = {Cancer},
      pages = {12024-12024},
      published = {1},
      tag = {}
    }
  20. “Neoadjuvant treatment of HER2-positive breast cancer: has the era of antibody-drug conjugates arrived?”.
    A. Papakonstantinou and T. Foukakis.
    Ann Oncol, vol. 36, no. 6, pp. 603–605, Jun. 2025

    BIB
    @article{papakonstantinou_neoadjuvant_2025,
      title = {Neoadjuvant treatment of {HER2}-positive breast cancer: has the era of antibody-drug conjugates arrived?},
      volume = {36},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/40194621},
      doi = {10.1016/j.annonc.2025.03.022},
      language = {eng},
      number = {6},
      journal = {Ann Oncol},
      author = {Papakonstantinou, A and Foukakis, T},
      month = jun,
      year = {2025},
      note = {Publisher: England},
      pages = {603-605},
      published = {1},
      tag = {}
    }
  21. “Transcriptomic profiles of endocrine-resistant breast cancer.”.
    C. Schagerholm Stanev et al.
    BMC Cancer, vol. 25, no. 1, p. 1556, Oct. 2025

    BIB
    @article{schagerholm_stanev_transcriptomic_2025,
      title = {Transcriptomic profiles of endocrine-resistant breast cancer.},
      volume = {25},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/41083955},
      doi = {10.1186/s12885-025-14826-1},
      language = {eng},
      number = {1},
      journal = {BMC Cancer},
      author = {Schagerholm Stanev, C and Sifakis, EG and Hases, L and Chen, X and Williams, C and Robertson, S and Hartman, J},
      month = oct,
      year = {2025},
      note = {Publisher: England},
      keywords = {Estrogen Receptor alpha},
      pages = {1556},
      published = {1},
      tag = {}
    }
  22. “Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer.”.
    E. Shinn et al.
    Breast Cancer Research and Treatment, vol. 211, no. 2, pp. 385–397, Jun. 2025

    BIB
    @article{shinn_impact_2025,
      title = {Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized {PALLAS} randomized trial in patients with early breast cancer.},
      volume = {211},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/40140172},
      doi = {10.1007/s10549-025-07653-2},
      language = {eng},
      number = {2},
      journal = {Breast Cancer Research and Treatment},
      author = {Shinn, E and Zahrieh, D and DeMichele, A and Zdenkowski, N and Lemieux, J and Mao, J and Bjelic-Radisic, V and Naughton, MJ and Pfeiler, G and Gelmon, K and Balko, JM and Egle, D and Zoppoli, G and Traina, T and Jimenez, MM and Novoa, SA and Haddad, T and Chan, A and Ring, A and Wolff, A and Symmans, WF and Ponce Lorenzo, J and Sabanathan, D and Burstein, HJ and Nowecki, ZI and Pristauz-Telsnigg, G and Brufsky, A and Bellet-Ezquerra, M and Foukakis, T and Novik, Y and Rubovszky, G and Singer, CF and Muehlbacher, K and Filho, OM and Goulioti, T and Law, E and Partridge, AH and Carey, LA and Zoroufy, A and Hlauschek, D and Fesl, C and Mayer, EL and Gnant, M},
      month = jun,
      year = {2025},
      note = {Publisher: Netherlands},
      keywords = {Medication Adherence},
      pages = {385-397},
      published = {1},
      tag = {}
    }
  23. “Pathological response to pembrolizumab-based neoadjuvant therapy in ER-low vs. ER-zero breast cancer: a Swedish population-based cohort study.”.
    S. Steen et al.
    Breast Cancer Research, vol. 27, no. 1, p. 213, Nov. 2025

    BIB
    @article{steen_pathological_2025,
      title = {Pathological response to pembrolizumab-based neoadjuvant therapy in {ER}-low vs. {ER}-zero breast cancer: a {Swedish} population-based cohort study.},
      volume = {27},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/41316480},
      doi = {10.1186/s13058-025-02179-3},
      language = {eng},
      number = {1},
      journal = {Breast Cancer Research},
      author = {Steen, S and Karlsson, E and Bjornheden, I and Rask, G and Thurfjell, V and Nobin, H and Kolodziej, B and Boden, A and Bauer, A and Einefors, R and Nilsson, P and Zerdes, I and Papakonstantinou, A and Foukakis, T and Fredriksson, I and Rantalainen, M and Colon-Cervantes, E and Kovacs, A and Acs, B and Hartman, J},
      month = nov,
      year = {2025},
      note = {Publisher: England},
      keywords = {Triple negative breast cancer},
      pages = {213},
      published = {1},
      tag = {}
    }
  24. “The interplay between the immune response and neoadjuvant therapy in breast cancer.”.
    N. Thomas, T. Foukakis, and K. Willard-Gallo.
    Front Oncol, vol. 15, p. 1469982, 2025

    BIB
    @article{thomas_interplay_2025,
      title = {The interplay between the immune response and neoadjuvant therapy in breast cancer.},
      volume = {15},
      issn = {2234-943X},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/40421087},
      doi = {10.3389/fonc.2025.1469982},
      language = {eng},
      journal = {Front Oncol},
      author = {Thomas, N and Foukakis, T and Willard-Gallo, K},
      year = {2025},
      note = {Publisher: Switzerland},
      keywords = {tumor infiltrating lymphocytes},
      pages = {1469982},
      published = {1},
      tag = {}
    }
  25. “Prognostic significance of tumour Ki-67 dynamics during neoadjuvant treatment in patients with breast cancer: a population-based cohort study.”.
    M. A. Toli et al.
    Lancet Regional Health Europe, vol. 58, p. 101432, Nov. 2025

    BIB
    @article{toli_prognostic_2025,
      title = {Prognostic significance of tumour {Ki}-67 dynamics during neoadjuvant treatment in patients with breast cancer: a population-based cohort study.},
      volume = {58},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/40980814},
      doi = {10.1016/j.lanepe.2025.101432},
      language = {eng},
      journal = {Lancet Regional Health Europe},
      author = {Toli, MA and Liu, X and Massa, D and Lando, S and Boman, C and Tsiknakis, N and Tranchell, C and Papakonstantinou, A and Fotia, G and Vernieri, C and Guarneri, V and Bergh, J and Dieci, MV and Bergman, LE and Matikas, A and Foukakis, T},
      month = nov,
      year = {2025},
      note = {Publisher: England},
      keywords = {Survival},
      pages = {101432},
      published = {1},
      tag = {},
      trial = {panther}
    }
  26. “Gene Expression patterns in early ER+/HER2-breast cancer treated with neoadjuvant chemotherapy versus CDK4/6 inhibitor therapy: results from the Swedish PREDIX Luminal B trial”.
    E. Tzoras et al.
    CLINICAL Cancer Research, vol. 31, no. 12, pp. P20130–P20130, Jun. 2025

    BIB
    @article{tzoras_gene_2025,
      title = {Gene {Expression} patterns in early {ER}+/{HER2}-breast cancer treated with neoadjuvant chemotherapy versus {CDK4}/6 inhibitor therapy: results from the {Swedish} {PREDIX} {Luminal} {B} trial},
      volume = {31},
      issn = {1078-0432},
      url = {https://www.webofscience.com/api/gateway?GWVersion=2\&SrcApp=kielementsprod\&SrcAuth=WosAPI\&KeyUT=WOS:001551270100014\&DestLinkType=FullRecord\&DestApp=WOS_CPL},
      doi = {10.1158/1557-3265.SABCS24-P2-01-30},
      number = {12},
      journal = {CLINICAL Cancer Research},
      author = {Tzoras, E and Sarafidis, M and Sifakis, EG and Salgkamis, D and Acs, B and Sun, W and Zerdes, I and Wang, K and Bergh, J and Hatschek, T and Matikas, A and Foukakis, T},
      month = jun,
      year = {2025},
      pages = {P20130-P20130},
      published = {1},
      tag = {}
    }
  27. “BreastSubtypeR: a unified R/Bioconductor package for intrinsic molecular subtyping in breast Cancer Research.”.
    Q. Yang, J. Hartman, and E. G. Sifakis.
    NAR Genom Bioinform, vol. 7, no. 4, p. lqaf131, Dec. 2025

    BIB
    @article{yang_breastsubtyper_2025,
      title = {{BreastSubtypeR}: a unified {R}/{Bioconductor} package for intrinsic molecular subtyping in breast Cancer Research.},
      volume = {7},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/41064593},
      doi = {10.1093/nargab/lqaf131},
      language = {eng},
      number = {4},
      journal = {NAR Genom Bioinform},
      author = {Yang, Q and Hartman, J and Sifakis, EG},
      month = dec,
      year = {2025},
      note = {Publisher: England},
      keywords = {Reproducibility of Results},
      pages = {lqaf131},
      published = {1},
      tag = {}
    }
  28. “Combined immune-stromal score (CISS) is prognostic in early ER-positive/HER2-positive breast cancer”.
    Q. Yang et al.
    ANNALS OF ONCOLOGY, vol. 36, Sep. 2025

    BIB
    @article{yang_combined_2025,
      title = {Combined immune-stromal score ({CISS}) is prognostic in early {ER}-positive/{HER2}-positive breast cancer},
      volume = {36},
      issn = {0923-7534},
      url = {https://www.webofscience.com/api/gateway?GWVersion=2\&SrcApp=kielementsprod\&SrcAuth=WosAPI\&KeyUT=WOS:001632261800142\&DestLinkType=FullRecord\&DestApp=WOS_CPL},
      doi = {10.1016/j.annonc.2025.08.873},
      journal = {ANNALS OF ONCOLOGY},
      author = {Yang, Q and Ronnlund, C and Schagerholm, C and Chen, X and Foukakis, T and Fredriksson, I and Robertson, S and Sifakis, EG and Wang, K and Hartman, J},
      month = sep,
      year = {2025},
      published = {1},
      tag = {}
    }
  29. “Comprehensive genome profiling for treatment decisions in patients with metastatic tumors: real-world evidence meta-analysis and registry data implementation.”.
    I. Zerdes et al.
    J Natl Cancer Inst, vol. 117, no. 6, pp. 1117–1124, Jun. 2025

    BIB
    @article{zerdes_comprehensive_2025,
      title = {Comprehensive genome profiling for treatment decisions in patients with metastatic tumors: real-world evidence meta-analysis and registry data implementation.},
      volume = {117},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/39842854},
      doi = {10.1093/jnci/djaf015},
      language = {eng},
      number = {6},
      journal = {J Natl Cancer Inst},
      author = {Zerdes, I and Filis, P and Fountoukidis, G and El-Naggar, AI and Kalofonou, F and D'Alessio, A and Pouptsis, A and Foukakis, T and Pentheroudakis, G and Ahlgren, J and Smith, D and Valachis, A},
      month = jun,
      year = {2025},
      note = {Publisher: United States},
      keywords = {Clinical Decision-Making},
      pages = {1117-1124},
      published = {1},
      tag = {}
    }
  30. “Machine learning-based spatial characterization of tumor-immune microenvironment in the EORTC 10994/BIG 1-00 early breast cancer trial.”.
    I. Zerdes et al.
    NPJ Breast Cancer, vol. 11, no. 1, p. 23, Mar. 2025

    BIB
    @article{zerdes_machine_2025,
      title = {Machine learning-based spatial characterization of tumor-immune microenvironment in the {EORTC} 10994/{BIG} 1-00 early breast cancer trial.},
      volume = {11},
      issn = {2374-4677},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/40055382},
      doi = {10.1038/s41523-025-00730-1},
      language = {eng},
      number = {1},
      journal = {NPJ Breast Cancer},
      author = {Zerdes, I and Matikas, A and Mezheyeuski, A and Manikis, G and Acs, B and Johansson, H and Boyaci, C and Boman, C and Poncet, C and Ignatiadis, M and Bai, Y and Rimm, DL and Cameron, D and Bonnefoi, H and Bergh, J and MacGrogan, G and Foukakis, T},
      month = mar,
      year = {2025},
      note = {Publisher: United States},
      pages = {23},
      published = {1},
      tag = {}
    }
  31. “Effect of needle size on outcomes of vacuum-assisted excision of breast lesions. A randomized controlled trial.”.
    A. Zouzos, I. Fredriksson, A. Karakatsanis, I. Aristokleous, T. Foukakis, and F. Strand.
    Eur J Radiol, vol. 183, p. 111895, Feb. 2025

    BIB
    @article{zouzos_effect_2025,
      title = {Effect of needle size on outcomes of vacuum-assisted excision of breast lesions. {A} randomized controlled trial.},
      volume = {183},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/39724795},
      doi = {10.1016/j.ejrad.2024.111895},
      language = {eng},
      journal = {Eur J Radiol},
      author = {Zouzos, A and Fredriksson, I and Karakatsanis, A and Aristokleous, I and Foukakis, T and Strand, F},
      month = feb,
      year = {2025},
      note = {Publisher: Ireland},
      keywords = {Breast},
      pages = {111895},
      published = {1},
      tag = {}
    }
  32. “Patient experience and healthcare cost aspects of vacuum-assisted excision of breast lesions. A report from the Swedish VAE randomized clinical trial.”.
    A. Zouzos, I. Fredriksson, A. Karakatsanis, T. Foukakis, and F. Strand.
    Eur J Radiol, vol. 186, p. 112062, May 2025

    BIB
    @article{zouzos_patient_2025,
      title = {Patient experience and healthcare cost aspects of vacuum-assisted excision of breast lesions. {A} report from the {Swedish} {VAE} randomized clinical trial.},
      volume = {186},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/40127593},
      doi = {10.1016/j.ejrad.2025.112062},
      language = {eng},
      journal = {Eur J Radiol},
      author = {Zouzos, A and Fredriksson, I and Karakatsanis, A and Foukakis, T and Strand, F},
      month = may,
      year = {2025},
      note = {Publisher: Ireland},
      keywords = {Aged},
      pages = {112062},
      published = {1},
      tag = {}
    }
  33. “Variation in Pathological Appearance Across Repeated Sampling from Probably Benign Breast Lesions”.
    A. Zouzos, I. Fredriksson, T. Foukakis, J. Hartman, and F. Strand.
    Biomedicines, vol. 13, no. 12, p. 2897, Nov. 2025

    BIB
    @article{zouzos_variation_2025,
      title = {Variation in {Pathological} {Appearance} {Across} {Repeated} {Sampling} from {Probably} {Benign} {Breast} {Lesions}},
      volume = {13},
      issn = {2227-9059},
      doi = {10.3390/biomedicines13122897},
      number = {12},
      journal = {Biomedicines},
      author = {Zouzos, A and Fredriksson, I and Foukakis, T and Hartman, J and Strand, F},
      month = nov,
      year = {2025},
      note = {Publisher: MDPI},
      keywords = {Cancer},
      pages = {2897},
      published = {1},
      tag = {}
    }

2024

  1. “A population-based study on trajectories of HER2 status during neoadjuvant chemotherapy for early breast cancer and metastatic progression.”.
    C. Boman et al.
    Br J Cancer, vol. 131, no. 4, pp. 718–728, Sep. 2024

    BIB
    @article{boman_population-based_2024,
      title = {A population-based study on trajectories of {HER2} status during neoadjuvant chemotherapy for early breast cancer and metastatic progression.},
      volume = {131},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/38942987},
      doi = {10.1038/s41416-024-02777-6},
      language = {eng},
      number = {4},
      journal = {Br J Cancer},
      author = {Boman, C and Liu, X and Eriksson Bergman, L and Sun, W and Tranchell, C and Toli, MA and Acs, B and Bergh, J and Foukakis, T and Matikas, A},
      month = sep,
      year = {2024},
      note = {Publisher: England},
      keywords = {Neoplasm, Residual},
      pages = {718-728},
      published = {1},
      tag = {}
    }
  2. “Identification of a Notch transcriptomic signature for breast cancer.”.
    E.-B. Braune et al.
    Breast Cancer Research, vol. 26, no. 1, p. 4, Jan. 2024

    BIB
    @article{braune_identification_2024,
      title = {Identification of a {Notch} transcriptomic signature for breast cancer.},
      volume = {26},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/38172915},
      doi = {10.1186/s13058-023-01757-7},
      language = {eng},
      number = {1},
      journal = {Breast Cancer Research},
      author = {Braune, E-B and Geist, F and Tang, X and Kalari, K and Boughey, J and Wang, L and Leon-Ferre, RA and D'Assoro, AB and Ingle, JN and Goetz, MP and Kreis, J and Wang, K and Foukakis, T and Seshire, A and Wienke, D and Lendahl, U},
      month = jan,
      year = {2024},
      note = {Publisher: England},
      keywords = {Transcriptome},
      pages = {4},
      published = {1},
      tag = {}
    }
  3. “Clinically relevant gene signatures provide independent prognostic information in older breast cancer patients.”.
    M. Castresana-Aguirre, A. Johansson, A. Matikas, T. Foukakis, L. S. Lindstrom, and N. P. Tobin.
    Breast Cancer Research, vol. 26, no. 1, p. 38, Mar. 2024

    BIB
    @article{castresana-aguirre_clinically_2024,
      title = {Clinically relevant gene signatures provide independent prognostic information in older breast cancer patients.},
      volume = {26},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/38454481},
      doi = {10.1186/s13058-024-01797-7},
      language = {eng},
      number = {1},
      journal = {Breast Cancer Research},
      author = {Castresana-Aguirre, M and Johansson, A and Matikas, A and Foukakis, T and Lindstrom, LS and Tobin, NP},
      month = mar,
      year = {2024},
      note = {Publisher: England},
      keywords = {Kaplan-Meier Estimate},
      pages = {38},
      published = {1},
      tag = {}
    }
  4. “Grading the evidence for physical activity and all outcomes in cancer survivors: An umbrella review of more than 700 meta-analytic associations”.
    P. Filis et al.
    ANNALS OF ONCOLOGY, vol. 35, pp. S1112–S1112, Sep. 2024

    BIB
    @article{filis_grading_2024,
      title = {Grading the evidence for physical activity and all outcomes in cancer survivors: {An} umbrella review of more than 700 meta-analytic associations},
      volume = {35},
      issn = {0923-7534},
      url = {https://www.webofscience.com/api/gateway?GWVersion=2\&SrcApp=kielementsprod\&SrcAuth=WosAPI\&KeyUT=WOS:001326612902524\&DestLinkType=FullRecord\&DestApp=WOS_CPL},
      doi = {10.1016/j.annonc.2024.08.2126},
      journal = {ANNALS OF ONCOLOGY},
      author = {Filis, P and Markozannes, G and Chan, D and Mauri, D and Foukakis, T and Matikas, A and Droufakou, S and Pentheroudakis, G and Tsilidis, K},
      month = sep,
      year = {2024},
      pages = {S1112-S1112},
      published = {1},
      tag = {}
    }
  5. “A randomized trial of trastuzumab deruxtecan and biologydriven selection of neoadjuvant treatment for HER2-positive breast cancer (ARIADNE)”.
    T. Foukakis et al.
    ANNALS OF ONCOLOGY, vol. 35, pp. S356–S356, Sep. 2024

    BIB
    @article{foukakis_randomized_2024,
      title = {A randomized trial of trastuzumab deruxtecan and biologydriven selection of neoadjuvant treatment for {HER2}-positive breast cancer ({ARIADNE})},
      volume = {35},
      issn = {0923-7534},
      url = {https://www.webofscience.com/api/gateway?GWVersion=2\&SrcApp=kielementsprod\&SrcAuth=WosAPI\&KeyUT=WOS:001326612900335\&DestLinkType=FullRecord\&DestApp=WOS_CPL},
      doi = {10.1016/j.annonc.2024.08.278},
      journal = {ANNALS OF ONCOLOGY},
      author = {Foukakis, T and Naume, B and Karakatsanis, A and Andersson, A and Barnekow, E and Kessler, LE and Einbeigi, Z and Engebraten, O and Killander, F and Linderholm, BK and Schiza, A and Valachis, A and Bergh, J and Villacampa, G and Zouzos, A and Hellstrom, M and Hartman, J and Matikas, A},
      month = sep,
      year = {2024},
      pages = {S356-S356},
      published = {1},
      tag = {}
    }
  6. “EORTC-2129-BCG: Elacestrant for treating ER+/HER2-breast cancer patients with ctDNA relapse (TREAT ctDNA)”.
    M. Ignatiadis et al.
    ANNALS OF ONCOLOGY, vol. 35, pp. S355–S356, Sep. 2024

    BIB
    @article{ignatiadis_eortc-2129-bcg_2024,
      title = {{EORTC}-2129-{BCG}: {Elacestrant} for treating {ER}+/{HER2}-breast cancer patients with {ctDNA} relapse ({TREAT} {ctDNA})},
      volume = {35},
      issn = {0923-7534},
      url = {https://www.webofscience.com/api/gateway?GWVersion=2\&SrcApp=kielementsprod\&SrcAuth=WosAPI\&KeyUT=WOS:001326612900334\&DestLinkType=FullRecord\&DestApp=WOS_CPL},
      doi = {10.1016/j.annonc.2024.08.277},
      journal = {ANNALS OF ONCOLOGY},
      author = {Ignatiadis, M and Saloustros, E and Joaquim, A and Casas, JG and Kelly, CM and Razis, E and Lambertini, M and Foukakis, T and Fehr, M and van Oordt, CWM-VDH and Crestani, TA and Simon, SP and Bussels, B and Hanssens, M and Neven, P and Xenophontos, E and Meyskens, T and Bidard, FC and Poncet, C and Janni, W},
      month = sep,
      year = {2024},
      pages = {S355-S356},
      published = {1},
      tag = {}
    }
  7. “Estimating benefit from dose dense adjuvant chemotherapy for early breast cancer in the PANTHER randomized phase 3 trial.”.
    A. Matikas et al.
    Journal of Clinical Oncology, vol. 42, no. 16_suppl, pp. 521–521, Jun. 2024

    BIB
    @article{matikas_estimating_2024,
      title = {Estimating benefit from dose dense adjuvant chemotherapy for early breast cancer in the {PANTHER} randomized phase 3 trial.},
      volume = {42},
      issn = {0732-183X},
      journal = {Journal of Clinical Oncology},
      author = {Matikas, A and Gnant, M and Johansson, H and Untch, M and Tsiknakis, N and Greil, R and Loibl, S and Foukakis, T and Bergh, JCS},
      month = jun,
      year = {2024},
      note = {Publisher: American Society of Clinical Oncology (ASCO)},
      keywords = {Cancer},
      pages = {521-521},
      published = {1},
      tag = {}
    }
  8. “Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial.”.
    A. Matikas et al.
    Journal of Clinical Oncology, vol. 42, no. 26, pp. 3077–3082, Sep. 2024

    BIB
    @article{matikas_tailored_2024,
      title = {Tailored {Dose}-{Dense} {Versus} {Standard} {Adjuvant} {Chemotherapy} for {High}-{Risk} {Early} {Breast} {Cancer}: {End}-of-{Study} {Results} of the {Randomized} {PANTHER} {Trial}.},
      volume = {42},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/39018515},
      doi = {10.1200/JCO.24.00178},
      language = {eng},
      number = {26},
      journal = {Journal of Clinical Oncology},
      author = {Matikas, A and Mobus, V and Greil, R and Andersson, A and Steger, GG and Untch, M and Fornander, T and Malmstrom, P and Schmatloch, S and Johansson, H and Hellstrom, M and Brandberg, Y and Gnant, M and Loibl, S and Foukakis, T and Bergh, J and SweBCG, ABCSG and {GBG}},
      month = sep,
      year = {2024},
      note = {Publisher: United States},
      keywords = {Disease-Free Survival},
      pages = {3077-3082},
      published = {1},
      tag = {},
      trial = {panther}
    }
  9. “Gonadotropin Releasing Hormone agonist (GnRHa) during chemotherapy and post-cancer childbirths - a Nationwide population-based cohort study of 24,922 women diagnosed with cancer in Sweden.”.
    K. A. Rodriguez-Wallberg et al.
    EClinicalMedicine, vol. 67, p. 102335, Jan. 2024

    BIB
    @article{rodriguez-wallberg_gonadotropin_2024,
      title = {Gonadotropin {Releasing} {Hormone} agonist ({GnRHa}) during chemotherapy and post-cancer childbirths - a {Nationwide} population-based cohort study of 24,922 women diagnosed with cancer in {Sweden}.},
      volume = {67},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/38314058},
      doi = {10.1016/j.eclinm.2023.102335},
      language = {eng},
      journal = {EClinicalMedicine},
      author = {Rodriguez-Wallberg, KA and Kieler, H and Foukakis, T and Li, J and Gissler, M and Oberg, AS and Bergh, J and Lundberg, FE},
      month = jan,
      year = {2024},
      note = {Publisher: England},
      pages = {102335},
      published = {1},
      tag = {}
    }
  10. “Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer.”.
    C. Ronnlund et al.
    Breast Cancer Research, vol. 26, no. 1, p. 24, Feb. 2024

    BIB
    @article{ronnlund_prognostic_2024,
      title = {Prognostic impact of {HER2} biomarker levels in trastuzumab-treated early {HER2}-positive breast cancer.},
      volume = {26},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/38321542},
      doi = {10.1186/s13058-024-01779-9},
      language = {eng},
      number = {1},
      journal = {Breast Cancer Research},
      author = {Ronnlund, C and Sifakis, EG and Schagerholm, C and Yang, Q and Karlsson, E and Chen, X and Foukakis, T and Weidler, J and Bates, M and Fredriksson, I and Robertson, S and Hartman, J},
      month = feb,
      year = {2024},
      note = {Publisher: England},
      keywords = {Messenger, RNA},
      pages = {24},
      published = {1},
      tag = {}
    }
  11. “Systematic review and feasibility study on pre-analytical factors and genomic analyses on archival formalin-fixed paraffin-embedded breast cancer tissue.”.
    D. Salgkamis et al.
    Sci Rep, vol. 14, no. 1, p. 18275, Aug. 2024

    BIB
    @article{salgkamis_systematic_2024,
      title = {Systematic review and feasibility study on pre-analytical factors and genomic analyses on archival formalin-fixed paraffin-embedded breast cancer tissue.},
      volume = {14},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/39107471},
      doi = {10.1038/s41598-024-69285-8},
      language = {eng},
      number = {1},
      journal = {Sci Rep},
      author = {Salgkamis, D and Sifakis, EG and Agartz, S and Wirta, V and Hartman, J and Bergh, J and Foukakis, T and Matikas, A and Zerdes, I},
      month = aug,
      year = {2024},
      note = {Publisher: England},
      keywords = {Gene Expression Profiling},
      pages = {18275},
      published = {1},
      tag = {}
    }
  12. “AI-based selection of individuals for supplemental MRI in population-based breast cancer screening: the randomized ScreenTrustMRI trial.”.
    M. Salim et al.
    Nat Med, vol. 30, no. 9, pp. 2623–2630, Sep. 2024

    BIB
    @article{salim_ai-based_2024,
      volume = {30},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/38977914},
      doi = {10.1038/s41591-024-03093-5},
      language = {eng},
      number = {9},
      journal = {Nat Med},
      author = {Salim, M and Liu, Y and Sorkhei, M and Ntoula, D and Foukakis, T and Fredriksson, I and Wang, Y and Eklund, M and Azizpour, H and Smith, K and Strand, F},
      month = sep,
      year = {2024},
      note = {Publisher: United States},
      keywords = {Patient Selection},
      pages = {2623-2630},
      published = {1},
      tag = {}
    }
  13. “PIK3CA mutations in endocrine-resistant breast cancer.”.
    C. Schagerholm, S. Robertson, H. Toosi, E. G. Sifakis, and J. Hartman.
    Sci Rep, vol. 14, no. 1, p. 12542, May 2024

    BIB
    @article{schagerholm_pik3ca_2024,
      title = {{PIK3CA} mutations in endocrine-resistant breast cancer.},
      volume = {14},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/38822093},
      doi = {10.1038/s41598-024-62664-1},
      language = {eng},
      number = {1},
      journal = {Sci Rep},
      author = {Schagerholm, C and Robertson, S and Toosi, H and Sifakis, EG and Hartman, J},
      month = may,
      year = {2024},
      note = {Publisher: England},
      keywords = {ErbB-2, Receptor},
      pages = {12542},
      published = {1},
      tag = {}
    }
  14. “Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.”.
    P. Schmid et al.
    N Engl J Med, vol. 391, no. 21, pp. 1981–1991, Nov. 2024

    BIB
    @article{schmid_overall_2024,
      title = {Overall {Survival} with {Pembrolizumab} in {Early}-{Stage} {Triple}-{Negative} {Breast} {Cancer}.},
      volume = {391},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/39282906},
      doi = {10.1056/NEJMoa2409932},
      language = {eng},
      number = {21},
      journal = {N Engl J Med},
      author = {Schmid, P and Cortes, J and Dent, R and McArthur, H and Pusztai, L and Kummel, S and Denkert, C and Park, YH and Hui, R and Harbeck, N and Takahashi, M and Im, S-A and Untch, M and Fasching, PA and Mouret-Reynier, M-A and Foukakis, T and Ferreira, M and Cardoso, F and Zhou, X and Karantza, V and Tryfonidis, K and Aktan, G and O'Shaughnessy, J and Investigators, KEYNOTE-522},
      month = nov,
      year = {2024},
      note = {Publisher: United States},
      keywords = {Double-Blind Method},
      pages = {1981-1991},
      published = {1},
      tag = {}
    }
  15. “Ensuring Model Fairness via Stratified Training: TP53 Mutation Prediction with Estrogen Receptor Stratification in Breast Histopathology.”.
    N. Tsiknakis et al.
    Annu Int Conf IEEE Eng Med Biol Soc, 2024, vol. 2024, pp. 1–5

    BIB
    @inproceedings{tsiknakis_ensuring_2024,
      title = {Ensuring {Model} {Fairness} via {Stratified} {Training}: {TP53} {Mutation} {Prediction} with {Estrogen} {Receptor} {Stratification} in {Breast} {Histopathology}.},
      volume = {2024},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/40039878},
      doi = {10.1109/EMBC53108.2024.10782012},
      language = {eng},
      booktitle = {Annu {Int} {Conf} {IEEE} {Eng} {Med} {Biol} {Soc}},
      publisher = {United States},
      author = {Tsiknakis, N and Wang, K and Salgkamis, D and Tzoras, E and Manikis, GC and Sifakis, E and Bergh, J and Zerdes, I and Marias, K and Matikas, A and Foukakis, T},
      month = jul,
      year = {2024},
      keywords = {Female},
      pages = {1-5},
      published = {1},
      tag = {}
    }
  16. “Unveiling the Power of Model-Agnostic Multiscale Analysis for Enhancing Artificial Intelligence Models in Breast Cancer Histopathology Images.”.
    N. Tsiknakis et al.
    IEEE J Biomed Health Inform, vol. 28, no. 9, pp. 5312–5322, Sep. 2024

    BIB
    @article{tsiknakis_unveiling_2024,
      title = {Unveiling the {Power} of {Model}-{Agnostic} {Multiscale} {Analysis} for {Enhancing} {Artificial} {Intelligence} {Models} in {Breast} {Cancer} {Histopathology} {Images}.},
      volume = {28},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/38865229},
      doi = {10.1109/JBHI.2024.3413533},
      language = {eng},
      number = {9},
      journal = {IEEE J Biomed Health Inform},
      author = {Tsiknakis, N and Manikis, G and Tzoras, E and Salgkamis, D and Vidal, JM and Wang, K and Zaridis, D and Sifakis, E and Zerdes, I and Bergh, J and Hartman, J and Acs, B and Marias, K and Foukakis, T},
      month = sep,
      year = {2024},
      note = {Publisher: United States},
      keywords = {Breast},
      pages = {5312-5322},
      published = {1},
      tag = {}
    }
  17. “The analytical and clinical validity of AI algorithms to score TILs in TNBC: can we use different machine learning models interchangeably?”.
    J. M. Vidal et al.
    EClinicalMedicine, vol. 78, p. 102928, Dec. 2024

    BIB
    @article{vidal_analytical_2024,
      title = {The analytical and clinical validity of {AI} algorithms to score {TILs} in {TNBC}: can we use different machine learning models interchangeably?},
      volume = {78},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/39634035},
      doi = {10.1016/j.eclinm.2024.102928},
      language = {eng},
      journal = {EClinicalMedicine},
      author = {Vidal, JM and Tsiknakis, N and Staaf, J and Bosch, A and Ehinger, A and Nimeus, E and Salgado, R and Bai, Y and Rimm, DL and Hartman, J and Acs, B},
      month = dec,
      year = {2024},
      note = {Publisher: England},
      keywords = {Tumor infiltrating lymphocytes},
      pages = {102928},
      published = {1},
      tag = {}
    }
  18. “Longitudinal molecular profiling elucidates immunometabolism dynamics in breast cancer.”.
    K. Wang et al.
    Nature Communications, vol. 15, no. 1, p. 3837, May 2024

    BIB
    @article{wang_longitudinal_2024,
      title = {Longitudinal molecular profiling elucidates immunometabolism dynamics in breast cancer.},
      volume = {15},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/38714665},
      doi = {10.1038/s41467-024-47932-y},
      language = {eng},
      number = {1},
      journal = {Nature Communications},
      author = {Wang, K and Zerdes, I and Johansson, HJ and Sarhan, D and Sun, Y and Kanellis, DC and Sifakis, EG and Mezheyeuski, A and Liu, X and Loman, N and Hedenfalk, I and Bergh, J and Bartek, J and Hatschek, T and Lehtio, J and Matikas, A and Foukakis, T},
      month = may,
      year = {2024},
      note = {Publisher: England},
      keywords = {Single-Cell Analysis},
      pages = {3837},
      published = {1},
      tag = {},
      trial = {promix}
    }
  19. “Comprehensive cancer genome profiling as supportive tool for treatment decision-making in patients with metastatic solid tumors: Real-world evidence-based meta-analysis and nationwide cancer registry data implementation”.
    I. Zerdes et al.
    ANNALS OF ONCOLOGY, vol. 35, pp. S262–S262, Sep. 2024

    BIB
    @article{zerdes_comprehensive_2024,
      volume = {35},
      issn = {0923-7534},
      url = {https://www.webofscience.com/api/gateway?GWVersion=2\&SrcApp=kielementsprod\&SrcAuth=WosAPI\&KeyUT=WOS:001326612900121\&DestLinkType=FullRecord\&DestApp=WOS_CPL},
      doi = {10.1016/j.annonc.2024.08.129},
      journal = {ANNALS OF ONCOLOGY},
      author = {Zerdes, I and Filis, P and Fountoukidis, G and El-Naggar, AI and Kalofonou, F and D'Alessio, A and Pouptsis, A and Foukakis, T and Pentheroudakis, G and Ahlgren, J and Smith, D and Valachis, A},
      month = sep,
      year = {2024},
      pages = {S262-S262},
      published = {1},
      tag = {}
    }
  20. “The role of serum thymidine kinase 1 activity in neoadjuvant-treated HER2-positive breast cancer: biomarker analysis from the Swedish phase II randomized PREDIX HER2 trial.”.
    Y. Zhu et al.
    Breast Cancer Research and Treatment, vol. 204, no. 2, pp. 299–308, Apr. 2024

    BIB
    @article{zhu_role_2024,
      title = {The role of serum thymidine kinase 1 activity in neoadjuvant-treated {HER2}-positive breast cancer: biomarker analysis from the {Swedish} phase {II} randomized {PREDIX} {HER2} trial.},
      volume = {204},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/38175448},
      doi = {10.1007/s10549-023-07200-x},
      language = {eng},
      number = {2},
      journal = {Breast Cancer Research and Treatment},
      author = {Zhu, Y and Zerdes, I and Matikas, A and Cruz, IR and Bergqvist, M and Elinder, E and Bosch, A and Lindman, H and Einbeigi, Z and Andersson, A and Carlsson, L and Dreifaldt, AC and Isaksson-Friman, E and Hellstrom, M and Johansson, H and Wang, K and Bergh, JCS and Hatschek, T and Foukakis, T},
      month = apr,
      year = {2024},
      note = {Publisher: Netherlands},
      keywords = {Thymidine Kinase},
      pages = {299-308},
      published = {1},
      tag = {},
      trial = {predix_her2}
    }

2023

  1. “O-59 Preclinical evaluation of [89Zr]Zr-DFO*-sacituzumab, a PET tracer for imaging of whole body TROP-2 expression as a potential selection tool for treatment with TROP-2 antibody drug conjugates (ADC)”.
    K. Bratteby et al.
    Nuclear Medicine and Biology, vol. 126, p. 108455, Nov. 2023

    BIB
    @article{bratteby_o-59_2023,
      title = {O-59 {Preclinical} evaluation of [{89Zr}]{Zr}-{DFO}*-sacituzumab, a {PET} tracer for imaging of whole body {TROP}-2 expression as a potential selection tool for treatment with {TROP}-2 antibody drug conjugates ({ADC})},
      volume = {126},
      issn = {0969-8051},
      doi = {10.1016/j.nucmedbio.2023.108455},
      journal = {Nuclear Medicine and Biology},
      author = {Bratteby, K and Smertinaite, L and Omer, S and Lu, L and Milton, S and Jussing, E and Siikanen, J and Samen, E and Axelsson, R and Foukakis, T and Altena, R and Tran, T},
      month = nov,
      year = {2023},
      note = {Publisher: Elsevier},
      keywords = {Cancer},
      pages = {108455},
      published = {1},
      tag = {}
    }
  2. “Breast cancer patient-derived whole-tumor cell culture model for efficient drug profiling and treatment response prediction.”.
    X. Chen et al.
    Proc Natl Acad Sci U S A, vol. 120, no. 1, p. e2209856120, Jan. 2023

    BIB
    @article{chen_breast_2023,
      title = {Breast cancer patient-derived whole-tumor cell culture model for efficient drug profiling and treatment response prediction.},
      volume = {120},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/36574653},
      doi = {10.1073/pnas.2209856120},
      language = {eng},
      number = {1},
      journal = {Proc Natl Acad Sci U S A},
      author = {Chen, X and Sifakis, EG and Robertson, S and Neo, SY and Jun, S-H and Tong, L and Hui Min, AT and Lovrot, J and Hellgren, R and Margolin, S and Bergh, J and Foukakis, T and Lagergren, J and Lundqvist, A and Ma, R and Hartman, J},
      month = jan,
      year = {2023},
      note = {Publisher: United States},
      keywords = {Tumor Microenvironment},
      pages = {e2209856120},
      published = {1},
      tag = {}
    }
  3. “The ever-expanding landscape of antibody-drug conjugates (ADCs) in solid tumors: A systematic review.”.
    P. Filis, I. Zerdes, T. Soumala, A. Matikas, and T. Foukakis.
    Crit Rev Oncol Hematol, vol. 192, p. 104189, Dec. 2023

    BIB
    @article{filis_ever-expanding_2023,
      title = {The ever-expanding landscape of antibody-drug conjugates ({ADCs}) in solid tumors: {A} systematic review.},
      volume = {192},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/37866413},
      doi = {10.1016/j.critrevonc.2023.104189},
      language = {eng},
      journal = {Crit Rev Oncol Hematol},
      author = {Filis, P and Zerdes, I and Soumala, T and Matikas, A and Foukakis, T},
      month = dec,
      year = {2023},
      note = {Publisher: Netherlands},
      keywords = {Neoplasms},
      pages = {104189},
      published = {1},
      tag = {}
    }
  4. “P125 Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 KEYNOTE-522 study”.
    S. Kummel et al.
    The Breast, vol. 68, pp. s63–s64, Apr. 2023

    BIB
    @article{kummel_p125_2023,
      title = {P125 {Neoadjuvant} pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early {TNBC}: surgical outcomes from the phase 3 {KEYNOTE}-522 study},
      volume = {68},
      issn = {0960-9776},
      doi = {10.1016/s0960-9776(23)00242-4},
      journal = {The Breast},
      author = {Kummel, S and Schmid, P and Harbeck, N and Takahashi, M and Untch, M and Boileau, J-F and Cortes, J and McArthur, H and Dent, R and O'Shaughnessy, J and Pusztai, L and Foukakis, T and Park, YH and Hui, R and Cardoso, F and Denkert, C and Zhu, Y and Pan, W and Karantza, V and Fasching, P},
      month = apr,
      year = {2023},
      note = {Publisher: Elsevier},
      keywords = {6.1 Pharmaceuticals},
      pages = {s63-s64},
      published = {1},
      tag = {}
    }
  5. “FXYD3 functionally demarcates an ancestral breast cancer stem cell subpopulation with features of drug-tolerant persisters.”.
    M. Li et al.
    J Clin Invest, vol. 133, no. 22, Nov. 2023

    BIB
    @article{li_fxyd3_2023,
      title = {{FXYD3} functionally demarcates an ancestral breast cancer stem cell subpopulation with features of drug-tolerant persisters.},
      volume = {133},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/37966117},
      doi = {10.1172/JCI166666},
      language = {eng},
      number = {22},
      journal = {J Clin Invest},
      author = {Li, M and Nishimura, T and Takeuchi, Y and Hongu, T and Wang, Y and Shiokawa, D and Wang, K and Hirose, H and Sasahara, A and Yano, M and Ishikawa, S and Inokuchi, M and Ota, T and Tanabe, M and Tada, K-I and Akiyama, T and Cheng, X and Liu, C-C and Yamashita, T and Sugano, S and Uchida, Y and Chiba, T and Asahara, H and Nakagawa, M and Sato, S and Miyagi, Y and Shimamura, T and Nagai, LAE and Kanai, A and Katoh, M and Nomura, S and Nakato, R and Suzuki, Y and Tojo, A and Voon, DC and Ogawa, S and Okamoto, K and Foukakis, T and Gotoh, N},
      month = nov,
      year = {2023},
      note = {Publisher: United States},
      keywords = {Neoplasm Proteins},
      published = {1},
      tag = {}
    }
  6. “Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial.”.
    A. Matikas et al.
    Clin Cancer Res, vol. 29, no. 3, pp. 532–540, Feb. 2023

    BIB
    @article{matikas_survival_2023,
      title = {Survival {Outcomes}, {Digital} {TILs}, and {On}-treatment {PET}/{CT} {During} {Neoadjuvant} {Therapy} for {HER2}-positive {Breast} {Cancer}: {Results} from the {Randomized} {PREDIX} {HER2} {Trial}.},
      volume = {29},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/36449695},
      doi = {10.1158/1078-0432.CCR-22-2829},
      language = {eng},
      number = {3},
      journal = {Clin Cancer Res},
      author = {Matikas, A and Johansson, H and Gryback, P and Bjohle, J and Acs, B and Boyaci, C and Lekberg, T and Fredholm, H and Elinder, E and Margolin, S and Isaksson-Friman, E and Bosch, A and Lindman, H and Adra, J and Andersson, A and Agartz, S and Hellstrom, M and Zerdes, I and Hartman, J and Bergh, J and Hatschek, T and Foukakis, T},
      month = feb,
      year = {2023},
      note = {Publisher: United States},
      keywords = {Ado-Trastuzumab Emtansine},
      pages = {532-540},
      published = {1},
      tag = {},
      trial = {predix_her2}
    }
  7. “Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial.”.
    G. Pfeiler et al.
    Journal of Clinical Oncology, vol. 41, no. 33, pp. 5118–5130, Nov. 2023

    BIB
    @article{pfeiler_impact_2023,
      title = {Impact of {BMI} in {Patients} {With} {Early} {Hormone} {Receptor}-{Positive} {Breast} {Cancer} {Receiving} {Endocrine} {Therapy} {With} or {Without} {Palbociclib} in the {PALLAS} {Trial}.},
      volume = {41},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/37556775},
      doi = {10.1200/JCO.23.00126},
      language = {eng},
      number = {33},
      journal = {Journal of Clinical Oncology},
      author = {Pfeiler, G and Hlauschek, D and Mayer, EL and Deutschmann, C and Kacerovsky-Strobl, S and Martin, M and Meisel, JL and Zdenkowski, N and Loibl, S and Balic, M and Park, H and Prat, A and Isaacs, C and Bajetta, E and Balko, JM and Bellet-Ezquerra, M and Bliss, J and Burstein, H and Cardoso, F and Fohler, H and Foukakis, T and Gelmon, KA and Goetz, M and Haddad, TC and Iwata, H and Jassem, J and Lee, S-C and Linderholm, B and Los, M and Mamounas, EP and Miller, KD and Morris, PG and Munzone, E and Gal-Yam, EN and Ring, A and Shepherd, L and Singer, C and Thomssen, C and Tseng, L-M and Valagussa, P and Winer, EP and Wolff, AC and Zoppoli, G and Machacek-Link, J and Schurmans, C and Huang, X and Gauthier, E and Fesl, C and Dueck, AC and DeMichele, A and Gnant, M and Groups, PALLAS and {Investigators}},
      month = nov,
      year = {2023},
      note = {Publisher: United States},
      keywords = {ErbB-2, Receptor},
      pages = {5118-5130},
      published = {1},
      tag = {}
    }
  8. “ProFertil study protocol for the investigation of gonadotropin-releasing hormone agonists (GnRHa) during chemotherapy aiming at fertility protection of young women and teenagers with cancer in Sweden-a phase III randomised double-blinded placebo-controlled study.”.
    K. A. Rodriguez-Wallberg et al.
    BMJ Open, vol. 13, no. 12, p. e078023, Dec. 2023

    BIB
    @article{rodriguez-wallberg_profertil_2023,
      title = {{ProFertil} study protocol for the investigation of gonadotropin-releasing hormone agonists ({GnRHa}) during chemotherapy aiming at fertility protection of young women and teenagers with cancer in {Sweden}-a phase {III} randomised double-blinded placebo-controlled study.},
      volume = {13},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/38070906},
      doi = {10.1136/bmjopen-2023-078023},
      language = {eng},
      number = {12},
      journal = {BMJ Open},
      author = {Rodriguez-Wallberg, KA and Nilsson, HP and Bergh, J and Malmros, J and Ljungman, P and Foukakis, T and Stragliotto, CL and Friman, EI and Linderholm, B and Valachis, A and Andersson, A and Harrysson, S and Vennstrom, L and Frisk, P and Morse, H and Eloranta, S},
      month = dec,
      year = {2023},
      note = {Publisher: England},
      keywords = {Fertility Preservation},
      pages = {e078023},
      published = {1},
      tag = {}
    }
  9. “Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase III KEYNOTE-522 study”.
    P. Schmid et al.
    ANNALS OF ONCOLOGY, vol. 34, pp. S1257–S1257, Oct. 2023

    BIB
    @article{schmid_pembrolizumab_2023,
      title = {Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage {TNBC}: {Updated} {EFS} results from the phase {III} {KEYNOTE}-522 study},
      volume = {34},
      issn = {0923-7534},
      url = {https://www.webofscience.com/api/gateway?GWVersion=2\&SrcApp=kielementsprod\&SrcAuth=WosAPI\&KeyUT=WOS:001087480203495\&DestLinkType=FullRecord\&DestApp=WOS_CPL},
      doi = {10.1016/j.annonc.2023.10.008},
      journal = {ANNALS OF ONCOLOGY},
      author = {Schmid, P and Cortes, J and Dent, RA and Pusztai, L and McArthur, HL and Kummel, S and Denkert, C and Park, YH and Hui, R and Harbeck, N and Takahashi, M and Foukakis, T and Reynier, MAM and Ferreira, MIR and Im, SA and Cardoso, F and Ding, Y and Pan, W and Tryfonidis, KE and O'Shaughnessy, J},
      month = oct,
      year = {2023},
      pages = {S1257-S1257},
      published = {1},
      tag = {}
    }
  10. “Multiresolution Self-Supervised Feature Integration via Attention Multiple Instance Learning for Histopathology Analysis.”.
    N. Tsiknakis et al.
    Annu Int Conf IEEE Eng Med Biol Soc, 2023, vol. 2023, pp. 1–4

    BIB
    @inproceedings{tsiknakis_multiresolution_2023,
      title = {Multiresolution {Self}-{Supervised} {Feature} {Integration} via {Attention} {Multiple} {Instance} {Learning} for {Histopathology} {Analysis}.},
      volume = {2023},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/38083519},
      doi = {10.1109/EMBC40787.2023.10341061},
      language = {eng},
      booktitle = {Annu {Int} {Conf} {IEEE} {Eng} {Med} {Biol} {Soc}},
      publisher = {United States},
      author = {Tsiknakis, N and Tzoras, E and Zerdes, I and Manikis, GC and Acs, B and Hartman, J and Hatschek, T and Foukakis, T and Marias, K},
      month = jul,
      year = {2023},
      keywords = {Breast Neoplasms},
      pages = {1-4},
      published = {1},
      tag = {}
    }
  11. “The interplay between eosinophils and T cells in breast cancer immunotherapy.”.
    I. Zerdes, A. Matikas, and T. Foukakis.
    Mol Oncol, vol. 17, no. 4, pp. 545–547, Apr. 2023

    BIB
    @article{zerdes_interplay_2023,
      title = {The interplay between eosinophils and {T} cells in breast cancer immunotherapy.},
      volume = {17},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/36892326},
      doi = {10.1002/1878-0261.13413},
      language = {eng},
      number = {4},
      journal = {Mol Oncol},
      author = {Zerdes, I and Matikas, A and Foukakis, T},
      month = apr,
      year = {2023},
      note = {Publisher: United States},
      keywords = {Tumor Microenvironment},
      pages = {545-547},
      published = {1},
      tag = {}
    }

2022

  1. “Women with short survival after diagnosis of metastatic breast cancer: a population-based registry study.”.
    C. Boman, L. Edman Kessler, J. Bergh, A. Matikas, and T. Foukakis.
    Breast Cancer Research and Treatment, vol. 194, no. 1, pp. 49–56, Jul. 2022

    BIB
    @article{boman_women_2022,
      title = {Women with short survival after diagnosis of metastatic breast cancer: a population-based registry study.},
      volume = {194},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/35461374},
      doi = {10.1007/s10549-022-06591-7},
      language = {eng},
      number = {1},
      journal = {Breast Cancer Research and Treatment},
      author = {Boman, C and Edman Kessler, L and Bergh, J and Matikas, A and Foukakis, T},
      month = jul,
      year = {2022},
      note = {Publisher: Netherlands},
      keywords = {Retrospective Studies},
      pages = {49-56},
      published = {1},
      tag = {}
    }
  2. “Real World Evaluation of the Prosigna/PAM50 Test in a Node-Negative Postmenopausal Swedish Population: A Multicenter Study.”.
    U. Kjallquist et al.
    Cancers (Basel), vol. 14, no. 11, May 2022

    BIB
    @article{kjallquist_real_2022,
      title = {Real {World} {Evaluation} of the {Prosigna}/{PAM50} {Test} in a {Node}-{Negative} {Postmenopausal} {Swedish} {Population}: {A} {Multicenter} {Study}.},
      volume = {14},
      issn = {2072-6694},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/35681597},
      doi = {10.3390/cancers14112615},
      language = {eng},
      number = {11},
      journal = {Cancers (Basel)},
      author = {Kjallquist, U and Acs, B and Margolin, S and Karlsson, E and Kessler, LE and Garcia Hernandez, S and Ekholm, M and Lundgren, C and Olsson, E and Lindman, H and Foukakis, T and Matikas, A and Hartman, J},
      month = may,
      year = {2022},
      note = {Publisher: Switzerland},
      keywords = {impact},
      published = {1},
      tag = {}
    }
  3. “Inflammatory potential of diet and colorectal carcinogenesis: a prospective longitudinal cohort.”.
    Z. Li et al.
    Br J Cancer, vol. 126, no. 12, pp. 1735–1743, Jun. 2022

    BIB
    @article{li_inflammatory_2022,
      title = {Inflammatory potential of diet and colorectal carcinogenesis: a prospective longitudinal cohort.},
      volume = {126},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/35136208},
      doi = {10.1038/s41416-022-01731-8},
      language = {eng},
      number = {12},
      journal = {Br J Cancer},
      author = {Li, Z and Wang, K and Shivappa, N and Hebert, JR and Chen, H and Liu, H and Jiang, X},
      month = jun,
      year = {2022},
      note = {Publisher: England},
      keywords = {Risk Factors},
      pages = {1735-1743},
      published = {1},
      tag = {}
    }
  4. “Harmonization Strategies in Multicenter MRI-Based Radiomics.”.
    E. Stamoulou et al.
    J Imaging, vol. 8, no. 11, Nov. 2022

    BIB
    @article{stamoulou_harmonization_2022,
      title = {Harmonization {Strategies} in {Multicenter} {MRI}-{Based} {Radiomics}.},
      volume = {8},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/36354876},
      doi = {10.3390/jimaging8110303},
      language = {eng},
      number = {11},
      journal = {J Imaging},
      author = {Stamoulou, E and Spanakis, C and Manikis, GC and Karanasiou, G and Grigoriadis, G and Foukakis, T and Tsiknakis, M and Fotiadis, DI and Marias, K},
      month = nov,
      year = {2022},
      note = {Publisher: Switzerland},
      keywords = {variability},
      published = {1},
      tag = {}
    }
  5. “Dissecting Tumor-Immune Microenvironment in Breast Cancer at a Spatial and Multiplex Resolution.”.
    E. Tzoras et al.
    Cancers (Basel), vol. 14, no. 8, Apr. 2022

    BIB
    @article{tzoras_dissecting_2022,
      title = {Dissecting {Tumor}-{Immune} {Microenvironment} in {Breast} {Cancer} at a {Spatial} and {Multiplex} {Resolution}.},
      volume = {14},
      issn = {2072-6694},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/35454904},
      doi = {10.3390/cancers14081999},
      language = {eng},
      number = {8},
      journal = {Cancers (Basel)},
      author = {Tzoras, E and Zerdes, I and Tsiknakis, N and Manikis, GC and Mezheyeuski, A and Bergh, J and Matikas, A and Foukakis, T},
      month = apr,
      year = {2022},
      note = {Publisher: Switzerland},
      keywords = {spectral imaging},
      published = {1},
      tag = {}
    }
  6. “Integrated multi-omics profiling of high-grade estrogen receptor-positive, HER2-negative breast cancer.”.
    K. Wang et al.
    Mol Oncol, vol. 16, no. 12, pp. 2413–2431, Jun. 2022

    BIB
    @article{wang_integrated_2022,
      title = {Integrated multi-omics profiling of high-grade estrogen receptor-positive, {HER2}-negative breast cancer.},
      volume = {16},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/34146382},
      doi = {10.1002/1878-0261.13043},
      language = {eng},
      number = {12},
      journal = {Mol Oncol},
      author = {Wang, K and Li, L and Franch-Exposito, S and Le, X and Tang, J and Li, Q and Wu, Q and Bassaganyas, L and Camps, J and Zhang, X and Li, H and Foukakis, T and Xiang, T and Wu, J and Ren, G},
      month = jun,
      year = {2022},
      note = {Publisher: United States},
      keywords = {Progesterone, Receptors},
      pages = {2413-2431},
      published = {1},
      tag = {}
    }
  7. “Long-term outcomes for breast conservation plus radiotherapy versus mastectomy in early breast cancer after neoadjuvant systemic therapy: Results from the Swedish national breast cancer register (NKBC)”.
    K. Wang et al.
    Cancer Research, vol. 82, no. 4, Feb. 2022

    BIB
    @article{wang_long-term_2022,
      title = {Long-term outcomes for breast conservation plus radiotherapy versus mastectomy in early breast cancer after neoadjuvant systemic therapy: {Results} from the {Swedish} national breast cancer register ({NKBC})},
      volume = {82},
      issn = {0008-5472},
      url = {https://www.webofscience.com/api/gateway?GWVersion=2\&SrcApp=kielementsprod\&SrcAuth=WosAPI\&KeyUT=WOS:000772647601343\&DestLinkType=FullRecord\&DestApp=WOS_CPL},
      doi = {10.1158/1538-7445.SABCS21-P3-18-03},
      number = {4},
      journal = {Cancer Research},
      author = {Wang, K and Duinmeijer, A and Matikas, A and Altena, R and Johansson, H and Fredholm, H and Foukakis, T},
      month = feb,
      year = {2022},
      published = {1},
      tag = {}
    }
  8. “SARS-CoV-2 spike engagement of ACE2 primes S2 site cleavage and fusion initiation.”.
    S. Yu et al.
    Proc Natl Acad Sci U S A, vol. 119, no. 1, Jan. 2022

    BIB
    @article{yu_sars-cov-2_2022,
      title = {{SARS}-{CoV}-2 spike engagement of {ACE2} primes {S2} site cleavage and fusion initiation.},
      volume = {119},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/34930824},
      doi = {10.1073/pnas.2111199119},
      language = {eng},
      number = {1},
      journal = {Proc Natl Acad Sci U S A},
      author = {Yu, S and Zheng, X and Zhou, B and Li, J and Chen, M and Deng, R and Wong, G and Lavillette, D and Meng, G},
      month = jan,
      year = {2022},
      note = {Publisher: United States},
      keywords = {Virus Internalization},
      published = {1},
      tag = {}
    }
  9. “Expression patterns and prognostic implications of tumor-infiltrating lymphocytes dynamics in early breast cancer patients receiving neoadjuvant therapy: A systematic review and meta-analysis.”.
    Y. Zhu et al.
    Front Oncol, vol. 12, p. 999843, 2022

    BIB
    @article{zhu_expression_2022,
      title = {Expression patterns and prognostic implications of tumor-infiltrating lymphocytes dynamics in early breast cancer patients receiving neoadjuvant therapy: {A} systematic review and meta-analysis.},
      volume = {12},
      issn = {2234-943X},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/36531050},
      doi = {10.3389/fonc.2022.999843},
      language = {eng},
      journal = {Front Oncol},
      author = {Zhu, Y and Tzoras, E and Matikas, A and Bergh, J and Valachis, A and Zerdes, I and Foukakis, T},
      year = {2022},
      note = {Publisher: Switzerland},
      keywords = {tumor-infiltrating lymphocytes (TILs)},
      pages = {999843},
      published = {1},
      tag = {}
    }

2021

  1. “Discordance of PD-L1 status between primary and metastatic breast cancer: A systematic review and meta-analysis.”.
    C. Boman et al.
    Cancer Treatment Reviews, vol. 99, p. 102257, Sep. 2021

    BIB
    @article{boman_discordance_2021,
      title = {Discordance of {PD}-{L1} status between primary and metastatic breast cancer: {A} systematic review and meta-analysis.},
      volume = {99},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/34237488},
      doi = {10.1016/j.ctrv.2021.102257},
      language = {eng},
      journal = {Cancer Treatment Reviews},
      author = {Boman, C and Zerdes, I and Martensson, K and Bergh, J and Foukakis, T and Valachis, A and Matikas, A},
      month = sep,
      year = {2021},
      note = {Publisher: Netherlands},
      keywords = {Neoplasm Metastasis},
      pages = {102257},
      published = {1},
      tag = {}
    }
  2. “Benefit of pazopanib in advanced gastrointestinal stromal tumours: results from a phase II trial (SSG XXI, PAGIST).”.
    M. Eriksson et al.
    ESMO Open, vol. 6, no. 4, p. 100217, Aug. 2021

    BIB
    @article{eriksson_benefit_2021,
      title = {Benefit of pazopanib in advanced gastrointestinal stromal tumours: results from a phase {II} trial ({SSG} {XXI}, {PAGIST}).},
      volume = {6},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/34271307},
      doi = {10.1016/j.esmoop.2021.100217},
      language = {eng},
      number = {4},
      journal = {ESMO Open},
      author = {Eriksson, M and Reichardt, P and Joensuu, H and Krarup-Hansen, A and Hagberg, O and Hohenberger, P and Hagberg, H and Hansson, L and Foukakis, T and Pulkkanen, K and Bauer, S and Goplen, D and Blach Rossen, P and Sundby Hall, K},
      month = aug,
      year = {2021},
      note = {Publisher: England},
      keywords = {Sulfonamides},
      pages = {100217},
      published = {1},
      tag = {}
    }
  3. “Expert Discussion: HER2-Positive Breast Cancer.”.
    T. Foukakis, A. Matikas, O. Oikonomidou, E. Andreopoulou, and D. Mavroudis.
    Breast Care (Basel), vol. 16, no. 4, pp. 422–428, Aug. 2021

    BIB
    @article{foukakis_expert_2021,
      title = {Expert {Discussion}: {HER2}-{Positive} {Breast} {Cancer}.},
      volume = {16},
      issn = {1661-3791},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/34602950},
      doi = {10.1159/000516965},
      language = {eng},
      number = {4},
      journal = {Breast Care (Basel)},
      author = {Foukakis, T and Matikas, A and Oikonomidou, O and Andreopoulou, E and Mavroudis, D},
      month = aug,
      year = {2021},
      note = {Publisher: Switzerland},
      pages = {422-428},
      published = {1},
      tag = {}
    }
  4. “Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial.”.
    T. Hatschek et al.
    Jama Oncology, vol. 7, no. 9, pp. 1360–1367, Sep. 2021

    BIB
    @article{hatschek_neoadjuvant_2021,
      title = {Neoadjuvant {Trastuzumab}, {Pertuzumab}, and {Docetaxel} vs {Trastuzumab} {Emtansine} in {Patients} {With} {ERBB2}-{Positive} {Breast} {Cancer}: {A} {Phase} 2 {Randomized} {Clinical} {Trial}.},
      volume = {7},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/34165503},
      doi = {10.1001/jamaoncol.2021.1932},
      language = {eng},
      number = {9},
      journal = {Jama Oncology},
      author = {Hatschek, T and Foukakis, T and Bjohle, J and Lekberg, T and Fredholm, H and Elinder, E and Bosch, A and Pekar, G and Lindman, H and Schiza, A and Einbeigi, Z and Adra, J and Andersson, A and Carlsson, L and Dreifaldt, AC and Isaksson-Friman, E and Agartz, S and Azavedo, E and Gryback, P and Hellstrom, M and Johansson, H and Maes, C and Zerdes, I and Hartman, J and Brandberg, Y and Bergh, J},
      month = sep,
      year = {2021},
      note = {Publisher: United States},
      keywords = {Treatment Outcome},
      pages = {1360-1367},
      published = {1},
      tag = {},
      trial = {predix_her2}
    }
  5. “Axillary evaluation in ductal cancer in situ of the breast: challenging the diagnostic accuracy of clinical practice guidelines.”.
    A. Karakatsanis et al.
    Br J Surg, vol. 108, no. 9, pp. 1120–1125, Sep. 2021

    BIB
    @article{karakatsanis_axillary_2021,
      title = {Axillary evaluation in ductal cancer in situ of the breast: challenging the diagnostic accuracy of clinical practice guidelines.},
      volume = {108},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/34089583},
      doi = {10.1093/bjs/znab149},
      language = {eng},
      number = {9},
      journal = {Br J Surg},
      author = {Karakatsanis, A and Charalampoudis, P and Pistioli, L and Di Micco, R and Foukakis, T and Valachis, A and Group, SentiNot Trialists},
      month = sep,
      year = {2021},
      note = {Publisher: England},
      keywords = {Sentinel Lymph Node Biopsy},
      pages = {1120-1125},
      published = {1},
      tag = {}
    }
  6. “Long-term Survival Comparison of Repeated Breast-conserving Surgery Versus Mastectomy for Patients with DCIS with Ipsilateral Breast Tumor Recurrence: A Real-world Longitudinal Study.”.
    Q. Li et al.
    Clin Breast Cancer, vol. 21, no. 4, pp. 360–372, Aug. 2021

    BIB
    @article{li_long-term_2021,
      title = {Long-term {Survival} {Comparison} of {Repeated} {Breast}-conserving {Surgery} {Versus} {Mastectomy} for {Patients} with {DCIS} with {Ipsilateral} {Breast} {Tumor} {Recurrence}: {A} {Real}-world {Longitudinal} {Study}.},
      volume = {21},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/33846099},
      doi = {10.1016/j.clbc.2021.02.012},
      language = {eng},
      number = {4},
      journal = {Clin Breast Cancer},
      author = {Li, Q and Wang, K and Yang, L and Wu, Q and Zhu, W and Li, Z and Shi, Y and Zhang, X and Li, H},
      month = aug,
      year = {2021},
      note = {Publisher: United States},
      keywords = {Survival Rate},
      pages = {360-372},
      published = {1},
      tag = {}
    }
  7. “Citrobacter freundii Activation of NLRP3 Inflammasome via the Type VI Secretion System.”.
    L. Liu et al.
    J Infect Dis, vol. 223, no. 12, pp. 2174–2185, Jun. 2021

    BIB
    @article{liu_citrobacter_2021,
      title = {Citrobacter freundii {Activation} of {NLRP3} {Inflammasome} via the {Type} {VI} {Secretion} {System}.},
      volume = {223},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/33151309},
      doi = {10.1093/infdis/jiaa692},
      language = {eng},
      number = {12},
      journal = {J Infect Dis},
      author = {Liu, L and Song, L and Deng, R and Lan, R and Jin, W and Tran Van Nhieu, G and Cao, H and Liu, Q and Xiao, Y and Li, X and Meng, G and Ren, Z},
      month = jun,
      year = {2021},
      note = {Publisher: United States},
      keywords = {Type VI Secretion Systems},
      pages = {2174-2185},
      published = {1},
      tag = {}
    }
  8. “Prognostic role of serum thymidine kinase 1 kinetics during neoadjuvant chemotherapy for early breast cancer.”.
    A. Matikas et al.
    ESMO Open, vol. 6, no. 2, p. 100076, Apr. 2021

    BIB
    @article{matikas_prognostic_2021,
      title = {Prognostic role of serum thymidine kinase 1 kinetics during neoadjuvant chemotherapy for early breast cancer.},
      volume = {6},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/33714010},
      doi = {10.1016/j.esmoop.2021.100076},
      language = {eng},
      number = {2},
      journal = {ESMO Open},
      author = {Matikas, A and Wang, K and Lagoudaki, E and Acs, B and Zerdes, I and Hartman, J and Azavedo, E and Bjohle, J and Carlsson, L and Einbeigi, Z and Hedenfalk, I and Hellstrom, M and Lekberg, T and Loman, N and Saracco, A and von Wachenfeldt, A and Rotstein, S and Bergqvist, M and Bergh, J and Hatschek, T and Foukakis, T},
      month = apr,
      year = {2021},
      note = {Publisher: England},
      keywords = {Thymidine Kinase},
      pages = {100076},
      published = {1},
      tag = {},
      trial = {promix}
    }
  9. “SOLAR1s: alpelisib returns to earth?”.
    A. Matikas and T. Foukakis.
    Ann Oncol, vol. 32, no. 2, pp. 129–132, Feb. 2021

    BIB
    @article{matikas_solar1s_2021,
      title = {{SOLAR1s}: alpelisib returns to earth?},
      volume = {32},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/33309744},
      doi = {10.1016/j.annonc.2020.12.003},
      language = {eng},
      number = {2},
      journal = {Ann Oncol},
      author = {Matikas, A and Foukakis, T},
      month = feb,
      year = {2021},
      note = {Publisher: England},
      keywords = {Thiazoles},
      pages = {129-132},
      published = {1},
      tag = {}
    }
  10. “The prognostic and predictive impact of low estrogen receptor expression in early breast cancer: a systematic review and meta-analysis.”.
    N.-M. Paakkola, A. Karakatsanis, D. Mauri, T. Foukakis, and A. Valachis.
    ESMO Open, vol. 6, no. 6, p. 100289, Dec. 2021

    BIB
    @article{paakkola_prognostic_2021,
      title = {The prognostic and predictive impact of low estrogen receptor expression in early breast cancer: a systematic review and meta-analysis.},
      volume = {6},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/34678571},
      doi = {10.1016/j.esmoop.2021.100289},
      language = {eng},
      number = {6},
      journal = {ESMO Open},
      author = {Paakkola, N-M and Karakatsanis, A and Mauri, D and Foukakis, T and Valachis, A},
      month = dec,
      year = {2021},
      note = {Publisher: England},
      keywords = {Retrospective Studies},
      pages = {100289},
      published = {1},
      tag = {}
    }
  11. “Adjuvant abemaciclib for high-risk breast cancer: the story continues.”.
    L. Spring, A. Matikas, A. Bardia, and T. Foukakis.
    Ann Oncol, vol. 32, no. 12, pp. 1457–1459, Dec. 2021

    BIB
    @article{spring_adjuvant_2021,
      title = {Adjuvant abemaciclib for high-risk breast cancer: the story continues.},
      volume = {32},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/34815015},
      doi = {10.1016/j.annonc.2021.10.214},
      language = {eng},
      number = {12},
      journal = {Ann Oncol},
      author = {Spring, L and Matikas, A and Bardia, A and Foukakis, T},
      month = dec,
      year = {2021},
      note = {Publisher: England},
      keywords = {Humans},
      pages = {1457-1459},
      published = {1},
      tag = {}
    }
  12. “Cancer cells escape p53’s tumor suppression through ablation of ZDHHC1-mediated p53 palmitoylation.”.
    J. Tang et al.
    Oncogene, vol. 40, no. 35, pp. 5416–5426, Sep. 2021

    BIB
    @article{tang_cancer_2021,
      volume = {40},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/34282274},
      doi = {10.1038/s41388-021-01949-5},
      language = {eng},
      number = {35},
      journal = {Oncogene},
      author = {Tang, J and Peng, W and Feng, Y and Le, X and Wang, K and Xiang, Q and Li, L and Wang, Y and Xu, C and Mu, J and Xu, K and Ji, P and Tao, Q and Huang, A and Deng, C-X and Lin, Y and Xiang, T},
      month = sep,
      year = {2021},
      note = {Publisher: England},
      keywords = {DNA (Cytosine-5-)-Methyltransferases},
      pages = {5416-5426},
      published = {1},
      tag = {}
    }
  13. “Risk of hematologic malignancies after breast ductal carcinoma in situ treatment with ionizing radiation.”.
    K. Wang et al.
    NPJ Breast Cancer, vol. 7, no. 1, p. 21, Mar. 2021

    BIB
    @article{wang_risk_2021,
      title = {Risk of hematologic malignancies after breast ductal carcinoma in situ treatment with ionizing radiation.},
      volume = {7},
      issn = {2374-4677},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/33654083},
      doi = {10.1038/s41523-021-00228-6},
      language = {eng},
      number = {1},
      journal = {NPJ Breast Cancer},
      author = {Wang, K and Li, Z and Chen, X and Zhang, J and Xiong, Y and Zhong, G and Shi, Y and Li, Q and Zhang, X and Li, H and Xiang, T and Foukakis, T and Radivoyevitch, T and Ren, G},
      month = mar,
      year = {2021},
      note = {Publisher: United States},
      pages = {21},
      published = {1},
      tag = {}
    }
  14. “Vitamin K intake and breast cancer incidence and death: results from a prospective cohort study.”.
    K. Wang et al.
    Clin Nutr, vol. 40, no. 5, pp. 3370–3378, May 2021

    BIB
    @article{wang_vitamin_2021,
      title = {Vitamin {K} intake and breast cancer incidence and death: results from a prospective cohort study.},
      volume = {40},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/33277073},
      doi = {10.1016/j.clnu.2020.11.009},
      language = {eng},
      number = {5},
      journal = {Clin Nutr},
      author = {Wang, K and Wu, Q and Li, Z and Reger, MK and Xiong, Y and Zhong, G and Li, Q and Zhang, X and Li, H and Foukakis, T and Xiang, T and Zhang, J and Ren, G},
      month = may,
      year = {2021},
      note = {Publisher: England},
      keywords = {Vitamin K},
      pages = {3370-3378},
      published = {1},
      tag = {}
    }
  15. “Discordance of PD-L1 Expression at the Protein and RNA Levels in Early Breast Cancer.”.
    I. Zerdes et al.
    Cancers (Basel), vol. 13, no. 18, Sep. 2021

    BIB
    @article{zerdes_discordance_2021,
      title = {Discordance of {PD}-{L1} {Expression} at the {Protein} and {RNA} {Levels} in {Early} {Breast} {Cancer}.},
      volume = {13},
      issn = {2072-6694},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/34572882},
      doi = {10.3390/cancers13184655},
      language = {eng},
      number = {18},
      journal = {Cancers (Basel)},
      author = {Zerdes, I and Karafousia, V and Mezheyeuski, A and Stogiannitsi, M and Kuiper, R and Moreno Ruiz, P and Rassidakis, G and Bergh, J and Hatschek, T and Foukakis, T and Matikas, A},
      month = sep,
      year = {2021},
      note = {Publisher: Switzerland},
      keywords = {multiplex immunohistochemistry},
      published = {1},
      tag = {}
    }
  16. “Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study.”.
    I. Zerdes et al.
    NPJ Breast Cancer, vol. 7, no. 1, p. 144, Nov. 2021

    BIB
    @article{zerdes_interplay_2021,
      title = {Interplay between copy number alterations and immune profiles in the early breast cancer {Scandinavian} {Breast} {Group} 2004-1 randomized phase {II} trial: results from a feasibility study.},
      volume = {7},
      issn = {2374-4677},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/34799582},
      doi = {10.1038/s41523-021-00352-3},
      language = {eng},
      number = {1},
      journal = {NPJ Breast Cancer},
      author = {Zerdes, I and Simonetti, M and Matikas, A and Harbers, L and Acs, B and Boyaci, C and Zhang, N and Salgkamis, D and Agartz, S and Moreno-Ruiz, P and Bai, Y and Rimm, DL and Hartman, J and Mezheyeuski, A and Bergh, J and Crosetto, N and Foukakis, T},
      month = nov,
      year = {2021},
      note = {Publisher: United States},
      pages = {144},
      published = {1},
      tag = {},
      trial = {sbg}
    }
  17. “Association of ultra-processed food consumption with cardiovascular mortality in the US population: long-term results from a large prospective multicenter study.”.
    G.-C. Zhong et al.
    Int J Behav Nutr Phys Act, vol. 18, no. 1, p. 21, Feb. 2021

    BIB
    @article{zhong_association_2021,
      title = {Association of ultra-processed food consumption with cardiovascular mortality in the {US} population: long-term results from a large prospective multicenter study.},
      volume = {18},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/33536027},
      doi = {10.1186/s12966-021-01081-3},
      language = {eng},
      number = {1},
      journal = {Int J Behav Nutr Phys Act},
      author = {Zhong, G-C and Gu, H-T and Peng, Y and Wang, K and Wu, Y-Q-L and Hu, T-Y and Jing, F-C and Hao, F-B},
      month = feb,
      year = {2021},
      note = {Publisher: England},
      keywords = {United States},
      pages = {21},
      published = {1},
      tag = {}
    }
  18. “Low-carbohydrate diets and the risk of pancreatic cancer: a large prospective cohort study.”.
    G.-C. Zhong et al.
    Carcinogenesis, vol. 42, no. 5, pp. 724–732, May 2021

    BIB
    @article{zhong_low-carbohydrate_2021,
      title = {Low-carbohydrate diets and the risk of pancreatic cancer: a large prospective cohort study.},
      volume = {42},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/33480980},
      doi = {10.1093/carcin/bgab006},
      language = {eng},
      number = {5},
      journal = {Carcinogenesis},
      author = {Zhong, G-C and Li, Q-J and Yang, P-F and Wang, Y-B and Hao, F-B and Wang, K and Hu, J-J and Wu, J-J},
      month = may,
      year = {2021},
      note = {Publisher: England},
      keywords = {Weight Loss},
      pages = {724-732},
      published = {1},
      tag = {}
    }

2020

  1. “Five-Year Results of the Preoperative Accelerated Partial Breast Irradiation (PAPBI) Trial.”.
    S. C. J. Bosma et al.
    Int J Radiat Oncol Biol Phys, vol. 106, no. 5, pp. 958–967, Apr. 2020

    BIB
    @article{bosma_five-year_2020,
      title = {Five-{Year} {Results} of the {Preoperative} {Accelerated} {Partial} {Breast} {Irradiation} ({PAPBI}) {Trial}.},
      volume = {106},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/31987957},
      doi = {10.1016/j.ijrobp.2019.12.037},
      language = {eng},
      number = {5},
      journal = {Int J Radiat Oncol Biol Phys},
      author = {Bosma, SCJ and Leij, F and Vreeswijk, S and Maaker, MD and Wesseling, J and Vijver, MVD and Scholten, A and Rivera, S and Bourgier, C and Auzac, G and Foukakis, T and Lekberg, T and Bongard, D and Loo, C and Rutgers, E and Bartelink, H and Elkhuizen, PHM},
      month = apr,
      year = {2020},
      note = {Publisher: United States},
      keywords = {Treatment Outcome},
      pages = {958-967},
      published = {1},
      tag = {}
    }
  2. “Long-term (up to 16 months) health-related quality of life after adjuvant tailored dose-dense chemotherapy vs. standard three-weekly chemotherapy in women with high-risk early breast cancer.”.
    Breast Cancer Research and Treatment, vol. 181, no. 1, pp. 87–96, May 2020

    BIB
    @article{brandberg_long-term_2020,
      title = {Long-term (up to 16 months) health-related quality of life after adjuvant tailored dose-dense chemotherapy vs. standard three-weekly chemotherapy in women with high-risk early breast cancer.},
      volume = {181},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/32232698},
      doi = {10.1007/s10549-020-05602-9},
      language = {eng},
      number = {1},
      journal = {Breast Cancer Research and Treatment},
      author = {},
      month = may,
      year = {2020},
      note = {Publisher: Netherlands},
      keywords = {Young Adult},
      pages = {87-96},
      published = {1},
      tag = {}
    }
  3. “One-year follow-up of health-related quality of life in the Swedish PREDIX HER 2 trial, evaluating docetaxel, trastuzumab sc, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2 positive breast cancer.”.
    Y. Brandberg et al.
    Journal of Clinical Oncology, vol. 38, no. 15_suppl, pp. 590–590, May 2020

    BIB
    @article{brandberg_one-year_2020,
      title = {One-year follow-up of health-related quality of life in the {Swedish} {PREDIX} {HER} 2 trial, evaluating docetaxel, trastuzumab sc, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of {HER2} positive breast cancer.},
      volume = {38},
      issn = {0732-183X},
      journal = {Journal of Clinical Oncology},
      author = {Brandberg, Y and Foukakis, T and Andersson, A and Bjohle, J and Bosch, A and Carlsson, L and Einbeigi, Z and Fredholm, H and Isaksson-Friman, E and Hellstrom, M and Johansson, H and Lekberg, T and Lindman, H and Bergh, JCS and Hatschek, T},
      month = may,
      year = {2020},
      note = {Publisher: American Society of Clinical Oncology (ASCO)},
      keywords = {Cancer},
      pages = {590-590},
      published = {1},
      tag = {}
    }
  4. “Chemotherapy use near the end-of-life in patients with metastatic breast cancer.”.
    L. Edman Kessler et al.
    Breast Cancer Research and Treatment, vol. 181, no. 3, pp. 645–651, Jun. 2020

    BIB
    @article{edman_kessler_chemotherapy_2020,
      title = {Chemotherapy use near the end-of-life in patients with metastatic breast cancer.},
      volume = {181},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/32383058},
      doi = {10.1007/s10549-020-05663-w},
      language = {eng},
      number = {3},
      journal = {Breast Cancer Research and Treatment},
      author = {Edman Kessler, L and Sigfridsson, J and Hatzidaki, D and Bergh, J and Foukakis, T and Georgoulias, V and Matikas, A},
      month = jun,
      year = {2020},
      note = {Publisher: Netherlands},
      keywords = {Young Adult},
      pages = {645-651},
      published = {1},
      tag = {}
    }
  5. “Efficacy and safety of cyclin dependent kinases 4/6 inhibitors in the treatment of metastatic breast cancer: a real-world experience.”.
    L. Edman Kessler, O. Wiklander, E. Hamberg, J. Bergh, T. Foukakis, and A. Matikas.
    Acta Oncol, vol. 59, no. 11, pp. 1382–1387, Nov. 2020

    BIB
    @article{edman_kessler_efficacy_2020,
      title = {Efficacy and safety of cyclin dependent kinases 4/6 inhibitors in the treatment of metastatic breast cancer: a real-world experience.},
      volume = {59},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/32783667},
      doi = {10.1080/0284186X.2020.1804613},
      language = {eng},
      number = {11},
      journal = {Acta Oncol},
      author = {Edman Kessler, L and Wiklander, O and Hamberg, E and Bergh, J and Foukakis, T and Matikas, A},
      month = nov,
      year = {2020},
      note = {Publisher: Sweden},
      keywords = {Sweden},
      pages = {1382-1387},
      published = {1},
      tag = {}
    }
  6. “Axillary Evaluation in the Setting of a Preoperative Ductal Cancer in Situ (DCIS) Diagnosis. Do Guidelines (Mis)Guide?”.
    A. Karakatsanis et al.
    European Journal of Surgical Oncology, vol. 46, no. 2, p. e63, Feb. 2020

    BIB
    @article{karakatsanis_axillary_2020,
      title = {Axillary {Evaluation} in the {Setting} of a {Preoperative} {Ductal} {Cancer} in {Situ} ({DCIS}) {Diagnosis}. {Do} {Guidelines} ({Mis}){Guide}?},
      volume = {46},
      issn = {0748-7983},
      doi = {10.1016/j.ejso.2019.11.136},
      number = {2},
      journal = {European Journal of Surgical Oncology},
      author = {Karakatsanis, A and Valachis, A and Pistioli, L and Charalampoudis, P and DiMicco, R and Foukakis, T and Warnberg, F},
      month = feb,
      year = {2020},
      note = {Publisher: Elsevier},
      keywords = {Cancer},
      pages = {e63},
      published = {1},
      tag = {}
    }
  7. “Incidence of second primary malignancy after breast cancer and related risk factors-Is breast-conserving surgery safe? A nested case-control study.”.
    Z. Li, K. Wang, Y. Shi, X. Zhang, and J. Wen.
    Int J Cancer, vol. 146, no. 2, pp. 352–362, Jan. 2020

    BIB
    @article{li_incidence_2020,
      title = {Incidence of second primary malignancy after breast cancer and related risk factors-{Is} breast-conserving surgery safe? {A} nested case-control study.},
      volume = {146},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/30861567},
      doi = {10.1002/ijc.32259},
      language = {eng},
      number = {2},
      journal = {Int J Cancer},
      author = {Li, Z and Wang, K and Shi, Y and Zhang, X and Wen, J},
      month = jan,
      year = {2020},
      note = {Publisher: United States},
      keywords = {Young Adult},
      pages = {352-362},
      published = {1},
      tag = {}
    }
  8. “PD-1 protein and gene expression as prognostic factors in early breast cancer.”.
    A. Matikas et al.
    ESMO Open, vol. 5, no. 6, p. e001032, Nov. 2020

    BIB
    @article{matikas_pd-1_2020,
      title = {{PD}-1 protein and gene expression as prognostic factors in early breast cancer.},
      volume = {5},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/33172959},
      doi = {10.1136/esmoopen-2020-001032},
      language = {eng},
      number = {6},
      journal = {ESMO Open},
      author = {Matikas, A and Zerdes, I and Lovrot, J and Sifakis, E and Richard, F and Sotiriou, C and Rassidakis, G and Bergh, J and Valachis, A and Foukakis, T},
      month = nov,
      year = {2020},
      note = {Publisher: England},
      keywords = {Transcriptome},
      pages = {e001032},
      published = {1},
      tag = {}
    }
  9. “Effects of Exercise on Chemotherapy Completion and Hospitalization Rates: The OptiTrain Breast Cancer Trial.”.
    S. Mijwel, K. A. Bolam, J. Gerrevall, T. Foukakis, Y. Wengstrom, and H. Rundqvist.
    Oncologist, vol. 25, no. 1, pp. 23–32, Jan. 2020

    BIB
    @article{mijwel_effects_2020,
      title = {Effects of {Exercise} on {Chemotherapy} {Completion} and {Hospitalization} {Rates}: {The} {OptiTrain} {Breast} {Cancer} {Trial}.},
      volume = {25},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/31391297},
      doi = {10.1634/theoncologist.2019-0262},
      language = {eng},
      number = {1},
      journal = {Oncologist},
      author = {Mijwel, S and Bolam, KA and Gerrevall, J and Foukakis, T and Wengstrom, Y and Rundqvist, H},
      month = jan,
      year = {2020},
      note = {Publisher: England},
      keywords = {Young Adult},
      pages = {23-32},
      published = {1},
      tag = {}
    }
  10. “Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and trastuzumab for resected HER2-positive breast cancer: Results from the phase 3 PANTHER trial.”.
    A. Papakonstantinou et al.
    Cancer, vol. 126, no. 6, pp. 1175–1182, Mar. 2020

    BIB
    @article{papakonstantinou_efficacy_2020,
      title = {Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and trastuzumab for resected {HER2}-positive breast cancer: {Results} from the phase 3 {PANTHER} trial.},
      volume = {126},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/31851385},
      doi = {10.1002/cncr.32653},
      language = {eng},
      number = {6},
      journal = {Cancer},
      author = {Papakonstantinou, A and Matikas, A and Bengtsson, NO and Malmstrom, P and Hedayati, E and Steger, G and Untch, M and Hubbert, L and Johansson, H and Hellstrom, M and Gnant, M and Loibl, S and Greil, R and Moebus, V and Foukakis, T and Bergh, J},
      month = mar,
      year = {2020},
      note = {Publisher: United States},
      keywords = {Young Adult},
      pages = {1175-1182},
      published = {1},
      tag = {},
      trial = {panther}
    }
  11. “Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancer.”.
    A. Papakonstantinou et al.
    Acta Oncol, vol. 59, no. 1, pp. 75–81, Jan. 2020

    BIB
    @article{papakonstantinou_neutropenic_2020,
      title = {Neutropenic complications in the {PANTHER} phase {III} study of adjuvant tailored dose-dense chemotherapy in early breast cancer.},
      volume = {59},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/31583943},
      doi = {10.1080/0284186X.2019.1670353},
      language = {eng},
      number = {1},
      journal = {Acta Oncol},
      author = {Papakonstantinou, A and Hedayati, E and Hellstrom, M and Johansson, H and Gnant, M and Steger, G and Greil, R and Untch, M and Moebus, V and Loibl, S and Foukakis, T and Bergh, J and Matikas, A},
      month = jan,
      year = {2020},
      note = {Publisher: Sweden},
      keywords = {Young Adult},
      pages = {75-81},
      published = {1},
      tag = {},
      trial = {panther}
    }
  12. “Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial.”.
    K. Ribi et al.
    Br J Cancer, vol. 122, no. 7, p. 1119, Mar. 2020

    BIB
    @article{ribi_correction_2020,
      title = {Correction: {Quality} of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the {SOLE} randomised phase 3 trial.},
      volume = {122},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/31949268},
      doi = {10.1038/s41416-019-0709-x},
      language = {eng},
      number = {7},
      journal = {Br J Cancer},
      author = {Ribi, K and Luo, W and Colleoni, M and Karlsson, P and Chirgwin, J and Aebi, S and Jerusalem, G and Neven, P and Di Lauro, V and Gomez, HL and Ruhstaller, T and Abdi, E and Biganzoli, L and Muller, B and Barbeaux, A and Graas, M-P and Rabaglio, M and Francis, PA and Foukakis, T and Pagani, O and Graiff, C and Vorobiof, D and Maibach, R and Di Leo, A and Gelber, RD and Goldhirsch, A and Coates, AS and Regan, MM and Bernhard, J and Investigators, SOLE},
      month = mar,
      year = {2020},
      note = {Publisher: England},
      pages = {1119},
      published = {1},
      tag = {}
    }
  13. “External Evaluation of 3 Commercial Artificial Intelligence Algorithms for Independent Assessment of Screening Mammograms.”.
    M. Salim et al.
    Jama Oncology, vol. 6, no. 10, pp. 1581–1588, Oct. 2020

    BIB
    @article{salim_external_2020,
      title = {External {Evaluation} of 3 {Commercial} {Artificial} {Intelligence} {Algorithms} for {Independent} {Assessment} of {Screening} {Mammograms}.},
      volume = {6},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/32852536},
      doi = {10.1001/jamaoncol.2020.3321},
      language = {eng},
      number = {10},
      journal = {Jama Oncology},
      author = {Salim, M and Wahlin, E and Dembrower, K and Azavedo, E and Foukakis, T and Liu, Y and Smith, K and Eklund, M and Strand, F},
      month = oct,
      year = {2020},
      note = {Publisher: United States},
      keywords = {Retrospective Studies},
      pages = {1581-1588},
      published = {1},
      tag = {}
    }
  14. “Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study.”.
    P. Schmid et al.
    Ann Oncol, vol. 31, no. 5, pp. 569–581, May 2020

    BIB
    @article{schmid_pembrolizumab_2020,
      title = {Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort {KEYNOTE}-173 study.},
      volume = {31},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/32278621},
      doi = {10.1016/j.annonc.2020.01.072},
      language = {eng},
      number = {5},
      journal = {Ann Oncol},
      author = {Schmid, P and Salgado, R and Park, YH and Munoz-Couselo, E and Kim, SB and Sohn, J and Im, S-A and Foukakis, T and Kuemmel, S and Dent, R and Yin, L and Wang, A and Tryfonidis, K and Karantza, V and Cortes, J and Loi, S},
      month = may,
      year = {2020},
      note = {Publisher: England},
      keywords = {Triple Negative Breast Neoplasms},
      pages = {569-581},
      published = {1},
      tag = {}
    }
  15. “Pembrolizumab for Early Triple-Negative Breast Cancer.”.
    P. Schmid et al.
    N Engl J Med, vol. 382, no. 9, pp. 810–821, Feb. 2020

    BIB
    @article{schmid_pembrolizumab_2020-1,
      title = {Pembrolizumab for {Early} {Triple}-{Negative} {Breast} {Cancer}.},
      volume = {382},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/32101663},
      doi = {10.1056/NEJMoa1910549},
      language = {eng},
      number = {9},
      journal = {N Engl J Med},
      author = {Schmid, P and Cortes, J and Pusztai, L and McArthur, H and Kummel, S and Bergh, J and Denkert, C and Park, YH and Hui, R and Harbeck, N and Takahashi, M and Foukakis, T and Fasching, PA and Cardoso, F and Untch, M and Jia, L and Karantza, V and Zhao, J and Aktan, G and Dent, R and O'Shaughnessy, J and Investigators, KEYNOTE-522},
      month = feb,
      year = {2020},
      note = {Publisher: United States},
      keywords = {Triple Negative Breast Neoplasms},
      pages = {810-821},
      published = {1},
      tag = {}
    }
  16. “MYC as a driver of stochastic chromatin networks: implications for the fitness of cancer cells.”.
    N. Sumida et al.
    Nucleic Acids Res, vol. 48, no. 19, pp. 10867–10876, Nov. 2020

    BIB
    @article{sumida_myc_2020,
      title = {{MYC} as a driver of stochastic chromatin networks: implications for the fitness of cancer cells.},
      volume = {48},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/33051686},
      doi = {10.1093/nar/gkaa817},
      language = {eng},
      number = {19},
      journal = {Nucleic Acids Res},
      author = {Sumida, N and Sifakis, EG and Kiani, NA and Ronnegren, AL and Scholz, BA and Vestlund, J and Gomez-Cabrero, D and Tegner, J and Gondor, A and Ohlsson, R},
      month = nov,
      year = {2020},
      note = {Publisher: England},
      keywords = {Stochastic Processes},
      pages = {10867-10876},
      published = {1},
      tag = {}
    }
  17. “Long-term anti-inflammatory diet in relation to improved breast cancer prognosis: a prospective cohort study”.
    K. Wang et al.
    NPJ BREAST CANCER, vol. 6, no. 1, Aug. 2020

    BIB
    @article{wang_long-term_2020,
      title = {Long-term anti-inflammatory diet in relation to improved breast cancer prognosis: a prospective cohort study},
      volume = {6},
      url = {https://www.webofscience.com/api/gateway?GWVersion=2\&SrcApp=kielementsprod\&SrcAuth=WosAPI\&KeyUT=WOS:000562850500002\&DestLinkType=FullRecord\&DestApp=WOS_CPL},
      doi = {10.1038/s41523-020-00179-4},
      number = {1},
      journal = {NPJ BREAST CANCER},
      author = {Wang, K and Sun, J-Z and Wu, Q-X and Li, Z-Y and Li, D-X and Xiong, Y-F and Zhong, G-C and Shi, Y and Li, Q and Zheng, J and Shivappa, N and Hebert, JR and Foukakis, T and Zhang, X and Li, H-Y and Xiang, T-X and Ren, G-S},
      month = aug,
      year = {2020},
      keywords = {Risk factors},
      published = {1},
      tag = {}
    }
  18. “Genome-Wide Transcriptional Analysis Reveals Alternative Splicing Event Profiles in Hepatocellular Carcinoma and Their Prognostic Significance.”.
    Y. Xiong et al.
    Front Genet, vol. 11, p. 879, 2020

    BIB
    @article{xiong_genome-wide_2020,
      title = {Genome-{Wide} {Transcriptional} {Analysis} {Reveals} {Alternative} {Splicing} {Event} {Profiles} in {Hepatocellular} {Carcinoma} and {Their} {Prognostic} {Significance}.},
      volume = {11},
      issn = {1664-8021},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/32849842},
      doi = {10.3389/fgene.2020.00879},
      language = {eng},
      journal = {Front Genet},
      author = {Xiong, Y and Yang, G and Wang, K and Riaz, M and Xu, J and Lv, Z and Zhou, H and Li, Q and Li, W and Sun, J and Tao, T and Li, J},
      year = {2020},
      note = {Publisher: Switzerland},
      keywords = {prognosis},
      pages = {879},
      published = {1},
      tag = {}
    }
  19. “Programmed death-ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21-gene and 70-gene signatures in estrogen receptor-positive disease.”.
    I. Zerdes et al.
    Mol Oncol, vol. 14, no. 5, pp. 951–963, May 2020

    BIB
    @article{zerdes_programmed_2020,
      title = {Programmed death-ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21-gene and 70-gene signatures in estrogen receptor-positive disease.},
      volume = {14},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/32115850},
      doi = {10.1002/1878-0261.12654},
      language = {eng},
      number = {5},
      journal = {Mol Oncol},
      author = {Zerdes, I and Sifakis, EG and Matikas, A and Chretien, S and Tobin, NP and Hartman, J and Rassidakis, GZ and Bergh, J and Foukakis, T},
      month = may,
      year = {2020},
      note = {Publisher: United States},
      keywords = {Young Adult},
      pages = {951-963},
      published = {1},
      tag = {}
    }
  20. “Dietary inflammatory index and incidence of and death from primary liver cancer: A prospective study of 103,902 American adults.”.
    G.-C. Zhong et al.
    Int J Cancer, vol. 147, no. 4, pp. 1050–1058, Aug. 2020

    BIB
    @article{zhong_dietary_2020,
      title = {Dietary inflammatory index and incidence of and death from primary liver cancer: {A} prospective study of 103,902 {American} adults.},
      volume = {147},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/32142166},
      doi = {10.1002/ijc.32954},
      language = {eng},
      number = {4},
      journal = {Int J Cancer},
      author = {Zhong, G-C and Wang, K and Peng, Y and Shivappa, N and Hebert, JR and Wu, Y-Q-L and Gong, J-P},
      month = aug,
      year = {2020},
      note = {Publisher: United States},
      keywords = {United States},
      pages = {1050-1058},
      published = {1},
      tag = {}
    }
  21. “Magnesium intake and primary liver cancer incidence and mortality in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.”.
    G.-C. Zhong et al.
    Int J Cancer, vol. 147, no. 6, pp. 1577–1586, Sep. 2020

    BIB
    @article{zhong_magnesium_2020,
      title = {Magnesium intake and primary liver cancer incidence and mortality in the {Prostate}, {Lung}, {Colorectal} and {Ovarian} {Cancer} {Screening} {Trial}.},
      volume = {147},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/32105342},
      doi = {10.1002/ijc.32939},
      language = {eng},
      number = {6},
      journal = {Int J Cancer},
      author = {Zhong, G-C and Peng, Y and Wang, K and Wan, L and Wu, Y-Q-L and Hao, F-B and Hu, J-J and Gu, H-T},
      month = sep,
      year = {2020},
      note = {Publisher: United States},
      keywords = {Survival Analysis},
      pages = {1577-1586},
      published = {1},
      tag = {}
    }
  22. “Total Antioxidant Capacity and Pancreatic Cancer Incidence and Mortality in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.”.
    G.-C. Zhong et al.
    Cancer Epidemiol Biomarkers Prev, vol. 29, no. 5, pp. 1019–1028, May 2020

    BIB
    @article{zhong_total_2020,
      title = {Total {Antioxidant} {Capacity} and {Pancreatic} {Cancer} {Incidence} and {Mortality} in the {Prostate}, {Lung}, {Colorectal}, and {Ovarian} {Cancer} {Screening} {Trial}.},
      volume = {29},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/32051196},
      doi = {10.1158/1055-9965.EPI-19-1511},
      language = {eng},
      number = {5},
      journal = {Cancer Epidemiol Biomarkers Prev},
      author = {Zhong, G-C and Pu, J-Y and Wu, Y-L and Yi, Z-J and Wan, L and Wang, K and Hao, F-B and Zhao, Y and Gong, J-P},
      month = may,
      year = {2020},
      note = {Publisher: United States},
      keywords = {United States},
      pages = {1019-1028},
      published = {1},
      tag = {}
    }

2019

  1. “Gasdermin D Drives the Nonexosomal Secretion of Galectin-3, an Insulin Signal Antagonist.”.
    Y. Chen et al.
    J Immunol, vol. 203, no. 10, pp. 2712–2723, Nov. 2019

    BIB
    @article{chen_gasdermin_2019,
      title = {Gasdermin {D} {Drives} the {Nonexosomal} {Secretion} of {Galectin}-3, an {Insulin} {Signal} {Antagonist}.},
      volume = {203},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/31597705},
      doi = {10.4049/jimmunol.1900212},
      language = {eng},
      number = {10},
      journal = {J Immunol},
      author = {Chen, Y and Wang, H and Shen, J and Deng, R and Yao, X and Guo, Q and Lu, A and Sun, B and Zhang, Y and Meng, G},
      month = nov,
      year = {2019},
      note = {Publisher: England},
      keywords = {Transfection},
      pages = {2712-2723},
      published = {1},
      tag = {}
    }
  2. “Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy.”.
    S. Chretien, I. Zerdes, J. Bergh, A. Matikas, and T. Foukakis.
    Cancers (Basel), vol. 11, no. 5, May 2019

    BIB
    @article{chretien_beyond_2019,
      title = {Beyond {PD}-1/{PD}-{L1} {Inhibition}: {What} the {Future} {Holds} for {Breast} {Cancer} {Immunotherapy}.},
      volume = {11},
      issn = {2072-6694},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/31060337},
      doi = {10.3390/cancers11050628},
      language = {eng},
      number = {5},
      journal = {Cancers (Basel)},
      author = {Chretien, S and Zerdes, I and Bergh, J and Matikas, A and Foukakis, T},
      month = may,
      year = {2019},
      note = {Publisher: Switzerland},
      keywords = {novel targets},
      published = {1},
      tag = {}
    }
  3. “Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials.”.
    E. B. C. T. C. Group (EBCTCG).
    Lancet, vol. 393, no. 10179, pp. 1440–1452, Apr. 2019

    BIB
    @article{group_ebctcg_increasing_2019,
      title = {Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials.},
      volume = {393},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/30739743},
      doi = {10.1016/S0140-6736(18)33137-4},
      language = {eng},
      number = {10179},
      journal = {Lancet},
      author = {Group (EBCTCG), Early Breast Cancer Trialists' Collaborative},
      month = apr,
      year = {2019},
      note = {Publisher: England},
      keywords = {Humans},
      pages = {1440-1452},
      published = {1},
      tag = {}
    }
  4. “The long-term prognostic and predictive capacity of cyclin D1 gene amplification in 2305 breast tumours.”.
    A. Lundberg et al.
    Breast Cancer Research, vol. 21, no. 1, p. 34, Feb. 2019

    BIB
    @article{lundberg_long-term_2019,
      title = {The long-term prognostic and predictive capacity of cyclin {D1} gene amplification in 2305 breast tumours.},
      volume = {21},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/30819233},
      doi = {10.1186/s13058-019-1121-4},
      language = {eng},
      number = {1},
      journal = {Breast Cancer Research},
      author = {Lundberg, A and Lindstrom, LS and Li, J and Harrell, JC and Darai-Ramqvist, E and Sifakis, EG and Foukakis, T and Perou, CM and Czene, K and Bergh, J and Tobin, NP},
      month = feb,
      year = {2019},
      note = {Publisher: England},
      keywords = {Survival Analysis},
      pages = {34},
      published = {1},
      tag = {}
    }
  5. “Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?”.
    A. Matikas, T. Foukakis, S. Swain, and J. Bergh.
    Ann Oncol, vol. 30, no. 7, pp. 1044–1050, Jul. 2019

    BIB
    @article{matikas_avoiding_2019,
      title = {Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?},
      volume = {30},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/31131397},
      doi = {10.1093/annonc/mdz126},
      language = {eng},
      number = {7},
      journal = {Ann Oncol},
      author = {Matikas, A and Foukakis, T and Swain, S and Bergh, J},
      month = jul,
      year = {2019},
      note = {Publisher: England},
      keywords = {Transcriptome},
      pages = {1044-1050},
      published = {1},
      tag = {}
    }
  6. “Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective PANTHER study with focus on obese patients.”.
    A. Matikas et al.
    Ann Oncol, vol. 30, no. 1, pp. 109–114, Jan. 2019

    BIB
    @article{matikas_dose_2019,
      title = {Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective {PANTHER} study with focus on obese patients.},
      volume = {30},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/30357310},
      doi = {10.1093/annonc/mdy475},
      language = {eng},
      number = {1},
      journal = {Ann Oncol},
      author = {Matikas, A and Foukakis, T and Moebus, V and Greil, R and Bengtsson, N-O and Steger, GG and Untch, M and Johansson, H and Hellstrom, M and Malmstrom, P and Gnant, M and Loibl, S and Bergh, J},
      month = jan,
      year = {2019},
      note = {Publisher: England},
      keywords = {Survival Rate},
      pages = {109-114},
      published = {1},
      tag = {},
      trial = {panther}
    }
  7. “Minimally invasive tissue access as a tool for delivering personalized medicine - with focus on oncology.”.
    A. Matikas, T. Foukakis, and J. Bergh.
    J Intern Med, vol. 285, no. 4, pp. 395–397, Apr. 2019

    BIB
    @article{matikas_minimally_2019,
      title = {Minimally invasive tissue access as a tool for delivering personalized medicine - with focus on oncology.},
      volume = {285},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/30488991},
      doi = {10.1111/joim.12860},
      language = {eng},
      number = {4},
      journal = {J Intern Med},
      author = {Matikas, A and Foukakis, T and Bergh, J},
      month = apr,
      year = {2019},
      note = {Publisher: England},
      keywords = {Swine},
      pages = {395-397},
      published = {1},
      tag = {}
    }
  8. “Prognostic Implications of PD-L1 Expression in Breast Cancer: Systematic Review and Meta-analysis of Immunohistochemistry and Pooled Analysis of Transcriptomic Data.”.
    A. Matikas et al.
    Clin Cancer Res, vol. 25, no. 18, pp. 5717–5726, Sep. 2019

    BIB
    @article{matikas_prognostic_2019,
      title = {Prognostic {Implications} of {PD}-{L1} {Expression} in {Breast} {Cancer}: {Systematic} {Review} and {Meta}-analysis of {Immunohistochemistry} and {Pooled} {Analysis} of {Transcriptomic} {Data}.},
      volume = {25},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/31227501},
      doi = {10.1158/1078-0432.CCR-19-1131},
      language = {eng},
      number = {18},
      journal = {Clin Cancer Res},
      author = {Matikas, A and Zerdes, I and Lovrot, J and Richard, F and Sotiriou, C and Bergh, J and Valachis, A and Foukakis, T},
      month = sep,
      year = {2019},
      note = {Publisher: United States},
      keywords = {Transcriptome},
      pages = {5717-5726},
      published = {1},
      tag = {}
    }
  9. “Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial.”.
    K. Ribi et al.
    Br J Cancer, vol. 120, no. 10, pp. 959–967, May 2019

    BIB
    @article{ribi_quality_2019,
      title = {Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the {SOLE} randomised phase 3 trial.},
      volume = {120},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/30967649},
      doi = {10.1038/s41416-019-0435-4},
      language = {eng},
      number = {10},
      journal = {Br J Cancer},
      author = {Ribi, K and Luo, W and Colleoni, M and Karlsson, P and Chirgwin, J and Aebi, S and Jerusalem, G and Neven, P and Di Lauro, V and Gomez, HL and Ruhstaller, T and Abdi, E and Biganzoli, L and Muller, B and Barbeaux, A and Graas, M-P and Rabaglio, M and Francis, PA and Foukakis, T and Pagani, O and Graiff, C and Vorobiof, D and Maibach, R and Di Leo, A and Gelber, RD and Goldhirsch, A and Coates, AS and Regan, MM and Bernhard, J and Investigators, SOLE},
      month = may,
      year = {2019},
      note = {Publisher: England},
      keywords = {Quality of Life},
      pages = {959-967},
      published = {1},
      tag = {}
    }
  10. “LBA8_PR KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)”.
    P. Schmid et al.
    Annals of Oncology, vol. 30, pp. v853–v854, Oct. 2019

    BIB
    @article{schmid_lba8_pr_2019,
      title = {{LBA8}\_PR {KEYNOTE}-522: {Phase} {III} study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer ({TNBC})},
      volume = {30},
      issn = {0923-7534},
      doi = {10.1093/annonc/mdz394.003},
      journal = {Annals of Oncology},
      author = {Schmid, P and Cortes, J and Dent, R and Pusztai, L and McArthur, HL and Kuemmel, S and Bergh, J and Denkert, C and Park, YH and Hui, R and Harbeck, N and Takahashi, M and Foukakis, T and Fasching, PA and Cardoso, F and Jia, L and Karantza, V and Zhao, J and Aktan, G and O'Shaughnessy, J},
      month = oct,
      year = {2019},
      note = {Publisher: Elsevier},
      keywords = {6.1 Pharmaceuticals},
      pages = {v853-v854},
      published = {1},
      tag = {}
    }
  11. “Pembrolizumab Plus Chemotherapy as Neoadjuvant Treatment for Locally Advanced Triple-Negative Breast Cancer: Results from the Phase 1b Open-Label, Multicohort KEYNOTE-173 Study”.
    P. Schmid et al.
    Jul. 2019

    BIB
    @article{schmid_pembrolizumab_2019,
      title = {Pembrolizumab {Plus} {Chemotherapy} as {Neoadjuvant} {Treatment} for {Locally} {Advanced} {Triple}-{Negative} {Breast} {Cancer}: {Results} from the {Phase} 1b {Open}-{Label}, {Multicohort} {KEYNOTE}-173 {Study}},
      author = {Schmid, P and Salgado, R and Park, YH and Munoz-Couselo, E and Kim, S-B and Sohn, J and Foukakis, T and Kuemmel, S and Dent, R and Yin, L and Wang, A and Tryfonidis, K and Karantza, V and Cortes, J and Loi, S},
      month = jul,
      year = {2019},
      published = {1},
      tag = {}
    }
  12. “WNT signaling and AHCTF1 promote oncogenic MYC expression through super-enhancer-mediated gene gating.”.
    B. A. Scholz et al.
    Nat Genet, vol. 51, no. 12, pp. 1723–1731, Dec. 2019

    BIB
    @article{scholz_wnt_2019,
      title = {{WNT} signaling and {AHCTF1} promote oncogenic {MYC} expression through super-enhancer-mediated gene gating.},
      volume = {51},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/31784729},
      doi = {10.1038/s41588-019-0535-3},
      language = {eng},
      number = {12},
      journal = {Nat Genet},
      author = {Scholz, BA and Sumida, N and de Lima, CDM and Chachoua, I and Martino, M and Tzelepis, I and Nikoshkov, A and Zhao, H and Mehmood, R and Sifakis, EG and Bhartiya, D and Gondor, A and Ohlsson, R},
      month = dec,
      year = {2019},
      note = {Publisher: United States},
      keywords = {beta Catenin},
      pages = {1723-1731},
      published = {1},
      tag = {}
    }
  13. “Clinicopathologic and Prognostic Significance of Body Mass Index (BMI) among Breast Cancer Patients in Western China: A Retrospective Multicenter Cohort Based on Western China Clinical Cooperation Group (WCCCG).”.
    K. Wang et al.
    Biomed Res Int, vol. 2019, p. 3692093, 2019

    BIB
    @article{wang_clinicopathologic_2019,
      title = {Clinicopathologic and {Prognostic} {Significance} of {Body} {Mass} {Index} ({BMI}) among {Breast} {Cancer} {Patients} in {Western} {China}: {A} {Retrospective} {Multicenter} {Cohort} {Based} on {Western} {China} {Clinical} {Cooperation} {Group} ({WCCCG}).},
      volume = {2019},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/31119166},
      doi = {10.1155/2019/3692093},
      language = {eng},
      journal = {Biomed Res Int},
      author = {Wang, K and Wu, Y-T and Zhang, X and Chen, L and Zhu, W-M and Zhang, A-J and Zheng, K and Yin, X-D and Li, F and Kong, L-Q and Ma, B-L and Li, H and Liu, J-P and Jiang, J and Li, Z-Y and Shi, Y and Ren, G-S and Li, H-Y},
      year = {2019},
      note = {Publisher: United States},
      keywords = {Prognosis},
      pages = {3692093},
      published = {1},
      tag = {}
    }
  14. “Development and validation of nomograms integrating immune-related genomic signatures with clinicopathologic features to improve prognosis and predictive value of triple-negative breast cancer: A gene expression-based retrospective study.”.
    K. Wang et al.
    Cancer Med, vol. 8, no. 2, pp. 686–700, Feb. 2019

    BIB
    @article{wang_development_2019,
      title = {Development and validation of nomograms integrating immune-related genomic signatures with clinicopathologic features to improve prognosis and predictive value of triple-negative breast cancer: {A} gene expression-based retrospective study.},
      volume = {8},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/30677255},
      doi = {10.1002/cam4.1880},
      language = {eng},
      number = {2},
      journal = {Cancer Med},
      author = {Wang, K and Li, H-L and Xiong, Y-F and Shi, Y and Li, Z-Y and Li, J and Zhang, X and Li, H-Y},
      month = feb,
      year = {2019},
      note = {Publisher: United States},
      keywords = {Triple Negative Breast Neoplasms},
      pages = {686-700},
      published = {1},
      tag = {}
    }
  15. “Long-Term Survival Differences Between T1-2 Invasive Lobular Breast Cancer and Corresponding Ductal Carcinoma After Breast-Conserving Surgery: A Propensity-Scored Matched Longitudinal Cohort Study.”.
    K. Wang, G.-Q. Zhu, Y. Shi, Z.-Y. Li, X. Zhang, and H.-Y. Li.
    Clin Breast Cancer, vol. 19, no. 1, pp. e101–e115, Feb. 2019

    BIB
    @article{wang_long-term_2019,
      title = {Long-{Term} {Survival} {Differences} {Between} {T1}-2 {Invasive} {Lobular} {Breast} {Cancer} and {Corresponding} {Ductal} {Carcinoma} {After} {Breast}-{Conserving} {Surgery}: {A} {Propensity}-{Scored} {Matched} {Longitudinal} {Cohort} {Study}.},
      volume = {19},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/30502219},
      doi = {10.1016/j.clbc.2018.10.010},
      language = {eng},
      number = {1},
      journal = {Clin Breast Cancer},
      author = {Wang, K and Zhu, G-Q and Shi, Y and Li, Z-Y and Zhang, X and Li, H-Y},
      month = feb,
      year = {2019},
      note = {Publisher: United States},
      keywords = {Survival Rate},
      pages = {e101-e115},
      published = {1},
      tag = {}
    }
  16. “Metastatic pattern discriminates survival benefit of primary surgery for de novo stage IV breast cancer: A real-world observational study.”.
    K. Wang et al.
    Eur J Surg Oncol, vol. 45, no. 8, pp. 1364–1372, Aug. 2019

    BIB
    @article{wang_metastatic_2019,
      title = {Metastatic pattern discriminates survival benefit of primary surgery for de novo stage {IV} breast cancer: {A} real-world observational study.},
      volume = {45},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/30837102},
      doi = {10.1016/j.ejso.2019.02.013},
      language = {eng},
      number = {8},
      journal = {Eur J Surg Oncol},
      author = {Wang, K and Shi, Y and Li, Z-Y and Xiao, Y-L and Li, J and Zhang, X and Li, H-Y},
      month = aug,
      year = {2019},
      note = {Publisher: England},
      keywords = {United States},
      pages = {1364-1372},
      published = {1},
      tag = {}
    }
  17. “Risk Reduction and Survival Benefit of Risk-Reducing Salpingo-oophorectomy in Hereditary Breast Cancer: Meta-analysis and Systematic Review.”.
    Y.-L. Xiao, K. Wang, Q. Liu, J. Li, X. Zhang, and H.-Y. Li.
    Clin Breast Cancer, vol. 19, no. 1, pp. e48–e65, Feb. 2019

    BIB
    @article{xiao_risk_2019,
      title = {Risk {Reduction} and {Survival} {Benefit} of {Risk}-{Reducing} {Salpingo}-oophorectomy in {Hereditary} {Breast} {Cancer}: {Meta}-analysis and {Systematic} {Review}.},
      volume = {19},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/30470623},
      doi = {10.1016/j.clbc.2018.09.011},
      language = {eng},
      number = {1},
      journal = {Clin Breast Cancer},
      author = {Xiao, Y-L and Wang, K and Liu, Q and Li, J and Zhang, X and Li, H-Y},
      month = feb,
      year = {2019},
      note = {Publisher: United States},
      keywords = {Survival Rate},
      pages = {e48-e65},
      published = {1},
      tag = {}
    }
  18. “STAT3 Activity Promotes Programmed-Death Ligand 1 Expression and Suppresses Immune Responses in Breast Cancer.”.
    I. Zerdes et al.
    Cancers (Basel), vol. 11, no. 10, Oct. 2019

    BIB
    @article{zerdes_stat3_2019,
      title = {{STAT3} {Activity} {Promotes} {Programmed}-{Death} {Ligand} 1 {Expression} and {Suppresses} {Immune} {Responses} in {Breast} {Cancer}.},
      volume = {11},
      issn = {2072-6694},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/31581535},
      doi = {10.3390/cancers11101479},
      language = {eng},
      number = {10},
      journal = {Cancers (Basel)},
      author = {Zerdes, I and Wallerius, M and Sifakis, EG and Wallmann, T and Betts, S and Bartish, M and Tsesmetzis, N and Tobin, NP and Coucoravas, C and Bergh, J and Rassidakis, GZ and Rolny, C and Foukakis, T},
      month = oct,
      year = {2019},
      note = {Publisher: Switzerland},
      keywords = {breast cancer},
      published = {1},
      tag = {}
    }

2018

  1. “Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.”.
    M. Colleoni et al.
    Lancet Oncol, vol. 19, no. 1, pp. 127–138, Jan. 2018

    BIB
    @article{colleoni_extended_2018,
      title = {Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer ({SOLE}): a multicentre, open-label, randomised, phase 3 trial.},
      volume = {19},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/29158011},
      doi = {10.1016/S1470-2045(17)30715-5},
      language = {eng},
      number = {1},
      journal = {Lancet Oncol},
      author = {Colleoni, M and Luo, W and Karlsson, P and Chirgwin, J and Aebi, S and Jerusalem, G and Neven, P and Hitre, E and Graas, M-P and Simoncini, E and Kamby, C and Thompson, A and Loibl, S and Gavila, J and Kuroi, K and Marth, C and Muller, B and O'Reilly, S and Di Lauro, V and Gombos, A and Ruhstaller, T and Burstein, H and Ribi, K and Bernhard, J and Viale, G and Maibach, R and Rabaglio-Poretti, M and Gelber, RD and Coates, AS and Di Leo, A and Regan, MM and Goldhirsch, A and Investigators, SOLE},
      month = jan,
      year = {2018},
      note = {Publisher: England},
      keywords = {Triazoles},
      pages = {127-138},
      published = {1},
      tag = {}
    }
  2. “Prognosis in patients diagnosed with loco-regional failure of breast cancer: 34 years longitudinal data from the Stockholm-Gotland cancer registry.”.
    C. Falato et al.
    Breast Cancer Research and Treatment, vol. 172, no. 3, pp. 703–712, Dec. 2018

    BIB
    @article{falato_prognosis_2018,
      title = {Prognosis in patients diagnosed with loco-regional failure of breast cancer: 34 years longitudinal data from the {Stockholm}-{Gotland} cancer registry.},
      volume = {172},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/30225620},
      doi = {10.1007/s10549-018-4936-2},
      language = {eng},
      number = {3},
      journal = {Breast Cancer Research and Treatment},
      author = {Falato, C and Taylor, SK and Szulkin, R and Nordblom, A and Eriksson, L and Sofiadis, A and Fredriksson, I and Hartman, J and Bergh, J and Foukakis, T},
      month = dec,
      year = {2018},
      note = {Publisher: Netherlands},
      keywords = {Registries},
      pages = {703-712},
      published = {1},
      tag = {}
    }
  3. “Carboplatin in the neoadjuvant treatment of triple-negative breast cancer-ready for prime time?”.
    T. Foukakis.
    Ann Oncol, vol. 29, no. 12, pp. 2278–2280, Dec. 2018

    BIB
    @article{foukakis_carboplatin_2018,
      title = {Carboplatin in the neoadjuvant treatment of triple-negative breast cancer-ready for prime time?},
      volume = {29},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/30395152},
      doi = {10.1093/annonc/mdy494},
      language = {eng},
      number = {12},
      journal = {Ann Oncol},
      author = {Foukakis, T},
      month = dec,
      year = {2018},
      note = {Publisher: England},
      keywords = {Triple Negative Breast Neoplasms},
      pages = {2278-2280},
      published = {1},
      tag = {}
    }
  4. “Immune gene expression and response to chemotherapy in advanced breast cancer.”.
    T. Foukakis et al.
    Br J Cancer, vol. 118, no. 4, pp. 480–488, Feb. 2018

    BIB
    @article{foukakis_immune_2018,
      title = {Immune gene expression and response to chemotherapy in advanced breast cancer.},
      volume = {118},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/29370583},
      doi = {10.1038/bjc.2017.446},
      language = {eng},
      number = {4},
      journal = {Br J Cancer},
      author = {Foukakis, T and Lovrot, J and Matikas, A and Zerdes, I and Lorent, J and Tobin, N and Suzuki, C and Brage, SE and Carlsson, L and Einbeigi, Z and Linderholm, B and Loman, N and Malmberg, M and Ferno, M and Skoog, L and Bergh, J and Hatschek, T},
      month = feb,
      year = {2018},
      note = {Publisher: England},
      keywords = {Treatment Outcome},
      pages = {480-488},
      published = {1},
      tag = {},
      trial = {tex}
    }
  5. “Ribociclib in premenopausal women with advanced breast cancer.”.
    T. Foukakis.
    Lancet Oncol, vol. 19, no. 7, pp. 850–852, Jul. 2018

    BIB
    @article{foukakis_ribociclib_2018,
      title = {Ribociclib in premenopausal women with advanced breast cancer.},
      volume = {19},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/29804904},
      doi = {10.1016/S1470-2045(18)30367-X},
      language = {eng},
      number = {7},
      journal = {Lancet Oncol},
      author = {Foukakis, T},
      month = jul,
      year = {2018},
      note = {Publisher: England},
      keywords = {Purines},
      pages = {850-852},
      published = {1},
      tag = {}
    }
  6. “Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing.”.
    C. Kim et al.
    Cell, vol. 173, no. 4, pp. 879–893.e13, May 2018

    BIB
    @article{kim_chemoresistance_2018,
      title = {Chemoresistance {Evolution} in {Triple}-{Negative} {Breast} {Cancer} {Delineated} by {Single}-{Cell} {Sequencing}.},
      volume = {173},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/29681456},
      doi = {10.1016/j.cell.2018.03.041},
      language = {eng},
      number = {4},
      journal = {Cell},
      author = {Kim, C and Gao, R and Sei, E and Brandt, R and Hartman, J and Hatschek, T and Crosetto, N and Foukakis, T and Navin, NE},
      month = may,
      year = {2018},
      note = {Publisher: United States},
      keywords = {Triple Negative Breast Neoplasms},
      pages = {879-893.e13},
      published = {1},
      tag = {},
      trial = {promix}
    }
  7. “Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancer.”.
    A. Matikas et al.
    Oncoimmunology, vol. 7, no. 9, p. e1466017, 2018

    BIB
    @article{matikas_dynamic_2018,
      title = {Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, {HER2} negative breast cancer.},
      volume = {7},
      issn = {2162-4011},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/30228933},
      doi = {10.1080/2162402X.2018.1466017},
      language = {eng},
      number = {9},
      journal = {Oncoimmunology},
      author = {Matikas, A and Lovrot, J and Ramberg, A and Eriksson, M and Lindsten, T and Lekberg, T and Hedenfalk, I and Loman, N and Bergh, J and Hatschek, T and Erlandsson, A and Foukakis, T},
      year = {2018},
      note = {Publisher: United States},
      keywords = {tumor infiltrating lymphocytes},
      pages = {e1466017},
      published = {1},
      tag = {},
      trial = {promix}
    }
  8. “RE: Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis.”.
    A. Matikas, T. Foukakis, and J. Bergh.
    J Natl Cancer Inst, vol. 110, no. 11, pp. 1280–1281, Nov. 2018

    BIB
    @article{matikas_re_2018,
      title = {{RE}: {Receptor} {Conversion} in {Distant} {Breast} {Cancer} {Metastases}: {A} {Systematic} {Review} and {Meta}-analysis.},
      volume = {110},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/29618043},
      doi = {10.1093/jnci/djy046},
      language = {eng},
      number = {11},
      journal = {J Natl Cancer Inst},
      author = {Matikas, A and Foukakis, T and Bergh, J},
      month = nov,
      year = {2018},
      note = {Publisher: United States},
      keywords = {Progesterone, Receptors},
      pages = {1280-1281},
      published = {1},
      tag = {}
    }
  9. “Correction: Histone demethylase LSD1 restricts influenza A virus infection by erasing IFITM3-K88 monomethylation.”.
    J. Shan et al.
    PLoS Pathog, vol. 14, no. 4, p. e1007037, Apr. 2018

    BIB
    @article{shan_correction_2018,
      title = {Correction: {Histone} demethylase {LSD1} restricts influenza {A} virus infection by erasing {IFITM3}-{K88} monomethylation.},
      volume = {14},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/29709037},
      doi = {10.1371/journal.ppat.1007037},
      language = {eng},
      number = {4},
      journal = {PLoS Pathog},
      author = {Shan, J and Zhao, B and Shan, Z and Nie, J and Deng, R and Xiong, R and Tsun, A and Pan, W and Zhao, H and Chen, L and Jin, Y and Qian, Z and Lui, K and Liang, R and Li, D and Sun, B and Lavillette, D and Xu, K and Li, B},
      month = apr,
      year = {2018},
      note = {Publisher: United States},
      pages = {e1007037},
      published = {1},
      tag = {}
    }
  10. “Treatment response assessment with (R)-[11CPAQ PET in the MMTV-PyMT mouse model of breast cancer.”.
    T. Tegnebratt et al.
    EJNMMI Res, vol. 8, no. 1, p. 25, Apr. 2018

    BIB
    @article{tegnebratt_treatment_2018,
      title = {Treatment response assessment with ({R})-[{11CPAQ} {PET} in the {MMTV}-{PyMT} mouse model of breast cancer.},
      volume = {8},
      issn = {2191-219X},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/29616369},
      doi = {10.1186/s13550-018-0380-x},
      language = {eng},
      number = {1},
      journal = {EJNMMI Res},
      author = {Tegnebratt, T and Lu, L and Eksborg, S and Chireh, A and Damberg, P and Nikkhou-Aski, S and Foukakis, T and Rundqvist, H and Holmin, S and Kuiper, RV and Samen, E},
      month = apr,
      year = {2018},
      note = {Publisher: Germany},
      keywords = {VEGFR-2},
      pages = {25},
      published = {1},
      tag = {}
    }
  11. “Correlation Between Contrast-enhanced Ultrasound Characteristics (Qualitative and Quantitative) and Pathological Prognostic Factors in Breast Cancer.”.
    I. Vraka et al.
    In Vivo, vol. 32, no. 4, pp. 945–954, 2018

    BIB
    @article{vraka_correlation_2018,
      title = {Correlation {Between} {Contrast}-enhanced {Ultrasound} {Characteristics} ({Qualitative} and {Quantitative}) and {Pathological} {Prognostic} {Factors} in {Breast} {Cancer}.},
      volume = {32},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/29936484},
      doi = {10.21873/invivo.11333},
      language = {eng},
      number = {4},
      journal = {In Vivo},
      author = {Vraka, I and Panourgias, E and Sifakis, E and Koureas, A and Galanis, P and Dellaportas, D and Gouliamos, A and Antoniou, A},
      year = {2018},
      note = {Publisher: Greece},
      keywords = {Ultrasonography},
      pages = {945-954},
      published = {1},
      tag = {}
    }
  12. “A Potential Prognostic Long Noncoding RNA Signature to Predict Recurrence among ER-positive Breast Cancer Patients Treated with Tamoxifen.”.
    K. Wang, J. Li, Y.-F. Xiong, Z. Zeng, X. Zhang, and H.-Y. Li.
    Sci Rep, vol. 8, no. 1, p. 3179, Feb. 2018

    BIB
    @article{wang_potential_2018,
      title = {A {Potential} {Prognostic} {Long} {Noncoding} {RNA} {Signature} to {Predict} {Recurrence} among {ER}-positive {Breast} {Cancer} {Patients} {Treated} with {Tamoxifen}.},
      volume = {8},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/29453409},
      doi = {10.1038/s41598-018-21581-w},
      language = {eng},
      number = {1},
      journal = {Sci Rep},
      author = {Wang, K and Li, J and Xiong, Y-F and Zeng, Z and Zhang, X and Li, H-Y},
      month = feb,
      year = {2018},
      note = {Publisher: England},
      keywords = {Transcriptome},
      pages = {3179},
      published = {1},
      tag = {}
    }
  13. “Predictors of internal mammary lymph nodes (IMLN) metastasis and disease-free survival comparison between IMLN-positive and IMLN-negative breast cancer patients: Results from Western China Clinical Cooperation Group (WCCCG) database (CONSORT).”.
    K. Wang et al.
    Medicine (Baltimore), vol. 97, no. 28, p. e11296, Jul. 2018

    BIB
    @article{wang_predictors_2018,
      title = {Predictors of internal mammary lymph nodes ({IMLN}) metastasis and disease-free survival comparison between {IMLN}-positive and {IMLN}-negative breast cancer patients: {Results} from {Western} {China} {Clinical} {Cooperation} {Group} ({WCCCG}) database ({CONSORT}).},
      volume = {97},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/29995764},
      doi = {10.1097/MD.0000000000011296},
      language = {eng},
      number = {28},
      journal = {Medicine (Baltimore)},
      author = {Wang, K and Zhang, X and Zheng, K and Yin, X-D and Xing, L and Zhang, A-J and Shi, Y and Kong, L-Q and Li, F and Ma, B-L and Li, H and Liu, J-P and Jiang, J and Ren, G-S and Li, H-Y},
      month = jul,
      year = {2018},
      note = {Publisher: United States},
      keywords = {Tumor Burden},
      pages = {e11296},
      published = {1},
      tag = {}
    }
  14. “Survival Comparisons Between Early Male and Female Breast Cancer Patients.”.
    K. Wang et al.
    Sci Rep, vol. 8, no. 1, p. 8900, Jun. 2018

    BIB
    @article{wang_survival_2018,
      title = {Survival {Comparisons} {Between} {Early} {Male} and {Female} {Breast} {Cancer} {Patients}.},
      volume = {8},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/29891971},
      doi = {10.1038/s41598-018-26199-6},
      language = {eng},
      number = {1},
      journal = {Sci Rep},
      author = {Wang, K and Wang, Q-J and Xiong, Y-F and Shi, Y and Yang, W-J and Zhang, X and Li, H-Y},
      month = jun,
      year = {2018},
      note = {Publisher: England},
      keywords = {Young Adult},
      pages = {8900},
      published = {1},
      tag = {}
    }
  15. “Profiles of alternative splicing in colorectal cancer and their clinical significance: A study based on large-scale sequencing data.”.
    Y. Xiong et al.
    EBioMedicine, vol. 36, pp. 183–195, Oct. 2018

    BIB
    @article{xiong_profiles_2018,
      title = {Profiles of alternative splicing in colorectal cancer and their clinical significance: {A} study based on large-scale sequencing data.},
      volume = {36},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/30243491},
      doi = {10.1016/j.ebiom.2018.09.021},
      language = {eng},
      journal = {EBioMedicine},
      author = {Xiong, Y and Deng, Y and Wang, K and Zhou, H and Zheng, X and Si, L and Fu, Z},
      month = oct,
      year = {2018},
      note = {Publisher: Netherlands},
      keywords = {Transcriptome},
      pages = {183-195},
      published = {1},
      tag = {}
    }
  16. “Profiles of immune infiltration in colorectal cancer and their clinical significant: A gene expression-based study.”.
    Y. Xiong, K. Wang, H. Zhou, L. Peng, W. You, and Z. Fu.
    Cancer Med, vol. 7, no. 9, pp. 4496–4508, Sep. 2018

    BIB
    @article{xiong_profiles_2018-1,
      title = {Profiles of immune infiltration in colorectal cancer and their clinical significant: {A} gene expression-based study.},
      volume = {7},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/30117315},
      doi = {10.1002/cam4.1745},
      language = {eng},
      number = {9},
      journal = {Cancer Med},
      author = {Xiong, Y and Wang, K and Zhou, H and Peng, L and You, W and Fu, Z},
      month = sep,
      year = {2018},
      note = {Publisher: United States},
      keywords = {Tumor Microenvironment},
      pages = {4496-4508},
      published = {1},
      tag = {}
    }
  17. “Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations.”.
    I. Zerdes, A. Matikas, J. Bergh, G. Z. Rassidakis, and T. Foukakis.
    Oncogene, vol. 37, no. 34, pp. 4639–4661, Aug. 2018

    BIB
    @article{zerdes_genetic_2018,
      title = {Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations.},
      volume = {37},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/29765155},
      doi = {10.1038/s41388-018-0303-3},
      language = {eng},
      number = {34},
      journal = {Oncogene},
      author = {Zerdes, I and Matikas, A and Bergh, J and Rassidakis, GZ and Foukakis, T},
      month = aug,
      year = {2018},
      note = {Publisher: England},
      keywords = {Genetic, Transcription},
      pages = {4639-4661},
      published = {1},
      tag = {}
    }

2017

  1. “[Chemotherapy and targeted drugs to reinforce each other].”.
    T. Foukakis and J. Bergh.
    Lakartidningen, vol. 114, Feb. 2017

    BIB
    @article{foukakis_chemotherapy_2017,
      title = {[{Chemotherapy} and targeted drugs to reinforce each other].},
      volume = {114},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/28221400},
      language = {swe},
      journal = {Lakartidningen},
      author = {Foukakis, T and Bergh, J},
      month = feb,
      year = {2017},
      note = {Publisher: Sweden},
      keywords = {ErbB-2, Receptor},
      published = {1},
      tag = {}
    }
  2. “Nanogrid single-nucleus RNA sequencing reveals phenotypic diversity in breast cancer.”.
    R. Gao et al.
    Nature Communications, vol. 8, no. 1, p. 228, Aug. 2017

    BIB
    @article{gao_nanogrid_2017,
      title = {Nanogrid single-nucleus {RNA} sequencing reveals phenotypic diversity in breast cancer.},
      volume = {8},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/28794488},
      doi = {10.1038/s41467-017-00244-w},
      language = {eng},
      number = {1},
      journal = {Nature Communications},
      author = {Gao, R and Kim, C and Sei, E and Foukakis, T and Crosetto, N and Chan, L-K and Srinivasan, M and Zhang, H and Meric-Bernstam, F and Navin, N},
      month = aug,
      year = {2017},
      note = {Publisher: England},
      keywords = {Triple Negative Breast Neoplasms},
      pages = {228},
      published = {1},
      tag = {}
    }
  3. “Association between pioglitazone use and the risk of bladder cancer among subjects with diabetes mellitus: a dose-response meta-analysis .”.
    Z. Li, M. Sun, F. Wang, J. Shi, and K. Wang.
    Int J Clin Pharmacol Ther, vol. 55, no. 3, pp. 210–219, Mar. 2017

    BIB
    @article{li_association_2017,
      title = {Association between pioglitazone use and the risk of bladder cancer among subjects with diabetes mellitus: a dose-response meta-analysis .},
      volume = {55},
      issn = {0946-1965},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/28025963},
      doi = {10.5414/CP202670},
      language = {eng},
      number = {3},
      journal = {Int J Clin Pharmacol Ther},
      author = {Li, Z and Sun, M and Wang, F and Shi, J and Wang, K},
      month = mar,
      year = {2017},
      note = {Publisher: Germany},
      keywords = {Urinary Bladder Neoplasms},
      pages = {210-219},
      published = {1},
      tag = {}
    }
  4. “Gene Expression Signatures and Immunohistochemical Subtypes Add Prognostic Value to Each Other in Breast Cancer Cohorts.”.
    A. Lundberg et al.
    Clin Cancer Res, vol. 23, no. 24, pp. 7512–7520, Dec. 2017

    BIB
    @article{lundberg_gene_2017,
      title = {Gene {Expression} {Signatures} and {Immunohistochemical} {Subtypes} {Add} {Prognostic} {Value} to {Each} {Other} in {Breast} {Cancer} {Cohorts}.},
      volume = {23},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/28972043},
      doi = {10.1158/1078-0432.CCR-17-1535},
      language = {eng},
      number = {24},
      journal = {Clin Cancer Res},
      author = {Lundberg, A and Lindstrom, LS and Harrell, JC and Falato, C and Carlson, JW and Wright, PK and Foukakis, T and Perou, CM and Czene, K and Bergh, J and Tobin, NP},
      month = dec,
      year = {2017},
      note = {Publisher: United States},
      keywords = {Transcriptome},
      pages = {7512-7520},
      published = {1},
      tag = {}
    }
  5. “Dose intense, dose dense and tailored dose adjuvant chemotherapy for early breast cancer: an evolution of concepts.”.
    A. Matikas, T. Foukakis, and J. Bergh.
    Acta Oncol, vol. 56, no. 9, pp. 1143–1151, Sep. 2017

    BIB
    @article{matikas_dose_2017,
      title = {Dose intense, dose dense and tailored dose adjuvant chemotherapy for early breast cancer: an evolution of concepts.},
      volume = {56},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/28537808},
      doi = {10.1080/0284186X.2017.1329593},
      language = {eng},
      number = {9},
      journal = {Acta Oncol},
      author = {Matikas, A and Foukakis, T and Bergh, J},
      month = sep,
      year = {2017},
      note = {Publisher: Sweden},
      keywords = {Humans},
      pages = {1143-1151},
      published = {1},
      tag = {}
    }
  6. “Implementing neoadjuvant endocrine strategies in ER-positive, HER2-negative breast cancer.”.
    A. Matikas, T. Foukakis, I. Michalakis, and V. Georgoulias.
    Expert Rev Anticancer Ther, vol. 17, no. 4, pp. 319–326, Apr. 2017

    BIB
    @article{matikas_implementing_2017,
      title = {Implementing neoadjuvant endocrine strategies in {ER}-positive, {HER2}-negative breast cancer.},
      volume = {17},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/28128984},
      doi = {10.1080/14737140.2017.1288105},
      language = {eng},
      number = {4},
      journal = {Expert Rev Anticancer Ther},
      author = {Matikas, A and Foukakis, T and Michalakis, I and Georgoulias, V},
      month = apr,
      year = {2017},
      note = {Publisher: England},
      keywords = {Treatment Outcome},
      pages = {319-326},
      published = {1},
      tag = {}
    }
  7. “Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 (SBG 2004-1) randomized trial of tailored dose adjuvant chemotherapy for early breast cancer.”.
    A. Matikas et al.
    JOURNAL OF CLINICAL ONCOLOGY, vol. 35, May 2017

    BIB
    @article{matikas_long-term_2017,
      title = {Long-term safety and survival outcomes from the {Scandinavian} {Breast} {Group} 2004-1 ({SBG} 2004-1) randomized trial of tailored dose adjuvant chemotherapy for early breast cancer.},
      volume = {35},
      issn = {0732-183X},
      url = {https://www.webofscience.com/api/gateway?GWVersion=2\&SrcApp=kielementsprod\&SrcAuth=WosAPI\&KeyUT=WOS:000411895701057\&DestLinkType=FullRecord\&DestApp=WOS_CPL},
      journal = {JOURNAL OF CLINICAL ONCOLOGY},
      author = {Matikas, A and Margolin, S and Hellstrom, M and Johansson, H and Bengtsson, N-O and Carlsson, L and Edlund, P and Karlsson, P and Lidbrink, E and Linderholm, BK and Lindman, H and Malmstrom, P and Villman, KK and Foukakis, T and Bergh, JCS},
      month = may,
      year = {2017},
      published = {1},
      tag = {},
      trial = {sbg}
    }
  8. “Tackling endocrine resistance in ER-positive HER2-negative advanced breast cancer: A tale of imprecision medicine.”.
    A. Matikas, T. Foukakis, and J. Bergh.
    Crit Rev Oncol Hematol, vol. 114, pp. 91–101, Jun. 2017

    BIB
    @article{matikas_tackling_2017,
      title = {Tackling endocrine resistance in {ER}-positive {HER2}-negative advanced breast cancer: {A} tale of imprecision medicine.},
      volume = {114},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/28477750},
      doi = {10.1016/j.critrevonc.2017.04.002},
      language = {eng},
      journal = {Crit Rev Oncol Hematol},
      author = {Matikas, A and Foukakis, T and Bergh, J},
      month = jun,
      year = {2017},
      note = {Publisher: Netherlands},
      keywords = {Treatment Outcome},
      pages = {91-101},
      published = {1},
      tag = {}
    }
  9. “Off-tumor targets compromise antiangiogenic drug sensitivity by inducing kidney erythropoietin production.”.
    M. Nakamura et al.
    Proc Natl Acad Sci U S A, vol. 114, no. 45, pp. E9635–E9644, Nov. 2017

    BIB
    @article{nakamura_off-tumor_2017,
      title = {Off-tumor targets compromise antiangiogenic drug sensitivity by inducing kidney erythropoietin production.},
      volume = {114},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/29078273},
      doi = {10.1073/pnas.1703431114},
      language = {eng},
      number = {45},
      journal = {Proc Natl Acad Sci U S A},
      author = {Nakamura, M and Zhang, Y and Yang, Y and Sonmez, C and Zheng, W and Huang, G and Seki, T and Iwamoto, H and Ding, B and Yin, L and Foukakis, T and Hatschek, T and Li, X and Hosaka, K and Li, J and Yu, G and Wang, X and Liu, Y and Cao, Y},
      month = nov,
      year = {2017},
      note = {Publisher: United States},
      keywords = {Vascular Endothelial Growth Factor A},
      pages = {E9635-E9644},
      published = {1},
      tag = {}
    }
  10. “An HIF-1a/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression.”.
    A. Palazon et al.
    Cancer Cell, vol. 32, no. 5, pp. 669–683.e5, Nov. 2017

    BIB
    @article{palazon_hif-1vegf-axis_2017,
      title = {An {HIF}-1a/{VEGF}-{A} {Axis} in {Cytotoxic} {T} {Cells} {Regulates} {Tumor} {Progression}.},
      volume = {32},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/29136509},
      doi = {10.1016/j.ccell.2017.10.003},
      language = {eng},
      number = {5},
      journal = {Cancer Cell},
      author = {Palazon, A and Tyrakis, PA and Macias, D and Velica, P and Rundqvist, H and Fitzpatrick, S and Vojnovic, N and Phan, AT and Loman, N and Hedenfalk, I and Hatschek, T and Lovrot, J and Foukakis, T and Goldrath, AW and Bergh, J and Johnson, RS},
      month = nov,
      year = {2017},
      note = {Publisher: United States},
      keywords = {Vascular Endothelial Growth Factor A},
      pages = {669-683.e5},
      published = {1},
      tag = {}
    }
  11. “PAM50 Provides Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients.”.
    N. P. Tobin et al.
    Clin Cancer Res, vol. 23, no. 23, pp. 7225–7231, Dec. 2017

    BIB
    @article{tobin_pam50_2017,
      title = {{PAM50} {Provides} {Prognostic} {Information} {When} {Applied} to the {Lymph} {Node} {Metastases} of {Advanced} {Breast} {Cancer} {Patients}.},
      volume = {23},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/28972041},
      doi = {10.1158/1078-0432.CCR-17-2301},
      language = {eng},
      number = {23},
      journal = {Clin Cancer Res},
      author = {Tobin, NP and Lundberg, A and Lindstrom, LS and Harrell, JC and Foukakis, T and Carlsson, L and Einbeigi, Z and Linderholm, BK and Loman, N and Malmberg, M and Ferno, M and Czene, K and Perou, CM and Bergh, J and Hatschek, T and Group, TEX Trialists},
      month = dec,
      year = {2017},
      note = {Publisher: United States},
      keywords = {Proportional Hazards Models},
      pages = {7225-7231},
      published = {1},
      tag = {}
    }
  12. “Change in risk of breast cancer after receiving hormone replacement therapy by considering effect-modifiers: a systematic review and dose-response meta-analysis of prospective studies.”.
    K. Wang, F. Li, L. Chen, Y.-M. Lai, X. Zhang, and H.-Y. Li.
    Oncotarget, vol. 8, no. 46, pp. 81109–81124, Oct. 2017

    BIB
    @article{wang_change_2017,
      title = {Change in risk of breast cancer after receiving hormone replacement therapy by considering effect-modifiers: a systematic review and dose-response meta-analysis of prospective studies.},
      volume = {8},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/29113371},
      doi = {10.18632/oncotarget.20154},
      language = {eng},
      number = {46},
      journal = {Oncotarget},
      author = {Wang, K and Li, F and Chen, L and Lai, Y-M and Zhang, X and Li, H-Y},
      month = oct,
      year = {2017},
      note = {Publisher: United States},
      keywords = {hormone replacement therapy},
      pages = {81109-81124},
      published = {1},
      tag = {}
    }

2016

  1. “Intrinsic subtypes and genomic signatures of primary breast cancer and prognosis after systemic relapse.”.
    C. Falato, N. P. Tobin, J. Lorent, L. S. Lindstrom, J. Bergh, and T. Foukakis.
    Mol Oncol, vol. 10, no. 4, pp. 517–525, Apr. 2016

    BIB
    @article{falato_intrinsic_2016,
      title = {Intrinsic subtypes and genomic signatures of primary breast cancer and prognosis after systemic relapse.},
      volume = {10},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/26651914},
      doi = {10.1016/j.molonc.2015.11.004},
      language = {eng},
      number = {4},
      journal = {Mol Oncol},
      author = {Falato, C and Tobin, NP and Lorent, J and Lindstrom, LS and Bergh, J and Foukakis, T},
      month = apr,
      year = {2016},
      note = {Publisher: United States},
      keywords = {Survival Rate},
      pages = {517-525},
      published = {1},
      tag = {}
    }
  2. “A 21-Gene Expression Assay in Breast Cancer.”.
    T. Foukakis, C. Falato, and J. Bergh.
    N Engl J Med, vol. 374, no. 14, pp. 1386–1387, Apr. 2016

    BIB
    @article{foukakis_21-gene_2016,
      title = {A 21-{Gene} {Expression} {Assay} in {Breast} {Cancer}.},
      volume = {374},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/27050218},
      doi = {10.1056/NEJMc1515988},
      language = {eng},
      number = {14},
      journal = {N Engl J Med},
      author = {Foukakis, T and Falato, C and Bergh, J},
      month = apr,
      year = {2016},
      note = {Publisher: United States},
      keywords = {Local, Neoplasm Recurrence},
      pages = {1386-1387},
      published = {1},
      tag = {}
    }
  3. “Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.”.
    T. Foukakis et al.
    JAMA, vol. 316, no. 18, pp. 1888–1896, Nov. 2016

    BIB
    @article{foukakis_effect_2016,
      title = {Effect of {Tailored} {Dose}-{Dense} {Chemotherapy} vs {Standard} 3-{Weekly} {Adjuvant} {Chemotherapy} on {Recurrence}-{Free} {Survival} {Among} {Women} {With} {High}-{Risk} {Early} {Breast} {Cancer}: {A} {Randomized} {Clinical} {Trial}.},
      volume = {316},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/27825007},
      doi = {10.1001/jama.2016.15865},
      language = {eng},
      number = {18},
      journal = {JAMA},
      author = {Foukakis, T and von Minckwitz, G and Bengtsson, N-O and Brandberg, Y and Wallberg, B and Fornander, T and Mlineritsch, B and Schmatloch, S and Singer, CF and Steger, G and Egle, D and Karlsson, E and Carlsson, L and Loibl, S and Untch, M and Hellstrom, M and Johansson, H and Anderson, H and Malmstrom, P and Gnant, M and Greil, R and Mobus, V and Bergh, J and Swedish Breast Cancer Group (SweBCG), the German Breast Group (GBG) and Group (ABCSG), the Austrian Breast \& Colorectal Cancer Study},
      month = nov,
      year = {2016},
      note = {Publisher: United States},
      keywords = {Taxoids},
      pages = {1888-1896},
      published = {1},
      tag = {},
      trial = {panther}
    }
  4. “Is Estradiol Monitoring Necessary in Women Receiving Ovarian Suppression for Breast Cancer?”.
    A. Papakonstantinou, T. Foukakis, K. A. Rodriguez-Wallberg, and J. Bergh.
    Journal of Clinical Oncology, vol. 34, no. 14, pp. 1573–1579, May 2016

    BIB
    @article{papakonstantinou_is_2016,
      title = {Is {Estradiol} {Monitoring} {Necessary} in {Women} {Receiving} {Ovarian} {Suppression} for {Breast} {Cancer}?},
      volume = {34},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/26951320},
      doi = {10.1200/JCO.2015.65.3493},
      language = {eng},
      number = {14},
      journal = {Journal of Clinical Oncology},
      author = {Papakonstantinou, A and Foukakis, T and Rodriguez-Wallberg, KA and Bergh, J},
      month = may,
      year = {2016},
      note = {Publisher: United States},
      keywords = {Ovary},
      pages = {1573-1579},
      published = {1},
      tag = {}
    }
  5. “An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors.”.
    N. P. Tobin et al.
    Clin Cancer Res, vol. 22, no. 10, pp. 2417–2426, May 2016

    BIB
    @article{tobin_endothelial_2016,
      title = {An {Endothelial} {Gene} {Signature} {Score} {Predicts} {Poor} {Outcome} in {Patients} with {Endocrine}-{Treated}, {Low} {Genomic} {Grade} {Breast} {Tumors}.},
      volume = {22},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/26769751},
      doi = {10.1158/1078-0432.CCR-15-1691},
      language = {eng},
      number = {10},
      journal = {Clin Cancer Res},
      author = {Tobin, NP and Wennmalm, K and Lindstrom, LS and Foukakis, T and He, L and Genove, G and ostman, A and Landberg, G and Betsholtz, C and Bergh, J},
      month = may,
      year = {2016},
      note = {Publisher: United States},
      keywords = {Genetic, Transcription},
      pages = {2417-2426},
      published = {1},
      tag = {}
    }
  6. “Periostin is identified as a putative metastatic marker in breast cancer-derived exosomes.”.
    I. Vardaki, S. Ceder, D. Rutishauser, G. Baltatzis, T. Foukakis, and T. Panaretakis.
    Oncotarget, vol. 7, no. 46, pp. 74966–74978, Nov. 2016

    BIB
    @article{vardaki_periostin_2016,
      title = {Periostin is identified as a putative metastatic marker in breast cancer-derived exosomes.},
      volume = {7},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/27589561},
      doi = {10.18632/oncotarget.11663},
      language = {eng},
      number = {46},
      journal = {Oncotarget},
      author = {Vardaki, I and Ceder, S and Rutishauser, D and Baltatzis, G and Foukakis, T and Panaretakis, T},
      month = nov,
      year = {2016},
      note = {Publisher: United States},
      keywords = {Reproducibility of Results},
      pages = {74966-74978},
      published = {1},
      tag = {}
    }
  7. “Smoking increases risks of all-cause and breast cancer specific mortality in breast cancer individuals: a dose-response meta-analysis of prospective cohort studies involving 39725 breast cancer cases.”.
    K. Wang, F. Li, X. Zhang, Z. Li, and H. Li.
    Oncotarget, vol. 7, no. 50, pp. 83134–83147, Dec. 2016

    BIB
    @article{wang_smoking_2016,
      title = {Smoking increases risks of all-cause and breast cancer specific mortality in breast cancer individuals: a dose-response meta-analysis of prospective cohort studies involving 39725 breast cancer cases.},
      volume = {7},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/27863414},
      doi = {10.18632/oncotarget.13366},
      language = {eng},
      number = {50},
      journal = {Oncotarget},
      author = {Wang, K and Li, F and Zhang, X and Li, Z and Li, H},
      month = dec,
      year = {2016},
      note = {Publisher: United States},
      keywords = {Time Factors},
      pages = {83134-83147},
      published = {1},
      tag = {}
    }
  8. “Reproductive factors, menopausal hormone therapies and primary liver cancer risk: a systematic review and dose-response meta-analysis of observational studies.”.
    G.-C. Zhong et al.
    Hum Reprod Update, vol. 23, no. 1, pp. 126–138, Dec. 2016

    BIB
    @article{zhong_reproductive_2016,
      title = {Reproductive factors, menopausal hormone therapies and primary liver cancer risk: a systematic review and dose-response meta-analysis of observational studies.},
      volume = {23},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/27655589},
      doi = {10.1093/humupd/dmw037},
      language = {eng},
      number = {1},
      journal = {Hum Reprod Update},
      author = {Zhong, G-C and Liu, Y and Chen, N and Hao, F-B and Wang, K and Cheng, J-H and Gong, J-P and Ding, X},
      month = dec,
      year = {2016},
      note = {Publisher: England},
      keywords = {Sex Factors},
      pages = {126-138},
      published = {1},
      tag = {}
    }

2015

  1. “OC-0391: First results of the Preoperative Accelerated Partial Breast Irradiation (PAPBI) trial”.
    S. C. J. Bosma et al.
    Radiotherapy and Oncology, vol. 115, pp. s188–s189, Apr. 2015

    BIB
    @article{bosma_oc-0391_2015,
      title = {{OC}-0391: {First} results of the {Preoperative} {Accelerated} {Partial} {Breast} {Irradiation} ({PAPBI}) trial},
      volume = {115},
      issn = {0167-8140},
      doi = {10.1016/s0167-8140(15)40387-1},
      journal = {Radiotherapy and Oncology},
      author = {Bosma, SCJ and Van der Leij, F and Van de Vijver, MJ and Rivera, S and Foukakis, T and Van den Bongard, HJGD and Vreeswijk, SAOJ and Bartelink, H and Rutgers, EJ and Elkhuizen, PHM},
      month = apr,
      year = {2015},
      note = {Publisher: Elsevier},
      keywords = {3211 Oncology and Carcinogenesis},
      pages = {s188-s189},
      published = {1},
      tag = {}
    }
  2. “Immunohistochemistry-based subtypes and gene expression signatures as predictors of prognosis in metastatic breast cancer.”.
    C. Falato, N. Tobin, J. Lorent, L. S. Lindstrom, J. C. S. Bergh, and T. Foukakis.
    Journal of Clinical Oncology, vol. 33, no. 15_suppl, pp. e22090–e22090, May 2015

    BIB
    @article{falato_immunohistochemistry-based_2015,
      title = {Immunohistochemistry-based subtypes and gene expression signatures as predictors of prognosis in metastatic breast cancer.},
      volume = {33},
      issn = {0732-183X},
      journal = {Journal of Clinical Oncology},
      author = {Falato, C and Tobin, N and Lorent, J and Lindstrom, LS and Bergh, JCS and Foukakis, T},
      month = may,
      year = {2015},
      note = {Publisher: American Society of Clinical Oncology (ASCO)},
      keywords = {Cancer},
      pages = {e22090-e22090},
      published = {1},
      tag = {}
    }
  3. “Gene expression profiling of sequential metastatic biopsies for biomarker discovery in breast cancer.”.
    T. Foukakis et al.
    Mol Oncol, vol. 9, no. 7, pp. 1384–1391, Aug. 2015

    BIB
    @article{foukakis_gene_2015,
      title = {Gene expression profiling of sequential metastatic biopsies for biomarker discovery in breast cancer.},
      volume = {9},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/25888067},
      doi = {10.1016/j.molonc.2015.03.011},
      language = {eng},
      number = {7},
      journal = {Mol Oncol},
      author = {Foukakis, T and Lovrot, J and Sandqvist, P and Xie, H and Lindstrom, LS and Giorgetti, C and Jacobsson, H and Hedayati, E and Bergh, J},
      month = aug,
      year = {2015},
      note = {Publisher: United States},
      keywords = {Tomography, X-Ray Computed},
      pages = {1384-1391},
      published = {1},
      tag = {}
    }
  4. “Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.”.
    M. Gnant et al.
    Lancet, vol. 386, no. 9992, pp. 433–443, Aug. 2015

    BIB
    @article{gnant_adjuvant_2015,
      title = {Adjuvant denosumab in breast cancer ({ABCSG}-18): a multicentre, randomised, double-blind, placebo-controlled trial.},
      volume = {386},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/26040499},
      doi = {10.1016/S0140-6736(15)60995-3},
      language = {eng},
      number = {9992},
      journal = {Lancet},
      author = {Gnant, M and Pfeiler, G and Dubsky, PC and Hubalek, M and Greil, R and Jakesz, R and Wette, V and Balic, M and Haslbauer, F and Melbinger, E and Bjelic-Radisic, V and Artner-Matuschek, S and Fitzal, F and Marth, C and Sevelda, P and Mlineritsch, B and Steger, GG and Manfreda, D and Exner, R and Egle, D and Bergh, J and Kainberger, F and Talbot, S and Warner, D and Fesl, C and Singer, CF and Breast, Austrian and Group, Colorectal Cancer Study},
      month = aug,
      year = {2015},
      note = {Publisher: England},
      keywords = {Treatment Outcome},
      pages = {433-443},
      published = {1},
      tag = {}
    }
  5. “A retrospective safety and efficacy analysis of the first patients treated with eribulin for metastatic breast cancer in Stockholm, Sweden.”.
    L. Kessler, C. Falato, S. Margolin, J. Bergh, and T. Foukakis.
    Acta Oncol, vol. 54, no. 4, pp. 522–529, Apr. 2015

    BIB
    @article{kessler_retrospective_2015,
      title = {A retrospective safety and efficacy analysis of the first patients treated with eribulin for metastatic breast cancer in {Stockholm}, {Sweden}.},
      volume = {54},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/25383448},
      doi = {10.3109/0284186X.2014.973063},
      language = {eng},
      number = {4},
      journal = {Acta Oncol},
      author = {Kessler, L and Falato, C and Margolin, S and Bergh, J and Foukakis, T},
      month = apr,
      year = {2015},
      note = {Publisher: Sweden},
      keywords = {Tubulin Modulators},
      pages = {522-529},
      published = {1},
      tag = {}
    }
  6. “The importance of molecular markers for diagnosis and selection of targeted treatments in patients with cancer.”.
    N. P. Tobin, T. Foukakis, L. De Petris, and J. Bergh.
    J Intern Med, vol. 278, no. 6, pp. 545–570, Dec. 2015

    BIB
    @article{tobin_importance_2015,
      title = {The importance of molecular markers for diagnosis and selection of targeted treatments in patients with cancer.},
      volume = {278},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/26373821},
      doi = {10.1111/joim.12429},
      language = {eng},
      number = {6},
      journal = {J Intern Med},
      author = {Tobin, NP and Foukakis, T and De Petris, L and Bergh, J},
      month = dec,
      year = {2015},
      note = {Publisher: England},
      keywords = {Transcriptome},
      pages = {545-570},
      published = {1},
      tag = {}
    }
  7. “First results of the preoperative accelerated partial breast irradiation (PAPBI) trial.”.
    F. van der Leij et al.
    Radiother Oncol, vol. 114, no. 3, pp. 322–327, Mar. 2015

    BIB
    @article{van_der_leij_first_2015,
      title = {First results of the preoperative accelerated partial breast irradiation ({PAPBI}) trial.},
      volume = {114},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/25701298},
      doi = {10.1016/j.radonc.2015.02.002},
      language = {eng},
      number = {3},
      journal = {Radiother Oncol},
      author = {van der Leij, F and Bosma, SCJ and van de Vijver, MJ and Wesseling, J and Vreeswijk, S and Rivera, S and Bourgier, C and Garbay, J-R and Foukakis, T and Lekberg, T and van den Bongard, DHJGD and van Vliet-Vroegindeweij, C and Bartelink, H and Rutgers, EJ and Elkhuizen, PHM},
      month = mar,
      year = {2015},
      note = {Publisher: Ireland},
      keywords = {Treatment Outcome},
      pages = {322-327},
      published = {1},
      tag = {}
    }
  8. “PARP1- and CTCF-Mediated Interactions between Active and Repressed Chromatin at the Lamina Promote Oscillating Transcription.”.
    H. Zhao et al.
    Mol Cell, vol. 59, no. 6, pp. 984–997, Sep. 2015

    BIB
    @article{zhao_parp1-_2015,
      title = {{PARP1}- and {CTCF}-{Mediated} {Interactions} between {Active} and {Repressed} {Chromatin} at the {Lamina} {Promote} {Oscillating} {Transcription}.},
      volume = {59},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/26321255},
      doi = {10.1016/j.molcel.2015.07.019},
      language = {eng},
      number = {6},
      journal = {Mol Cell},
      author = {Zhao, H and Sifakis, EG and Sumida, N and Millan-Arino, L and Scholz, BA and Svensson, JP and Chen, X and Ronnegren, AL and Mallet de Lima, CD and Varnoosfaderani, FS and Shi, C and Loseva, O and Yammine, S and Israelsson, M and Rathje, LS and Nemeti, B and Fredlund, E and Helleday, T and Imreh, MP and Gondor, A},
      month = sep,
      year = {2015},
      note = {Publisher: United States},
      keywords = {Genetic, Transcription},
      pages = {984-997},
      published = {1},
      tag = {}
    }

2014

  1. “Time-dependent risk of developing distant metastasis in breast cancer patients according to treatment, age and tumour characteristics.”.
    E. Colzani et al.
    Br J Cancer, vol. 110, no. 5, pp. 1378–1384, Mar. 2014

    BIB
    @article{colzani_time-dependent_2014,
      title = {Time-dependent risk of developing distant metastasis in breast cancer patients according to treatment, age and tumour characteristics.},
      volume = {110},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/24434426},
      doi = {10.1038/bjc.2014.5},
      language = {eng},
      number = {5},
      journal = {Br J Cancer},
      author = {Colzani, E and Johansson, ALV and Liljegren, A and Foukakis, T and Clements, M and Adolfsson, J and Hall, P and Czene, K},
      month = mar,
      year = {2014},
      note = {Publisher: England},
      keywords = {Time Factors},
      pages = {1378-1384},
      published = {1},
      tag = {}
    }
  2. “Ki67 measured in metastatic tissue and prognosis in patients with advanced breast cancer.”.
    C. Falato et al.
    Breast Cancer Research and Treatment, vol. 147, no. 2, pp. 407–414, Sep. 2014

    BIB
    @article{falato_ki67_2014,
      title = {Ki67 measured in metastatic tissue and prognosis in patients with advanced breast cancer.},
      volume = {147},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/25129344},
      doi = {10.1007/s10549-014-3096-2},
      language = {eng},
      number = {2},
      journal = {Breast Cancer Research and Treatment},
      author = {Falato, C and Lorent, J and Tani, E and Karlsson, E and Wright, PK and Bergh, J and Foukakis, T},
      month = sep,
      year = {2014},
      note = {Publisher: Netherlands},
      keywords = {Sweden},
      pages = {407-414},
      published = {1},
      tag = {}
    }
  3. “Thyroid hormone inactivation in gastrointestinal stromal tumors.”.
    T. Foukakis, J. Lovrot, and J. Bergh.
    N Engl J Med, vol. 371, no. 1, pp. 84–85, Jul. 2014

    BIB
    @article{foukakis_thyroid_2014,
      title = {Thyroid hormone inactivation in gastrointestinal stromal tumors.},
      volume = {371},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/24988574},
      doi = {10.1056/NEJMc1405198},
      language = {eng},
      number = {1},
      journal = {N Engl J Med},
      author = {Foukakis, T and Lovrot, J and Bergh, J},
      month = jul,
      year = {2014},
      note = {Publisher: United States},
      keywords = {Thyroid Hormones},
      pages = {84-85},
      published = {1},
      tag = {}
    }
  4. “A composite framework for the statistical analysis of epidemiological DNA methylation data with the Infinium Human Methylation 450K BeadChip.”.
    I. Valavanis, E. G. Sifakis, P. Georgiadis, S. Kyrtopoulos, and A. A. Chatziioannou.
    IEEE J Biomed Health Inform, vol. 18, no. 3, pp. 817–823, May 2014

    BIB
    @article{valavanis_composite_2014,
      title = {A composite framework for the statistical analysis of epidemiological {DNA} methylation data with the {Infinium} {Human} {Methylation} {450K} {BeadChip}.},
      volume = {18},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/24808224},
      doi = {10.1109/JBHI.2014.2298351},
      language = {eng},
      number = {3},
      journal = {IEEE J Biomed Health Inform},
      author = {Valavanis, I and Sifakis, EG and Georgiadis, P and Kyrtopoulos, S and Chatziioannou, AA},
      month = may,
      year = {2014},
      note = {Publisher: United States},
      keywords = {Oligonucleotide Array Sequence Analysis},
      pages = {817-823},
      published = {1},
      tag = {}
    }
  5. “Validation of a novel procedure for quantification of the formation of phosphoramide mustard by individuals treated with cyclophosphamide.”.
    H. von Stedingk et al.
    Cancer Chemother Pharmacol, vol. 74, no. 3, pp. 549–558, Sep. 2014

    BIB
    @article{von_stedingk_validation_2014,
      title = {Validation of a novel procedure for quantification of the formation of phosphoramide mustard by individuals treated with cyclophosphamide.},
      volume = {74},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/25053385},
      doi = {10.1007/s00280-014-2524-7},
      language = {eng},
      number = {3},
      journal = {Cancer Chemother Pharmacol},
      author = {von Stedingk, H and Xie, H and Hatschek, T and Foukakis, T and Ryden, A and Bergh, J and Rydberg, P},
      month = sep,
      year = {2014},
      note = {Publisher: Germany},
      keywords = {Tandem Mass Spectrometry},
      pages = {549-558},
      published = {1},
      tag = {}
    }

2013

  1. “Clinical instability of breast cancer markers is reflected in long-term in vitro estrogen deprivation studies.”.
    J. Milosevic, J. Klinge, A.-L. Borg, T. Foukakis, J. Bergh, and N. P. Tobin.
    BMC Cancer, vol. 13, p. 473, Oct. 2013

    BIB
    @article{milosevic_clinical_2013,
      title = {Clinical instability of breast cancer markers is reflected in long-term in vitro estrogen deprivation studies.},
      volume = {13},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/24119434},
      doi = {10.1186/1471-2407-13-473},
      language = {eng},
      journal = {BMC Cancer},
      author = {Milosevic, J and Klinge, J and Borg, A-L and Foukakis, T and Bergh, J and Tobin, NP},
      month = oct,
      year = {2013},
      note = {Publisher: England},
      keywords = {Progesterone, Receptors},
      pages = {473},
      published = {1},
      tag = {}
    }

2012

  1. “A retrospective safety analysis of adult patients treated with high-dose methotrexate for osteosarcoma in Stockholm, Sweden.”.
    D. Alm, C. Linder Stragliotto, A. Folin, J. Bergh, and T. Foukakis.
    Journal of Clinical Oncology, vol. 30, no. 15_suppl, pp. 10083–10083, May 2012

    BIB
    @article{alm_retrospective_2012,
      title = {A retrospective safety analysis of adult patients treated with high-dose methotrexate for osteosarcoma in {Stockholm}, {Sweden}.},
      volume = {30},
      issn = {0732-183X},
      journal = {Journal of Clinical Oncology},
      author = {Alm, D and Linder Stragliotto, C and Folin, A and Bergh, J and Foukakis, T},
      month = may,
      year = {2012},
      note = {Publisher: American Society of Clinical Oncology (ASCO)},
      keywords = {3 Good Health and Well Being},
      pages = {10083-10083},
      published = {1},
      tag = {}
    }
  2. “When to order a biopsy to characterise a metastatic relapse in breast cancer.”.
    T. Foukakis, G. astrom, L. Lindstrom, T. Hatschek, and J. Bergh.
    Ann Oncol, vol. 23 Suppl 10, pp. x349–x353, Sep. 2012

    BIB
    @article{foukakis_when_2012,
      title = {When to order a biopsy to characterise a metastatic relapse in breast cancer.},
      volume = {23 Suppl 10},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/22987990},
      doi = {10.1093/annonc/mds297},
      language = {eng},
      journal = {Ann Oncol},
      author = {Foukakis, T and astrom, G and Lindstrom, L and Hatschek, T and Bergh, J},
      month = sep,
      year = {2012},
      note = {Publisher: England},
      keywords = {Retrospective Studies},
      pages = {x349-x353},
      published = {1},
      tag = {}
    }
  3. “Safety and efficacy of eribulin in patients with advanced breast cancer treated outside of a clinical trial: A single institution experience.”.
    L. Kessler, J. Bergh, and T. Foukakis.
    Journal of Clinical Oncology, vol. 30, no. 15_suppl, pp. e11510–e11510, May 2012

    BIB
    @article{kessler_safety_2012,
      title = {Safety and efficacy of eribulin in patients with advanced breast cancer treated outside of a clinical trial: {A} single institution experience.},
      volume = {30},
      issn = {0732-183X},
      journal = {Journal of Clinical Oncology},
      author = {Kessler, L and Bergh, J and Foukakis, T},
      month = may,
      year = {2012},
      note = {Publisher: American Society of Clinical Oncology (ASCO)},
      keywords = {3 Good Health and Well Being},
      pages = {e11510-e11510},
      published = {1},
      tag = {}
    }
  4. “Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.”.
    J. P. Neoptolemos et al.
    JAMA, vol. 308, no. 2, pp. 147–156, Jul. 2012

    BIB
    @article{neoptolemos_effect_2012,
      title = {Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the {ESPAC}-3 periampullary cancer randomized trial.},
      volume = {308},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/22782416},
      doi = {10.1001/jama.2012.7352},
      language = {eng},
      number = {2},
      journal = {JAMA},
      author = {Neoptolemos, JP and Moore, MJ and Cox, TF and Valle, JW and Palmer, DH and McDonald, AC and Carter, R and Tebbutt, NC and Dervenis, C and Smith, D and Glimelius, B and Charnley, RM and Lacaine, F and Scarfe, AG and Middleton, MR and Anthoney, A and Ghaneh, P and Halloran, CM and Lerch, MM and Olah, A and Rawcliffe, CL and Verbeke, CS and Campbell, F and Buchler, MW and Cancer, European Study Group for Pancreatic},
      month = jul,
      year = {2012},
      note = {Publisher: United States},
      keywords = {Gemcitabine},
      pages = {147-156},
      published = {1},
      tag = {}
    }
  5. “Anaplastic carcinoma of the thyroid gland: treatment and outcome over 13 years at one institution.”.
    I. Segerhammar et al.
    J Surg Oncol, vol. 106, no. 8, pp. 981–986, Dec. 2012

    BIB
    @article{segerhammar_anaplastic_2012,
      title = {Anaplastic carcinoma of the thyroid gland: treatment and outcome over 13 years at one institution.},
      volume = {106},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/22674491},
      doi = {10.1002/jso.23177},
      language = {eng},
      number = {8},
      journal = {J Surg Oncol},
      author = {Segerhammar, I and Larsson, C and Nilsson, I-L and Backdahl, M and Hoog, A and Wallin, G and Foukakis, T and Zedenius, J},
      month = dec,
      year = {2012},
      note = {Publisher: United States},
      keywords = {Treatment Outcome},
      pages = {981-986},
      published = {1},
      tag = {}
    }
  6. “Evaluating the effect of various background correction methods regarding noise reduction, in two-channel microarray data.”.
    E. G. Sifakis, A. Prentza, D. Koutsouris, and A. A. Chatziioannou.
    Comput Biol Med, vol. 42, no. 1, pp. 19–29, Jan. 2012

    BIB
    @article{sifakis_evaluating_2012,
      title = {Evaluating the effect of various background correction methods regarding noise reduction, in two-channel microarray data.},
      volume = {42},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/22074762},
      doi = {10.1016/j.compbiomed.2011.10.003},
      language = {eng},
      number = {1},
      journal = {Comput Biol Med},
      author = {Sifakis, EG and Prentza, A and Koutsouris, D and Chatziioannou, AA},
      month = jan,
      year = {2012},
      note = {Publisher: United States},
      keywords = {Oligonucleotide Array Sequence Analysis},
      pages = {19-29},
      published = {1},
      tag = {}
    }
  7. “Proteomic profiling of follicular and papillary thyroid tumors.”.
    A. Sofiadis et al.
    Eur J Endocrinol, vol. 166, no. 4, pp. 657–667, Apr. 2012

    BIB
    @article{sofiadis_proteomic_2012,
      title = {Proteomic profiling of follicular and papillary thyroid tumors.},
      volume = {166},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/22275472},
      doi = {10.1530/EJE-11-0856},
      language = {eng},
      number = {4},
      journal = {Eur J Endocrinol},
      author = {Sofiadis, A and Becker, S and Hellman, U and Hultin-Rosenberg, L and Dinets, A and Hulchiy, M and Zedenius, J and Wallin, G and Foukakis, T and Hoog, A and Auer, G and Lehtio, J and Larsson, C},
      month = apr,
      year = {2012},
      note = {Publisher: England},
      keywords = {Validation Studies as Topic},
      pages = {657-667},
      published = {1},
      tag = {}
    }

2011

  1. “Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden.”.
    T. Foukakis, T. Fornander, T. Lekberg, H. Hellborg, J. Adolfsson, and J. Bergh.
    Breast Cancer Research and Treatment, vol. 130, no. 2, pp. 553–560, Nov. 2011

    BIB
    @article{foukakis_age-specific_2011,
      title = {Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in {Stockholm}, {Sweden}.},
      volume = {130},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/21617918},
      doi = {10.1007/s10549-011-1594-z},
      language = {eng},
      number = {2},
      journal = {Breast Cancer Research and Treatment},
      author = {Foukakis, T and Fornander, T and Lekberg, T and Hellborg, H and Adolfsson, J and Bergh, J},
      month = nov,
      year = {2011},
      note = {Publisher: Netherlands},
      keywords = {Sweden},
      pages = {553-560},
      published = {1},
      tag = {}
    }

2010

  1. “Proteomic study of thyroid tumors reveals frequent up-regulation of the Ca2+ -binding protein S100A6 in papillary thyroid carcinoma.”.
    A. Sofiadis et al.
    Thyroid, vol. 20, no. 10, pp. 1067–1076, Oct. 2010

    BIB
    @article{sofiadis_proteomic_2010,
      title = {Proteomic study of thyroid tumors reveals frequent up-regulation of the {Ca2}+ -binding protein {S100A6} in papillary thyroid carcinoma.},
      volume = {20},
      url = {https://www.ncbi.nlm.nih.gov/pubmed/20629554},
      doi = {10.1089/thy.2009.0400},
      language = {eng},
      number = {10},
      journal = {Thyroid},
      author = {Sofiadis, A and Dinets, A and Orre, LM and Branca, RM and Juhlin, CC and Foukakis, T and Wallin, G and Hoog, A and Hulchiy, M and Zedenius, J and Larsson, C and Lehtio, J},
      month = oct,
      year = {2010},
      note = {Publisher: United States},
      keywords = {Up-Regulation},
      pages = {1067-1076},
      published = {1},
      tag = {}
    }